Functional analysis of human enhancers using the zebrafish embryo by Miguel Escalada, Irene
 FUNCTIONAL ANALYSIS OF HUMAN ENHANCERS 
USING THE ZEBRAFISH EMBRYO 
by 
IRENE MIGUEL ESCALADA 
 
A thesis submitted to 
The University of Birmingham 
for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
Department of Medical and Molecular Genetics 
School of Clinical and Experimental Medicine 
College of Medical and Dental Sciences 
The University of Birmingham 
June 2014
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
Abstract 
In the post-genomic era the availability of genome-wide datasets has revealed an unexpected 
complexity of transcriptional regulation. In this context, where most enhancer predictions are 
based on computational analyses, functional validations are lacking. This thesis investigated the 
utility of the transgenic zebrafish embryo as an in vivo vertebrate model to study the function of 
candidate human enhancers, and detect subtle changes in enhancer function caused by disease-
associated variants. Our functional validations indicated that despite the evolutionary distance 
between human and fish, 60% of the conserved enhancers predicted by a combination of 
chromatin signatures, TF binding events and bidirectional transcription, lead to reporter 
expression that recapitulates the patterns of either zebrafish or human genes. To improve the 
reliability of zebrafish transgenesis, a targeted integration system mediated by PhiC31 integrase 
was validated for enhancer testing. I demonstrated that this method overcomes position effect 
variation commonly found in transposon-based assays. However, enhancer-driven expression 
could not be detected when I attempted to quantitate TCF7L2-associated enhancer variants, 
indicating the need for further studies to understand the limitations of the zebrafish model. Taken 
together, my results provide strong support for zebrafish as a valuable in vivo model to study the 
function of mammalian transcriptional regulatory elements. 
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Chapter One: GENERAL INTRODUCTION 
1.1 Transcriptional regulation mediated by RNA Polymerase II: overview 
The faithful execution of all biological processes in a cell including proliferation, differentiation 
and homeostasis, relies on the proper temporal and spatial control of gene expression. In 
eukaryotes protein-coding genes are transcribed by RNA Polymerase II (aka PolII, Weil 1979), 
whose activity is regulated through the integrated action of DNA binding proteins, including the 
general transcriptional machinery, DNA-specific transcription factors, activators and co-activators; 
and cis-regulatory elements, including promoters, enhancers, silencers and insulators, in response 
to developmental and environmental signals (Levine et al., 2014). 
Transcription mediated by PolII is divided into three stages: initiation, when the initiation complex 
is recruited to the promoter and mRNA synthesis begins, elongation, when the mRNA transcript is 
extended and termination, when both the transcript and PolII are released. It is traditionally 
believed that the most stringent regulation of gene expression occurs during transcriptional 
initiation, although there is a growing body of evidence suggesting that elongation is a limiting 
step as well (Nechaev and Adelman, 2011). 
Transcription is initiated when the highly conserved General or basal transcription factors (GTFs) 
that include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH bind sequentially to the core promoter to 
assemble the Pre Initiation Complex (PIC), which will bring RNA PolII to the Transcriptional Start 
Site (TSS) of the target gene (Orphanides et al., 1996; Roeder, 1996). In the traditional multi-step 
model of PIC assembly TFIID, a protein complex that comprises the TATA-box binding protein 
(TBP) and TBP-associated factors (TAFs), binds through its different subunits to core promoter 
elements. Subsequently TFIIB is recruited, followed by TFIIF-PolII complex and the binding of TFIIE 
and TFIIH, completing the formation of the PIC. Following PIC assembly TFIIH, which has ATPase, 
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kinase and helicase activities, will unwind the double helix of DNA and position PolII polymerase 
to start transcription (Goodrich and Tjian, 1994; Douziech et al., 2000). This early-elongating PolII 
will clear the core promoter facilitated by the phosphorylation of Serine-5 residue on its C-
terminal domain by a kinase subunit of TFIIH (Komarnitsky et al., 2000; Hirose and Ohkuma, 
2007). When the nascent mRNA transcript reaches 25-50 nucleotides, most of the GTFs are 
released, the elongation complex is established and PolII pauses (Rougvie and Lis, 1988; Marshall 
and Price, 1992; Liu et al., 2013). Phosphorylation of the Ser2 residue of PolII by P-TEFb kinase 
favours processive transcription and is required to recruit factors that are important for 
transcription elongation, termination and mRNA processing (Marshall and Price, 1995; Marshall et 
al., 1996; Ni et al., 2004; Hirose and Ohkuma, 2007). After this, the Polymerase is released and 
ready to reinitiate another transcription cycle. 
This textbook view of transcription, which portrays a universal and common mechanism of 
transcriptional initiation where PIC and the core promoter are static elements, has been 
challenged at different levels over the past years: i) even though GTFs were identified in TATA-box 
containing genes, they are actually a minority and core promoter elements are diverse (Cooper et 
al., 2006; Juven-Gershon et al., 2006; Kadonaga, 2012); ii) there are alternative functional TBP-
related factors in metazoa that can recognize TATA-box element (Dantonel et al., 1999); iii) apart 
from TBP some other TAFs, TFIIB and variant paralogs can generate alternative promoter 
recognition complexes (Verrijzer et al., 1995; Burke and Kadonaga, 1996; Burke and Kadonaga, 
1997; Lagrange et al., 1998); iv) TFIID is not ubiquitous, in fact there are tissue-specific subunits of 
TAFs in tissues like testis and ovary (Freiman et al., 2001; Pointud et al., 2003; Falender et al., 
2005); v) during muscle differentiation TFIID complex is rapidly degraded and replaced by a novel 
TRF3/TAF3 complex (Deato and Tjian, 2007). The existence of alternative initiation complexes that 
can assemble at distinct sets of promoters during different developmental times suggests an 
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unexpected complexity of transcriptional initiation (Goodrich and Tjian, 2010; Muller et al., 2010; 
Muller and Tora, 2014). Several aspects of such diversity will be discussed below. 
1.2 Cis-Regulatory Elements 
There are two main classes of cis-regulatory elements controlling genes transcribed by PolII: 
proximal elements, including the core promoter and proximal promoter and distal regulatory 
regions, including enhancers, silencers and insulators (Figure 1.1). All these cis-regulatory 
elements contain binding sites for trans-regulatory proteins (general transcription factors, 
activators or co-activators (Maston et al., 2006). 
 
Figure 1.1 Overview of transcriptional regulation. 
Schematic representation of proximal and distal cis-regulatory elements (CRE) and the integration 
of regulatory input in the core promoter region, encompassing the TSS of a gene (black arrow). 
Transcription factors bind to CREs by transcription factor binding sites (TFBS). Reproduced from 
(Lenhard et al., 2012). 
1.2.1 Core promoters 
The core promoter is a region in the immediate vicinity of the TSS of a gene, which contains 
multiple motifs, or core promoter elements (CPEs), for docking the PIC (Sandelin et al., 2007). 
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However, the core-promoter does not only serve this role, it integrates the total regulatory input 
from transcription factors (TF) binding to proximal and distal elements such as enhancer or 
repressors, and translates it into a refined and regulated rate of transcriptional initiation (Lenhard 
et al., 2012). Core promoter elements are diverse: there is no element present in all promoters 
and most likely more CPEs remain yet to be discovered (Figure 1.2, reviewed in (Kadonaga, 
2012)). 
- The TATA-box was the first element to be discovered and is the best characterized 
position-dependent core promoter motif. It is located about 30 nt upstream of the TSS  and it is 
predominantly bound by the TBP (TATA-box Binding Protein) subunit of the TFIID complex (Lifton 
et al., 1978). Both the TATA box and TBP are conserved from archaebacteria to humans. However, 
TATA-containing promoters are a minority compared to TATA-less ones (Juven-Gershon et al., 
2006). This element can also be recognised in metazoans by other members of the TBP family 
including TRF1, specific to Drosophila, TRF3, described in vertebrates and TBP2, described in 
zebrafish (Crowley et al., 1993; Hansen et al., 1997; Dantonel et al., 1999; Persengiev et al., 2003; 
Bartfai et al., 2004). 
 
Figure 1.2 Relative positioning of CPEs with roles in PolII-mediated transcription. 
All elements depicted in the image are approximately drawn to scale and their position relative to 
the dominant TSS of the gene (black arrow, +1). Importantly, promoters only exhibit a subset of 
these CPEs and there is no universal CPE present in all promoters. Adapted from (Kadonaga, 2012) 
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- The Initiator motif is a pyrimidine-rich 17 bp element that encompasses the TSS, thus 
located at +1, and can be found both in TATA-containing or TATA-less promoters (Smale and 
Baltimore, 1989). It can be recognized by the TAFI and TAFII subunits of the TFIID complex 
(Chalkley and Verrijzer, 1999). 
- The DPE (or Downstream Promoter Element) is a 7 bp motif highly conserved from 
Drosophila to humans located 30 nt downstream of TSS, mostly in TATA-less promoters. It is 
bound by TBP-associated factor TAF6 and TAF9 subunits of TFIID, but not by TBP (Burke and 
Kadonaga, 1996; Burke and Kadonaga, 1997). 
- The MTE (or Motif Ten Element) is located between +18 and +27 nt relative to the 
initiator, immediately downstream of the DPE. It can promote transcription independently of the 
TATA box and DPE but requires the initiator motif for its function (Lim et al., 2004). 
- BREs (or TFIIB Recognition Elements) are 7 bp elements located immediately upstream 
(BREu) or downstream (BREd) of the TATA element and act in conjunction with it. BRE motifs are 
recognised by TFIIB and it is believed that binding stabilizes the TFIID-DNA complex (Lagrange et 
al., 1998). 
- The TCT or polypyrimidine initiator is a recently described novel CPE that resembles the 
initiator motif and is specifically required for the transcription of ribosomal genes in Drosophila 
and mammals. It spans from -2 to +6, encompassing the TSS (Parry et al., 2010). 
1.2.1.1 Classification of core promoters 
The development of high-throughput technologies that permits mapping of the 5' end of mRNAs 
with single base pair resolution, such as CAGE (Shiraki et al., 2003), has shown that metazoan 
promoters are heterogeneous and exhibit a differential architecture. Based on the TSS 
distribution, core promoters in mammals can be divided into two classes (Carninci et al., 2006). A 
minority of promoters is considered “sharp”, as they have a single TSS. Sharp promoters often 
contain a TATA box and are associated with tissue-specific expression. On the contrary, “broad” 
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promoters typically contain a cluster of TSS and can start transcription in a range of 100 bp, 
generating mRNAs of different lengths but with the same coding content. These promoters are 
TATA-less, enriched in CpG islands, and usually correlate with ubiquitous or developmentally 
regulated expressed genes (Sandelin et al., 2007). These observations have recently been 
confirmed by the FANTOM5 Consortium, where 573 human and 128 mouse primary cell samples 
were analysed by single molecule CAGE (FANTOM Consortium, 2014). Additionally, due to the 
high depth coverage of the sequencing data, they were also able to determine the preferred TSS 
in broad promoters (FANTOM Consortium, 2014). A global description of TSS usage during the 
development of the zebrafish embryo has unveiled that zebrafish also contains "sharp" and 
"broad" promoters and interestingly, the usage of broad promoters increased after zygotic gene 
activation (Nepal et al., 2013). 
This dichotomy of promoters has been challenged since it has been shown in mammals that some 
"sharp" promoters overlap CpG islands and some "broad" promoters are not enriched in CpG 
nucleotides (Ponjavic et al., 2006). It has been proposed therefore to use a tripartition to 
distinguish mammalian promoter types (Rach et al., 2011; Lenhard et al., 2012). Type I promoters 
are TATA-enriched, have a low CpG content, and are associated with tissue-specific expression of 
genes. Type II promoters usually contain a short CpG island overlapping with the TSS and correlate 
with ubiquitously expressed genes. Type III promoters contain CpG islands that extend onto the 
gene body and are characteristic of developmentally regulated genes (Lenhard et al., 2012). 
1.2.2 Proximal promoter 
The proximal promoter is the region extending upstream of the core promoter (generally up to 
200 and 250 nt upstream of the TSS) and contains multiple binding sites for activators (Butler and 
Kadonaga, 2002). Proximal promoters might also contain tethering elements to recruit specific 
distal enhancers through homotypic binding of transcription factors (Calhoun et al., 2002). 
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Functional dissection of the proximal promoter area has revealed that the region from -300 to -50 
relative to the TSS contributes positively to core promoter activity, while there is often a negative 
regulatory region from -1000 to -500 (Cooper et al., 2006). 
1.2.3 Silencers 
Silencers are cis-regulatory elements that act by silencing or repressing the transcription of a 
gene. They were originally identified in yeast, and defined as elements that could switch off 
heterologous promoters in an orientation-independent manner and with relative independence 
to the position of the target promoter (Brand et al., 1985). These classical silencer elements are 
located upstream of the TSS and are bound by repressors that can interfere with PIC assembly 
(Maston et al., 2006). Examples of classical silencers include the distal element of the zen gene in 
Drosophila. It is located between -1.4 Kb and -1.2 Kb of the TSS and can actively repress 
transcription of the gene in the ventral region of the embryo (Doyle et al., 1989) through binding 
of the DSP1 repressor, which recruits TBP, displacing TFIIA and impeding PIC formation (Kirov et 
al., 1996). There is a second class of silencers that are also known as Negative Regulatory 
Elements (NRE). These silencers are position dependent and can passively repress transcriptional 
regulation by preventing the binding of TFs to their regulatory motifs, or by interfering with 
signals controlling splicing, polyadenylation or elongation (Ogbourne and Antalis, 1998).  
1.2.4 Insulators 
Insulators are boundary elements that limit the action of regulatory modules to certain genomic 
domains, protecting genes from neighbouring effects (Maston et al., 2006). They are usually short 
pieces of DNA between 0,5-3Kb in size that act in an orientation-independent but position 
dependent manner, reviewed in (Heger and Wiehe, 2014). They have two main properties: they 
can directionally block enhancer-promoter interactions, i.e. only if the insulator is located 
between them (Geyer and Corces, 1992); or they can prevent or limit the spread of 
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heterochromatin, acting as a barrier (Sun and Elgin, 1999). There are several DNA sequences that 
can function as insulators in the Drosophila genome. The first insulators to be identified were scs 
and scs´ flanking the proximal and distal ends of the hsp70 locus (Udvardy et al., 1985), which are 
bound by Zw5 and BEAF proteins respectively (Hart et al., 1997; Gaszner et al., 1999). Another 
well-known enhancer-blocking insulator is gypsy, a retrotransposable element responsible for 
multiple mutations in Drosophila, whose interaction with su(Hw) protein is essential for its 
function (Parkhurst et al., 1988; Geyer and Corces, 1992; Kuhn et al., 2003). However, in 
vertebrates all enhancer-blocking insulators identified so far contain binding sites for CCCTC-
binding factor (CTCF) (Heger and Wiehe, 2014). CTCF is an 11-zinc finger DNA binding protein, 
which is highly conserved in vertebrates (Filippova et al., 1996). Computational prediction of CTCF 
binding sites has revealed that they are spread throughout the genome and particularly enriched 
in conserved non-coding regions (Xie et al., 2007). Furthermore, CTCF-binding sites showing 
enhancer-blocking properties in vivo are evolutionarily conserved and syntenic between human 
and chicken (Martin et al., 2011). These sites act as barriers that define regulatory domains and 
flank transcription factor encoding genes, whose disruption could potentially affect development 
and lead to disease. Consistent with this idea, CTCF was also found enriched in the boundaries of 
the "topological domains" defined by genome-wide maps of tridimensional interactions (see 
section 1.3.4, (Dixon et al., 2012)).  
1.3 Enhancers 
Enhancers were originally described thirty years ago as regulatory elements acting in cis, capable 
of enhancing transcription in an orientation and distance independent manner (Banerji et al., 
1981). Enhancers can regulate gene expression with high spatio-temporal precision and are 
essential for vertebrate development. They serve as platforms for the binding of multiple TFs 
through 6-12 bp binding sites (Istrail and Davidson, 2005). When appropriate occupancy of TFs 
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occurs, transcriptional co-factors and chromatin remodelers are recruited, which then facilitates 
enhancer-promoter interaction, and ultimately activates transcription (Visel et al., 2009b). 
Enhancers are commonly found in intergenic regions or in the introns or exons of the genes they 
regulate or of neighbouring genes (Abbasi et al., 2007; Birnbaum et al., 2012; Ritter et al., 2012; 
Sanyal et al., 2012). Enhancers can also be clustered forming "super-enhancers" with crucial roles 
in regulating cell identity (Hnisz et al., 2013; Loven et al., 2013; Whyte et al., 2013) or spread at 
high frequencies along Genomic Regulatory Blocks (GRB), i.e. syntenic chromosomal segments 
conserved among vertebrates that contain their developmental target genes and unrelated 
"bystander genes" (Kikuta et al., 2007; Akalin et al., 2009). Enhancers can be very far away from 
their target gene: an extreme example is the limb enhancer of Shh, which resides 1 Mb away in 
the fifth intron of Lmbr1 (Lettice et al., 2003), highlighting the difficulty in predicting the distance 
of regulatory interactions and the challenges in assigning a target gene to an annotated enhancer. 
Approximately 80,000 putative enhancers have been identified in the human genome using 
multiple cell lines and a combination of genome-wide methods including DNase I hypersensitivity, 
TF binding and chromatin marks (Bernstein et al., 2012; Thurman et al., 2012). The importance of 
annotating enhancers has been underscored by the fact that enhancers have been shown to 
contribute to disease and that SNPs linked to human disorders by GWAS are enriched in non-
coding functional elements (Bernstein et al., 2012). 
1.3.1 Modularity and redundancy of enhancers 
An important characteristic of enhancers is their modular nature: complex patterns of gene 
expression across tissues result from the combined activity of multiple independent elements, 
each contributing to a sub-pattern of the complete activity (Visel et al., 2007). The apolipoprotein 
E (APOE) gene serves as a good example to explain this property. Human APOE gene is located in 
a gene cluster on chromosome 19 spanning 45 Kb. It encodes for a structural protein that is a 
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major component of mammalian lipoproteins, whose role is the re-distribution of cholesterol 
between the liver and peripheral tissues (Simonet et al., 1991). Tissue specificity is controlled by 
multiple independent cis-regulatory elements: a proximal region is responsible for expression in 
the kidney (Simonet et al., 1991), two enhancers located a few kb downstream the TSS drive 
expression in the liver (Simonet et al., 1993; Allan et al., 1995), one enhancer in an intergenic 
region is active in the skin (Simonet et al., 1991), two distal enhancers specify expression in 
macrophages and adipocytes (Shih et al., 2000), two distal enhancers control the production of 
apoE in astrocytes (Grehan et al., 2001) and a highly conserved enhancer was demonstrated to 
act in the brain (Zheng et al., 2004). 
Certain genes can also be regulated by several "redundant enhancers" driving very similar or 
overlapping expression patterns. This is the case of enhancers regulating Shh expression in 
mouse: while expression in the midbrain and diencephalon areas is controlled by unique 
elements, redundant enhancers regulate Shh expression in hindbrain, ventral spinal cord and 
telencephalic regions (Jeong et al., 2006). Similarly, a study mapping the occupancy of several TFs 
involved in dorso-ventral patterning in Drosophila embryos revealed two enhancers regulating the 
vnd locus, which were several kb away and directed very similar spatio-temporal expression 
patterns (Zeitlinger et al., 2007). This observation was extended to approximately half of the 
genes involved in dorso-ventral patterning in Drosophila, where a distant secondary enhancer 
directing overlapping activities with the primary enhancer was termed "shadow enhancer", in 
contrast to the primary enhancer that was close to the TSS of the target gene (Hong et al., 2008). 
It has been suggested that these apparently "redundant" enhancers confer phenotypic robustness 
against environmental and genetic fluctuations, thus although they might have a minimal 
contribution under laboratory conditions, they are maintained over long periods of time (Frankel 
et al., 2010). 
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Enhancers can also function in synergy. Prominent examples are the LT and M enhancers of Dll, 
which are involved in leg patterning in Drosophila (Estella et al., 2008). Neither element on its 
own can activate Dll expression pattern in the leg discs, but combined in a single construct, they 
recapitulate Dll activity, suggesting a synergistic mode of action (Estella et al., 2008). Similarly, the 
proximal and distal early stripe elements (PESE and DESE) in Drosophila on their own direct an 
incomplete activity but when combined in a composite construct they can fully recapitulate the 
pattern of their target gene slp1 (Prazak et al., 2010). 
1.3.2 Transcription factors and enhancer function 
Transcription factors are sequence specific DNA-binding proteins that bind to CREs by recognising 
small degenerate DNA sequences that will ultimately bring the transcriptional apparatus to the 
TSS of the gene leading to gene-specific transcriptional activation, as reviewed in (Levine, 2010; 
Todeschini et al., 2014). There are around 1,500 TFs in the human genome grouped into families 
that share similar properties (Vaquerizas et al., 2009). TFs have a modular structure typically 
composed of a DNA binding domain linked to one or more activating or repressing modules 
(Triezenberg, 1995; Ptashne and Gann, 1997) that can establish contacts with chromatin 
remodelers, histone modifiers or the basal transcriptional apparatus (Lee and Young, 2000).  
TFs bound to enhancers mediate the recruitment of a wide range of co-activator complexes 
(Kadonaga, 2004; Taatjes et al., 2004). Among these co-regulators there are complexes that serve 
as a "bridge" between the basal transcriptional machinery and the activators and facilitate the 
assembly of the PIC, such as the evolutionarily conserved Mediator (Flanagan et al., 1991; Malik 
and Roeder, 2010). Other co-regulators include chromatin remodeling complexes that mediate 
nucleosome eviction, such as the ATP-dependent SWI-SNI complex (Schwabish and Struhl, 2007); 
and enzymes that catalyze covalent histone modifications, such as p300/CBP or SAGA histone-
acetyl transferases (Figure 1.3). 
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Figure 1.3 Transcriptional initiation mediated by co-factors and PIC 
Activators assembled at distal enhancers (CRE) can recruit co-activator complexes, including 
Mediator, chromatin remodelling complexes (SWI/SNF or ISWI) and histone acetyl transferases 
(HAT). Together they create an accessible chromatin environment for the assembly and binding of 
PIC and PolII to the core promoter elements. Adapted from (Taatjes et al., 2004). 
Several studies using FISH (Fluorescent In Situ Hybridization) techniques and electron microscopy 
have suggested that active PolII and nascent mRNA might be concentrated at nuclear foci termed 
"transcription factories", where many units of PolII are pre-assembled and anchored, as reviewed 
in (Sutherland and Bickmore, 2009). This model suggests it is the loci that move to the factories, 
rather than the other way around (Iborra et al., 1996), which is consistent with the idea that 
active distal foci physically co-localize during transcription (Osborne et al., 2004). 
1.3.2.1 Binding of sequence-specific TFs to enhancers 
Enhancers need to integrate information coming from signalling cascades and TFs present in the 
cellular context and respond accordingly. TFs bind to enhancers by recognising small degenerate 
DNA sequences that usually cluster within them, creating a combinatorial code that results in 
tissue-specific expression patterns (Dynan, 1989), but how is this binding regulated? 
Several studies have demonstrated that TFs bind to hundreds of TFBS in a certain cell at a certain 
time (Walter et al., 1994; Farnham, 2009; Fisher et al., 2012). It has been proposed that the large 
size of eukaryote genomes coupled with the degenerate nature of binding sites leads to 
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widespread non-functional unspecific binding at several hundred binding sites at a time 
(Wunderlich and Mirny, 2009). Functional specificity is then achieved by clustering several binding 
sites, for example within an enhancer. We refer to "additive binding" when the transcriptional 
response of the enhancer is directly correlated with the concentration of the TFs, as 
demonstrated for genes regulated by NF-κB (Giorgetti et al., 2010). When increasing 
concentrations of TFs translates into an on/off binary response we refer to "cooperative binding", 
which is facilitated by protein-protein interactions between TFs bound adjacently or by another TF 
already bound to the DNA (Adams and Workman, 1995; Senger et al., 2004). This type of binding 
is common during development, leading to sharp expression patterns, such as with Bicoid target 
gene regulation in Drosophila (Lebrecht et al., 2005). 
1.3.2.2 Enhancer architecture: models of TF recruitment 
The orientation, order, and spacing of TFBS are often referred to as the enhancer's "grammar" or 
enhancer architecture (Figure 1.4). Depending on the enhancer´s grammar three types of TF 
recruitment can be distinguished. 
The "enhanceosome" model of action assumes that only the perfect formation of a TF complex 
following a rigid grammar would activate transcription of the target gene, generating a binary 
on/off type of response (Merika and Thanos, 2001). It entails the formation of a very stable 
nucleoprotein complex (enhanceosome), where specific binding of multiple TFs to the enhancer 
region through protein-protein interactions, triggers a transcriptional response. One of the best 
examples is the case of the interferon β (INF-β) gene (Thanos and Maniatis, 1995). INF-β is 
normally silenced, but following a viral infection it can be induced at very high levels. This 
induction is caused by an enhancer located between -110 and -45 bp relative to the TSS of the 
gene, which contains, among others, 4 binding sites for the high mobility group protein HMG I(Y). 
Upon binding of HMG I(Y) to the DNA, and through multiple protein-protein interactions requiring 
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a very strict spacing of binding sites, the "enhanceosome" is assembled (Thanos and Maniatis, 
1992; Thanos and Maniatis, 1995; Merika and Thanos, 2001). 
The "billboard" or "TF display" model implies an inherent flexibility of the enhancer where the TFs 
are more flexibly disposed and the bound TFs do not function as a single unit (Arnosti and 
Kulkarni, 2005). This model was exemplified by an experiment performed in vivo in Drosophila 
embryos, in which compact constructs containing different combinations of activators and 
repressors linked to a reporter gene were built. It was shown that the basal transcriptional 
 
 
Figure 1.4 Current models of enhancer action. 
In the enhanceosome model the DNA acts as a scaffold for the binding of several transcription 
factors that operate as a single unit. Disruption of a single binding site renders the enhancer 
inactive. In the billboard model the architecture is more flexible; the enhancer contains multiple 
binding sites that can interact independently with their targets and activate gene expression. The 
TF collective mode of action implies that subset of TFs can act in different enhancers, occupying 
each in a different manner. Adapted from (Spitz and Furlong, 2012). 
machinery "samples" activating and repressing binding sites within the enhancer, which would 
ultimately dictate the transcriptional output (Kulkarni and Arnosti, 2003). This model allows for a 
more flexible order of occupancy of TFBS, where TF can bind cooperatively or additively (Spitz and 
Furlong, 2012). 
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Contrary to these models, the "TF collective" model, described for a set of 5 cardiac TFs in 
Drosophila (Junion et al., 2012), proposes that certain enhancers function by recruiting several 
transcription factors as a collective unit in the absence of grammar, to the extent that not all the 
TFBS need to be present. This model proposes that some TFs bind with high-affinity to their sites 
while the others are recruited through protein-protein interactions or through co-factors such as 
CBP/p300 (Junion et al., 2012). 
1.3.2.3 Pioneer factors during development 
Chromatin environment also determines the efficiency of binding of TFs to their cognate TFBS. 
While most TFs cannot access their binding sites in compacted chromatin, "pioneer" factors are a 
special class that can access TFBS at developmental enhancers by actively mediating chromatin 
decompaction or passively acting as a landmark to recruit additional TFs (Zaret and Carroll, 2011). 
Members of the Forkhead Box (Fox) and GATA families of TFs are considered "pioneer" factors 
since they are thought to scan the chromatin fibre and bind to regulatory elements before there is 
active gene expression or lineage commitment (Bossard and Zaret, 1998; Zaret, 1999). 
The albumin gene enhancer Alb1 in mouse liver has been extensively studied in this regard. In 
non-liver tissues where the albumin gene is silent, the enhancer is not occupied by TFs and the 
chromatin is highly compact with nucleosomes randomly positioned over the enhancer 
(McPherson et al., 1993). However, in liver precursor cells, binding of FOXA1 and GATA4 mediates 
chromatin decompaction and creates a new region of DNase hypersensitivity (McPherson et al., 
1993; Cirillo et al., 2002). This renders the enhancer active and competent for further binding, 
which is essential to trigger liver developmental program (Lee et al., 2005). FOX factors have been 
shown to be more efficient than GATA factors in binding condensed chromatin (Cirillo et al., 
2002). It is thought that the structural similarity between their "winged-helix" DNA binding 
domain and the globular domain of linker histone H1 might explain this ability, since it allows 
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them to bind simultaneously to the minor and major groove of DNA while still being able to 
recruit TFs on the other side (Clark et al., 1993; Zaret et al., 2010). 
1.3.3 Enhancer-promoter specificity 
Enhancers can be very far away from their target promoters, as reviewed in (Krivega and Dean, 
2012), and scattered in large syntenic chromosomal regions containing "bystander genes" that 
they are not regulating (Kikuta et al., 2007), however, enhancers appear to selectively interact 
with core promoters. 
Early observations of lack of enhancer-promoter specificity emerged from studies in Drosophila, 
where enhancers could not interact with heterologous promoters of non-cognate genes (Li and 
Noll, 1994; Merli et al., 1996). In the case of neighbouring gsb and gsbn genes that are divergently 
transcribed, enhancers located in a common upstream region could not activate non-target genes 
because of an incompatible interaction (Li and Noll, 1994) that was unrelated to the presence of 
insulator elements (Merli et al., 1996). It was soon demonstrated that enhancer-promoter-
specificity was greatly determined by the presence of different CPEs (Ogbourne and Antalis, 1998; 
Butler and Kadonaga, 2001). Ohtsuki and colleagues used transgenesis assays in Drosophila to test 
the effect of TATA-box CPE in heterologous promoters and its capacity to interact with various 
developmental enhancers. They showed that AE1 and IAB5 enhancers preferentially interact with 
a TATA-containing promoter compared with a TATA-less one, while the enhancer NEE does not 
discriminate(Ohtsuki et al., 1998). Furthermore, Butler and Kadonaga, used transgenic lines 
containing DPE or TATA promoters in the same chromosomal location to demonstrate in vivo that 
transcriptional enhancers are specific for promoters and that the specificity depends, at least 
partly, on CPE composition (Butler and Kadonaga, 2001). Similarly, Caudal TF was shown to 
activate transcription in Hox genes with a higher preference for DPE-containing CREs, relative to 
TATA-box (Juven-Gershon et al., 2008).  
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In zebrafish, a high-throughput analysis of 202 enhancer-promoter combinations coupled with 
automated imaging software that could annotate tissue-specific reporter activity showed that 
promoters interact with enhancers with variable degrees of efficiency (Gehrig et al., 2009). This 
analysis identified a subset of heterologous promoters (krt4, hsp70 and eng2b) with a broad 
ability to interact with enhancers, which provides a useful resource for transgenesis studies in 
zebrafish and underlines the importance of enhancer-promoter specificity. 
1.3.4 Enhancer-promoter interactions 
Packaging DNA inside the nucleus imposes tremendous organisational challenges. Furthermore, 
given the evidence supporting long-range promoter-enhancer interactions, it is expected that 
tridimensional nuclear architecture is crucial for the regulation of gene expression in the cell. The 
mechanism by which enhancers establish a selective interaction with their target promoters is still 
under debate. The tracking or scanning theory suggests that activators bound to enhancers can 
move along the chromatin fibre until they find their target promoter (Blackwood and Kadonaga, 
1998). The looping theory postulates a direct interaction between enhancers and promoters 
through the looping of the DNA strand (Rippe et al., 1995). Specific protein-protein interactions 
between the activators that bind the enhancer and the transcription factors binding the promoter 
ensure the activation of the correct gene. These interactions have been shown experimentally 
using chromosome conformation capture technologies (3C) and its derivatives 4C (circularized 3C) 
and 5C (carbon-copy 3C) (reviewed in (de Wit and de Laat, 2012), Figure 1.5). 
3C-derived technologies use fixation with formaldehyde, so that all potentially distant physical 
contacts between DNA and proteins are cross-linked. While 3C Technology quantifies the 
frequency of interactions between 2 loci (Dekker et al., 2002), Chromosome conformation 
Capture-on-Chip or 4C technology is known as the "one versus all" strategy, since this method 
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screens the genome for all the sequences that interact with a selected genomic site (Simonis et 
al., 2006). 
Application of this methodology has shown how the β-globin locus interacts with a completely 
different set of genomic sites in a tissue where it is active (foetal liver) versus a tissue where it is 
inactive (brain), and how interactions are preferentially established with transcriptionally active 
loci (Simonis et al., 2006). On the contrary, when examining a housekeeping gene in the same 
tissues, the contacts are very similar, suggesting a differential nuclear architecture between active 
and inactive chromatin (de Laat and Duboule, 2013). 
An interesting question arising from these studies is how local and long-range interactions are 
established and whether transcription itself could help to re-shape the genome. It appears that in 
mammals, the DNA contacts established by the β-globin locus are not changed after drug-induced 
transcription inhibition (Palstra et al., 2008), suggesting that transcription is unnecessary for the 
formation of enhancer-promoter loops. However, loops are necessary for transcription, as 
demonstrated by experiments with engineered enhancer-promoter loops in the β-globin locus 
(Deng et al., 2012).  
5C Technology or Chromosome Conformation Capture Carbon Copy is a 3C-based method that 
allows to study interactions occurring between multiple loci, that is why it is also known as the 
"many to many "strategy (de Wit and de Laat, 2012). It requires the creation of a 3C library, to 
which oligonucleotides are ligated, and multiplex amplification; followed by analysis using 
microarrays or quantitative PCR (Dostie et al., 2006). The main limitation of this technique is the 
high number of oligos that would be needed to evaluate the entire genome (Dostie and Bickmore, 
2012). Hi-C technology overcomes this limitation, since it measures three-dimensional 
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interactions of whole genomes ("all to all" strategy), at a resolution of 1 Mb in mammalian 
systems (Lieberman-Aiden et al., 2009) 
 
 
Figure 1.5 Overview of 3C-derived methodologies. 
Top panel indicates processes that are common for all technologies (crosslinking of chromatin, 
digestion, ligation and reverse crosslinking); while the vertical panels show the specific steps for 
each technique. Reproduced from (Noordermeer and Duboule, 2013).  
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The analysis of the human and mouse genomes using Hi-C showed that it is pervasively 
segmented in megabase-size portions named "topological domains" (Dixon et al., 2012). Such 
organization seems to be a property of the genomes, since it is very well conserved between 
human and mouse, and stable between cell types, although the regions within each domain can 
be dynamic, potentially representing cell-type specific regulatory events. High levels of 
transcription might be involved in the creation of topological boundaries, since they are enriched 
in CTCF insulator, housekeeping genes and TSS, while enhancer or chromatin marks (H3K4me1 or 
H3K9me3) were depleted. (Dixon et al., 2012). A study focusing on X-chromosome inactivation in 
Drosophila embryos also showed a similar partitioning of the genome into discrete units at the 
sub-megabase scale, which they termed "Topologically Associated Domains" or TADs, the 
disruption of which results in long-range misregulation (Nora et al., 2012). 
ChIA-PET (or chromatin interaction analysis with paired-end tag sequencing) has been introduced 
as a technique that combines chromatin immunoprecipitation (ChIP) with 3C analysis, enabling 
the unbiased study of genome-wide long-range chromatin interactions bound to a certain protein 
or histone modification mark (Fullwood et al., 2009; Li et al., 2010a). The main limitation is that 
ChIA-PET can only analyse contacts bound by the selected factor. 
Overall, the chromosome capture technologies indicate that a physical contact is not equivalent 
to a functional interaction. It will be interesting to couple 3C-based technologies with high-
resolution single-cell live imaging, to measure cell-to-cell variations and investigate whether there 
is a connection between function and structure. 
1.4 Genome-wide strategies for enhancer prediction 
Contrary to promoters, which can be located by sequencing the 5’ end of its mRNA, the lack of 
distinguishing features in enhancers makes them inherently difficult to identify. Traditionally, non-
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coding regulatory regions were identified using arduous serial deletion assays (promoter bashing), 
whereby the function of the resulting fragments was tested in reporter gene assays (Arnosti et al., 
1996; Muller et al., 1999; Heckman et al., 2003). In the post-genomic era, genome-wide 
computational and experimental strategies for enhancer prediction have used various analyses of 
the DNA sequence and chromatin structure, as reviewed in (Wang et al., 2013). International 
Research Consortia including the FANTOM and ENCODE Projects set out to assign a function to all 
the elements in the mouse and human genomes, respectively. In parallel, the modENCODE 
project's aim was to annotate the genomes of two model organisms: Drosophila melanogaster 
and Caenorhabditis elegans. The release of the ENCODE data, with a pilot phase covering 1% of 
the genome (Birney et al., 2007) and a final report consisting of more than 40 papers in 2012, has 
unloaded an impressive amount of data on distinct functional elements and shed light on 
strategies for CRE prediction. 
1.4.1 Comparative genomics as a tool for the identification of non-coding 
functional elements 
The comparison of sequences across different species with the aim of identifying conserved 
elements that could be potential regulatory regions has been termed phylogenetic footprinting 
(Zhang and Gerstein, 2003). Cross-species sequence comparison methods rely on the principle 
that functionally relevant sequences are under purifying selection, i.e. conserved across long 
evolutionary periods, whereas non-functional regions evolve neutrally and eventually diverge 
beyond recognition (Ahituv et al., 2004). Interestingly non-coding conserved elements tend to 
cluster around genes coding for transcription factors involved in embryonic developmental 
processes shared by vertebrates, suggesting that they are CREs controlling gene expression during 
development (Sandelin et al., 2004; Woolfe et al., 2005)  
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Selecting the species to be used in comparative genomics usually represents a compromise. 
Comparing closely related species often obscures the identification of functional elements, due to 
the high degree of similarities between the two genomes. On the other hand, comparing distantly 
related species (e.g. human with a non-primate mammal or with a non-mammal vertebrate) 
might impair the discovery of lineage-specific elements; or elements might not be readily 
identifiable because they will have diverged too much (Boffelli et al., 2004; Nobrega and 
Pennacchio, 2004). In order to overcome these limitations and balance evolutionary distances, 
multiple species comparisons have been used to identify functional non-coding regions (Dubchak 
et al., 2000; Frazer et al., 2001; Gottgens et al., 2002; Nobrega et al., 2003; Santagati et al., 2003; 
Dermitzakis et al., 2004). 
Identification of human enhancers has been performed based solely on human-mouse sequence 
comparisons (Hardison et al., 1997; Wasserman et al., 2000; Dermitzakis et al., 2002; Patwardhan 
et al., 2012). Even though alignment of the human and mouse genomes, which diverged around 
75 million years ago, revealed a similarity of almost 40% at the nucleotide level (Schwartz et al., 
2003), their divergence is sufficient to identify functional elements.  
Distant species comparisons such as human-fish comparisons have also proven to be effective 
tools. Given the extensive divergence time between fish and human (around 450 million years 
ago, (Kumar and Hedges, 1998)) and inherent biological differences, it is possible that conserved 
sequences will represent CREs that are essential for common developmental processes and would 
have the most dramatic biological effect if disrupted. Nobel laureate Sydney Brenner proposed in 
1993 that the Tetraodontoid fish Fugu rubripes (pufferfish), with a compact genome of 400 Mb, 
which is 7.5 times smaller than the human genome, would represent an ideal model for 
deciphering the human genome, as it has all the specialized functions of higher vertebrates 
(Brenner et al., 1993). Not only have pufferfish-human comparisons allowed the identification of 
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around 1000 novel human genes (Aparicio et al., 2002) but also a pioneering study carried out 
years before the human genome sequence was available showed how these comparisons could 
be used to unveil non-coding functional elements (Marshall et al., 1994). Multiple studies have 
efficiently identified functional human enhancers using human-fish comparisons as the only filter 
(Miles et al., 1998; Bagheri-Fam et al., 2001; Nobrega et al., 2003; Woolfe et al., 2005; Allende et 
al., 2006; Pennacchio et al., 2006). Based on some of these reports, an arbitrary threshold was 
established for the identification of human-fish conserved elements, requiring 70% of 
conservation over 100 bp (Ahituv et al., 2004).  
Another approach to the identification of functional elements is to increase the stringency of 
conservation alignments between two closely related species (Bejerano et al., 2004; Visel et al., 
2008; McBride et al., 2011). Bejerano et al identified ultraconserved elements (100% sequence 
identity for at least 200bp) between human, mouse and rat, and found 481 conserved regions 
located in exons of genes involved in RNA processing, or in intergenic regions and introns of genes 
implicated in transcriptional regulation and embryonic development. Interestingly, some of these 
segments were also conserved in fish (Bejerano et al., 2004). This and other studies validate the 
use of both ancient human-fish conservation and human-mouse-rat ultraconservation parameters 
for the identification of functional non-coding elements that behave as enhancers in vivo.  
While these studies assume that a high level of sequence conservation is indicative of 
functionality there is evidence that some non-conserved fragments can maintain their regulatory 
function and direct transgene specific expression in several species (Fisher et al., 2006a; Hare et 
al., 2008; McGaughey et al., 2009; Swanson et al., 2010; Chatterjee et al., 2011). In zebrafish 
Fisher and colleagues tested discrete regulatory sequences of the human RET locus, a gene 
encoding a receptor tyrosine kinase, and their data suggested that functional conservation in fish 
was possible without sequence similarity (Fisher et al., 2006a). There are also studies showing 
24 
 
that TFBSs in cis-regulatory elements may be rapidly gained or lost during evolution. Schmidt et al 
showed that the majority of TF binding events in adult livers of 5 vertebrates are species-specific, 
while ultraconserved events are very rare (Schmidt et al., 2010). Recent reports have also 
proposed that the level of conservation may vary depending on the tissue type. Blow and 
colleagues demonstrated that heart enhancers are three times less well conserved than other 
tissue-specific enhancers in vertebrate evolution, such as forebrain enhancers (Blow et al., 2010). 
This suggests that the use of sequence conservation for enhancer identification should be 
complemented with other strategies. 
1.4.2 Open chromatin sites as indicators of CRE regions 
Packaging of histones into DNA normally prevents the binding of non-histone proteins (Luger et 
al., 1997). For stable binding the displacement or disruption of nucleosomes is necessary. Thus, 
open chromatin sites or nucleosome-depleted regions are good indicators of the presence of 
concentrated TFs and chromatin remodelling complexes, and therefore of regulatory elements 
(Workman, 2006).  
Disruption of chromatin structure can be experimentally identified by hypersensitivity to DNase I 
digestion (Galas and Schmitz, 1978; Wu, 1980). DNase I footprinting is a protection assay where 
cleavage of double-stranded DNA is inhibited by the specific binding of a ligand. Protected 
fragments will be indicated by a "gap" or footprint on a gel where the digestion products are 
resolved (Fox, 1997; Hampshire et al., 2007). Dnase I hypersensitive assays coupled to next-
generation sequencing have been used to predict CREs in cell lines (Mito et al., 2007; Li et al., 
2011; Song et al., 2011). Identification of DNase I hypersensitive Sites (DHS) in 6 human cell lines 
encompassing 1% of the human genome revealed that 22% of DHSs are shared among all cell 
types and mostly overlap with promoters or insulator elements, whereas cell type-specific DHSs 
correlate with known enhancer elements (Xi et al., 2007). The second phase of the ENCODE 
Project has mapped 2.89 million unique DNase I hypersensitive sites in 125 cell types by DNase I-
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Seq, most of which are distal to TSS, with an average of 205,109 sites per cell type (Bernstein et 
al., 2012; Thurman et al., 2012). Although DNase I analyses have so far only been applied to cell 
lines, the data can be used to identify functional developmental enhancers in embryos, as 
demonstrated by the identification of novel Pax6 enhancers in mouse that lacked evolutionary 
conservation (Kleinjan et al., 2001; McBride et al., 2011). 
A more recent technique called FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) 
has also been successfully used to map open chromatin sites (Giresi et al., 2007). FAIRE detects 
regions depleted of nucleosomes that strongly correlate with DNase I hypersensitive sites, 
allowing an effective identification of regulatory regions (Gaulton et al., 2010; Song et al., 2011). 
Nevertheless, the open chromatin sites detected by both techniques seem to differ slightly. While 
DNase I enzyme captures chromatin structures that are close to TSS, FAIRE tends to detect distal 
CREs that DNase I cannot cut (Song et al., 2011). 
1.4.3 Combinatorial binding of transcription factors define enhancers 
Because combinatorial binding of TFs is required for enhancer function, effort has been devoted 
to the computational and experimental prediction and mapping of TF binding sites. 
Computationally, motif clustering of TFBS has been used to predict the location of CREs, as 
reviewed in (Aerts, 2012). Experimentally, chromatin immunoprecipitation (ChIP) has been the 
primary method used to identify protein-DNA interactions, as reviewed in (Furey, 2012). It has 
been demonstrated that combinatorial binding predicts the location of enhancers (Hallikas et al., 
2006; Zinzen et al., 2009; He et al., 2011; Stefflova et al., 2013). Zinzen and colleagues profiled the 
genome-wide occupancy of 5 TFs involved in Drosophila mesoderm differentiation at multiple 
developmental times using ChIP-Chip, and used the observed profiles to computationally predict 
spatio-temporal patterns, which were very accurately matched in vivo in transgenic embryos 
(Zinzen et al., 2009). However, unlike approaches such as DNase I hypersensitivity, ChIP requires 
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prior knowledge about the factors to be tested, and each factor needs to be evaluated separately. 
Furthermore, ChIP-grade antibodies are not always available, hindering the systematic 
identification of enhancers. Currently, therefore, information derived from TFBS is coupled with 
other approaches such as sequence conservation, binding of general transcriptional co-factors or/ 
and histone modification marks, in order to predict more accurately transcriptional enhancers. 
1.4.4 Binding of general transcriptional co-factors: CBP/p300 mark enhancers 
Binding of general transcriptional co-factors has also been shown to help locate developmental 
enhancers (Visel et al., 2009a; Blow et al., 2010; Rada-Iglesias et al., 2011; Xu et al., 2011; May et 
al., 2012; Rada-Iglesias et al., 2012). CBP and p300 were originally identified as proteins binding 
cAMP-responsive transcription factor CREB (Chrivia et al., 1993) or the adenovirus E1A 
oncoprotein (Eckner et al., 1994), respectively. Both proteins exhibit adaptor properties and have 
high homology at the sequence level, which is why they are considered functional homologs and 
usually referred to as CBP/p300 (Eckner et al., 1996). CBP and p300 also contains intrinsic HAT 
activity (Bannister and Kouzarides, 1996; Ogryzko et al., 1996) mostly for H3K27 residue (Tie et al., 
2009). 
Heintzman and colleagues demonstrated that distal p300 binding sites displayed many enhancer-
like features, such as overlap with DHSs and contained evolutionarily conserved motifs 
(Heintzman et al., 2007). Subsequently, it was demonstrated in vivo that mapping of p300 binding 
sites by ChIP could be used to accurately predict active enhancers in numerous cell lines, in mouse 
embryonic forebrain, midbrain and limb tissues (Visel et al., 2009a), in flies (Negre et al., 2011), 
and human embryonic stem cells (hESC) (Rada-Iglesias et al., 2011; Rada-Iglesias et al., 2012; 
Rada-Iglesias et al., 2013) among others. Nevertheless, there are subsets of enhancers that lack 
p300 binding (Heintzman et al., 2007; Heintzman et al., 2009; He et al., 2011), so mapping of p300 
27 
 
is usually complemented with other strategies such as the profiling of tissue-specific TFs or 
histone modification marks. 
1.4.5 Histone modification marks as predictors of enhancers 
Histones serve a role beyond packaging DNA (Li et al., 2007). Initial evidence for the existence of a 
complex structure between histones and the double helix of DNA came from electron microscopy 
studies, X-ray crystallographic observations, and nucleosome digestions in the 1970s, as reviewed 
in (Kornberg, 1977). The nucleosome core contains two copies of H2A, H2B, H3 and H4 histone 
proteins assembled into an octamer with 145-147 bp of DNA wrapped around it. These core 
particles are further stabilised by linker histone H1 and linker DNA (Luger et al., 1997). 
Nucleosome arrays are folded like "beads on a string" into a 30nm diameter fibre (Finch and Klug, 
1976; Widom and Klug, 1985; Graziano et al., 1994). This chromatin fibre is further condensed in 
the form of metaphase chromosomes, where DNA is compacted 10,000 fold (Belmont et al., 1987; 
Woodcock and Ghosh, 2010). Nucleosomes are highly dynamic, both in terms of positioning and 
in terms of biochemical modifications. The NH2 terminus of the histones (or histone tails) 
protrude from the centre of the nucleosome core and are amenable to a wide-array of post-
translational modifications such as phosphorylation, methylation, acetylation, ubiquitilation etc., 
as reviewed in (Kouzarides, 2007). 
Recently, some modifications have been associated with different states of transcription, or have 
even been used to predict the location of cis-regulatory modules such as promoters or enhancers. 
Whether the presence of these marks is a cause or a consequence of enhancer function or TF 
occupancy remains unknown (Spitz and Furlong, 2012). The first indication that enhancers could 
be marked by histone modification marks came from the pilot ENCODE project and Bing Ren's lab. 
Ren and colleagues succeeded in identifying chromatin features that could distinguish promoters 
from enhancers (Heintzman et al., 2007). They showed that active promoters are enriched in tri-
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methylation of histone H3 lysine 4 (H3K4me3), lack mono-methylation of H3 lysine 4 (H3K4me1) 
and are marked by a nucleosome-free region near the TSS. In contrast, enhancers bound by the 
co-activator p300 are enriched in H3K4me1, lack H3K4me3, and usually lie on DNase I 
hypersensitivity sites and in evolutionary conserved regions. Furthermore, enhancers show cell-
type specific histone modifications that correlate strongly with gene expression, in contrast to the 
invariant pattern of chromatin state in promoters (Heintzman et al., 2009). These initial 
observations in cell lines were quickly confirmed in several genome-wide studies using different 
embryo model systems such as Drosophila (Negre et al., 2011), zebrafish (Aday et al., 2011) and 
mouse (Visel et al., 2009a). In Drosophila H3K9ac, H3K27ac and H3K4me1 were also found in 
promoters and H3K4me1 plus CBP-p300 was a common signature of enhancers (Negre et al., 
2011). In zebrafish it was also demonstrated that the 5' end of expressed genes were enriched in 
H3K4me3 (Wardle et al., 2006) and H3K4me1 (Aday et al., 2011) and that this association 
correlated well with the level of gene expression. It was also shown that H3K4me3 and H3K27ac 
modification marks were present in developmental genes, at the onset of zygotic transcription 
irrespective of their transcriptional activation (Vastenhouw et al., 2010), and that enhancers were 
enriched in H3K4me1 (Aday et al., 2011).  
Furthermore, it was shown that developmental enhancers in mouse and human ESC could exist in 
two different states: poised and active (Figure 1.6), which may be distinguished by the presence 
of H3K27ac mark (Creyghton et al., 2010; Rada-Iglesias et al., 2011). In both states, enhancer 
regions are marked by H3K4me1, bound by the co-activator p300, display low nucleosomal 
density and are depleted of H3K4me3 modification. In hESCs an association was found between 
“active enhancers” and H3K27ac enrichment, absence of H3K27me3 and a high level of 
transcription; while "poised enhancers” are enriched in H3K27me3, lack H3K27ac and are poorly 
expressed. Upon hESC differentiation poised enhancers acquire H3K27ac and can recruit RNA 
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PolII. More importantly, when tested in zebrafish, these elements can drive cell and stage specific 
expression, and function as developmental enhancers (Rada-Iglesias et al., 2011). This 
classification could explain why some previous studies had found H3K4me1 associated with non-
active enhancers (Heintzman et al., 2009; Rada-Iglesias et al., 2011). In mESC however, poised 
enhancers do not display any modification in the K27 residue of H3 (Creyghton et al., 2010) and 
the repressive mark H3K9me3 may also be distinctive of this category (Zentner et al., 2011). 
 
 
Figure 1.6 Chromatin signatures at active and poised developmental enhancers in hESCs. 
Both enhancers lie on DNase I hypersensitive sites, are bound by co-activator p300 and several 
transcription factors (TF1 and TF2), and are marked by H3K4me1. Active enhancers are also 
bound by PolII, which produces eRNA bidirectionally. Poised enhancers recruit Polycomb 
Repressive Complex 2 (PRC2) and are marked by H3K27me3 repressive mark. Bottom panels are 
Genome Browser screenshots of POU5F1/OCT4 distal and proximal active enhancers (DE and PE 
respectively), and EOMES poised enhancer, and their enrichment in p300, SMAD3, NANOG and 
OCT4 binding as well as enrichment in several histone modifications marks (H3K4me1, H3K27ac, 
H3K27me3). Reproduced from (Calo and Wysocka, 2013). 
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There are additional histone modification marks that have been associated with enhancers. In 
mESC, active enhancers were shown to produce RNA transcripts, so phosphorylation of Ser2-5 of 
PolII and H3K36me3, which are associated with transcript elongation (Kouzarides, 2007; 
Kolasinska-Zwierz et al., 2009), can be considered predictive marks (Zentner et al., 2011). In 
addition to that, H4K16ac modification has been shown to overlap with a subset of active 
enhancers in mESC that are not bound by p300 or enriched in H3K27ac mark, suggesting that it 
may be a novel mark for p300-independent regulatory regions (Taylor et al., 2013). 
Recently a computational method has been developed to predict enhancers on a genome-wide 
scale based on histone modification marks (Rajagopal et al., 2013). By integrating information 
from 24 histone modification profiles, DNase I hypersensitive sites and p300 binding sites in mESC 
and lung fibroblasts, the new algorithm can measure the relative importance of each modification 
mark in defining an enhancer and demonstrated that H3K4me1, H3K4me2 and H3K4me3 are the 
minimal marks required for robust enhancer prediction across cell lines and replicates, leading to 
a more accurate prediction of enhancers in different tissues. 
1.4.6 H2AZ histone variant correlates with nucleosome-free regions 
H2AZ is a highly conserved histone variant that diverges from the canonical H2A histone in terms 
of length and sequence of the C-terminal domain (Kamakaka and Biggins, 2005). In yeast, H2AZ 
prevents the spread of heterochromatin and is preferentially enriched in promoter regions, 
specifically on the nucleosomes that are displaced during transcriptional initiation (Raisner et al., 
2005; Zhang et al., 2005). A similar pattern has been found in humans, where H2AZ is found 
upstream and downstream of the TSS and also in nucleosome-free regions of enhancers and 
insulators (Barski et al., 2007). It has been suggested that nucleosomes containing the H2AZ 
histone variant are less stable and more easily displaced (Placek et al., 2005; Zhang et al., 2005). 
Consistent with this idea, the H3.3/H2AZ histone combination is preferentially located at 
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nucleosome-free regions and correlates well with cis-regulatory elements including promoters, 
silencers and enhancers (Jin et al., 2009). Thus, H2AZ has been successfully used as a marker for 
open chromatin in order to identify enhancers (Pham et al., 2012). 
1.4.7 Transcription from enhancers is pervasive and might aid in enhancer detection 
Even though most recent approaches to identify regulatory regions have been based on the 
analysis of chromatin marks, complementary strategies have been implemented. Although 
initially surprising, transcription from enhancers is now well documented across cell types and 
seems to be an additional feature of this type of CREs (Kim et al., 2010; Melgar et al., 2011; Wang 
et al., 2011a; Djebali et al., 2012). The transcripts produced by enhancers have been named eRNA 
(enhancer RNAs) and unlike protein-coding transcripts they are not marked by H3K4me3 and 
H3K36me3 along their length (Mikkelsen et al., 2007; De Santa et al., 2010). The exploitation of 
bidirectional transcription from enhancers as a prediction tool will be discussed in more depth in 
Chapter 5. 
Overall, in terms of predictive approaches, the integration of multiple layers of genomic 
information, such as sequence conservation, enrichment of key epigenetic marks, general co-
factor and transcription factors binding events, and possibly bidirectional transcription, will 
potentially yield the most comprehensive method for identifying active developmental enhancers. 
1.5 Cis-regulation and disease 
Over the past decades, thousands of mutations causing monogenic disorders have been identified 
in coding regions. By contrast, the number of disease-causing mutations in distal CREs and other 
non-coding CREs has been minimal, mainly because of the difficulties in identifying regulatory 
elements (Visel et al., 2009b). Nevertheless, variations in any component of the transcriptional 
machinery including transcription factors, co-factors, chromatin regulators or in regulatory 
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regions and non-coding RNAs are often associated with human disorders and can increase 
susceptibility to multifactorial diseases such as cancer, autoimmune diseases, diabetes, 
schizophrenia or obesity among others, as reviewed in (Lee and Young, 2013).  
Diseases can be caused by the removal or repositioning of distal regulatory elements leading to 
altered gene expression (Kleinjan and Lettice, 2008). Classic examples include some cases of 
thalassemias, where deletions or chromosome rearrangements reposition enhancers needed for 
normal β-globin gene expression (Kioussis et al., 1983; Semenza et al., 1984). In these cases the 
coding region of the gene was not disrupted but its transcriptional regulation was. Since their 
discovery, the term "position effect" is used to refer to changes in the level of gene expression 
when the location of the regulatory regions is changed in the chromosome, usually by 
translocation (Kleinjan and Lettice, 2008). 
There are also examples of human diseases caused by single-nucleotide changes in cis-regulatory 
regions. Preaxial polydactyly is among the most commonly observed human limb malformations 
and includes a broad range of digit abnormalities in hands and feet. Studies in transgenic mice 
have shown that Preaxial polydactyly is caused by mutations in the highly conserved limb-specific 
enhancer ZRS of Sonic Hedgehog (Shh), which lies 1 Mb away from the target gene within the 
intron of the neighbouring gene Lmbr1 (Lettice et al., 2002; Lettice et al., 2003). These single-
point mutations cause ectopic Shh expression and subsequently supernumerary digits and were 
also found in four families affected of PDD (Lettice et al., 2003; Lettice et al., 2008). Because there 
are several single point changes found throughout the length of ZRS, it is unlikely that PDD arises 
from the disruption of a single TFBS (Kleinjan and Lettice, 2008). 
Not only mutations in enhancers, but also mutations in proteins regulating enhancer function can 
lead to disease, as reviewed in (Smith and Shilatifard, 2014). For example, mutations in CBP/p300 
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HAT can lead to Rubinstein-Taybe syndrome (Roelfsema et al., 2005). Missense and non-sense 
mutations in MLL complexes, histone methyl transferases responsible for catalysing H3K4me1 in 
enhancers (Hu et al., 2013), have been associated with Kabuki syndrome (Ng et al., 2010). Also, 
mutations in pioneer transcription factors can lead to anemia or cancer (Zheng and Blobel, 2010). 
Common variants located in CREs can increase the susceptibility to certain multifactorial diseases. 
Hirschsprung disease (HSCR), or congenital aganglionosis with megacolon, is a multigenic disease 
in which RET proto-oncogen is the main gene implicated (Emison et al., 2005). A highly conserved 
region in the first intron of RET was found to be an enhancer by in vitro and in vivo transgenesis 
assays (Grice et al., 2005). This enhancer contains 3 SNPs that are in linkage disequilibrium (LD) 
with HSCR, one of which can explain a 10 to 20-fold greater susceptibility to the disease (Emison 
et al., 2005). Fuelled by the power of Genome-Wide Association Studies (GWAS) a growing 
number of single nucleotide polymorphisms (SNPs) located in non-coding regions have been 
linked to human diseases (Bernstein et al., 2012; Maurano et al., 2012), such as T2D (Dupuis et al., 
2010; Stitzel et al., 2010). Interestingly, so far validation of disease-associated enhancers has not 
been quantified in vivo, and in vitro analyses have revealed very subtle effects (Gaulton et al., 
2010; Stitzel et al., 2010; Rada-Iglesias et al., 2013). 
1.6 Zebrafish as a model organism 
Zebrafish (Danio rerio) is a tropical, freshwater bony fish of the Cyprinidae family. There are 
around 44 species of Danio distributed throughout East and South-East Asia, with the highest 
diversity in North-East India, Bangladesh and Myanmar, reviewed in (Spence et al., 2008). They 
are distinguished by their small size (usually < 120 mm) in adulthood and their distinctive pattern 
of alternative dark and white horizontal stripes.  
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Within the class of bony fishes or Teleostei there are three other fish model organisms worth 
mentioning. Medaka (Oryzias latipes), which has also been used as a model for developmental 
genetics and to functionally validate regulatory elements (Wittbrodt et al., 2002) and two 
pufferfish species, the Japanese pufferfish Takifugu rubripes (also known as Fugu rubripes) and 
the green spotted pufferfish or Tetraodon nigroviridis. The genome sequence of these three 
species is publicly available (Aparicio et al., 2002; Jaillon et al., 2004; Kasahara et al., 2007). The 
pufferfish species own the most compact genome known of all vertebrates, while maintaining the 
specialized functions of higher vertebrates. Therefore, pufferfish was proposed as a valuable 
model in the identification of conserved cis-regulatory elements through comparative genomic 
studies (Brenner et al., 1993; Aparicio et al., 2002). However, Fugu rubripes cannot be bred or 
kept in laboratory conditions, and the breeding and biology of Tetraodon nigroviridis is mostly 
unknown, hindering their use as a model system beyond comparative genomics (Muller et al., 
2002). The inability to carry out functional work with pufferfish has further contributed to widen 
the use of zebrafish, and Medaka to a lesser extent, as a developmental model among the 
scientific community. 
1.6.1 General characteristics 
Multiple features have resulted in zebrafish becoming a widely used vertebrate model system. 
Adult zebrafish can breed all year round in laboratory conditions and are easy and relatively cheap 
to maintain in the laboratory. A single female can spawn clutches of several hundreds of eggs and 
generation time is short, which makes it a high-throughput model when compared to rodents. 
Zebrafish present the additional advantage of embryo transparency, which allows for observation 
of internal organs and imaging using fluorescent marker proteins. Moreover zebrafish fertilization 
is external, which eases manipulation of the embryos. They exhibit a rapid development, with 
primary organ systems present between 36 hpf and 72 hpf, and all embryonic stages have been 
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described in detail and can be easily identified under the dissecting microscope (Kimmel et al., 
1995). 
1.6.2 Resources and tools available to the zebrafish community 
Zebrafish is increasingly being used to model human diseases, which requires a high quality 
sequenced genome. The zebrafish reference genome sequence was recently published (Howe et 
al., 2013b). However, the initial shotgun draft has been available and accessible to users since 
2002. There are 26,206 genes annotated in the zebrafish genome, 69% of which have an 
orthologous in human. Reciprocally 71.4% of human genes have an orthologous zebrafish gene 
(Howe et al., 2013b). Compared to humans and mice, the higher number of genes displayed by 
zebrafish is most likely a result of an ancient whole-genome duplication process specific to 
teleosts (Meyer and Schartl, 1999). 
In addition to the availability of the reference genome sequence, all mutant and transgenic lines 
available, morpholinos, antibodies, anatomical structures, phenotypes, publications and 
expression data are systematically curated and incorporated onto ZFIN website (Zebrafish Model 
Organism Database, http://zfin.org), which is a highly valuable resource for the zebrafish research 
community (Howe et al., 2013a). 
Zebrafish has become one of the most prominent vertebrate model systems used to study 
development, disease and regulatory mechanisms. The first studies using Danio rerio as a model 
organism for genetics began in 1981 (Streisinger et al., 1981). Since then, a large number of tools 
for forward and reverse genetics have been developed. Forward genetic approaches seek to 
identify genes and pathways involved in different developmental processes through the screening 
of populations of individuals displaying phenotypes induced by random mutations in their 
genome. Classical genetic screens have been successfully carried out using chemical mutagens 
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such as N-ethyl-N-nitrosourea (Driever et al., 1996) or retroviral insertions (Amsterdam et al., 
1999). All these approaches have identified thousands of mutations in genes that affect 
embryonic development. The small size of zebrafish larvae, fitting inside wells of a standard 96-
well plate), and the availability of large number of embryos are essential features for the 
automation and high-throughput scale needed for these screens. 
Reverse genetics seek to elucidate the function of known genes by knock-out and knock-down 
approaches. Methods for reverse genetics include morpholino oligonucleotides and engineered 
nucleases. Morpholinos are short antisense oligonucleotides (18-25 bp) that can effectively bind a 
target mRNA and function through an RNase-H independent mechanism as efficient translational 
inhibitors in vivo (Nasevicius and Ekker, 2000). When injected into zebrafish one-cell stage 
embryos, morpholinos mediate knock-down of a target gene, generating phenotypes that 
resemble loss-of-function mutants (Nasevicius and Ekker, 2000). However, they have some 
limitations: they are transient in nature, only are completely penetrant during the first 48 hpf and 
there are common off-target effects caused by non-specific binding (Dahm and Geisler, 2006). An 
additional reverse genomic tool is TILLINGS (Targeting Induced Local Lesions IN Genomes), which 
relies on the screen of mutagenized populations, generally produced by ENU, and subsequent 
analysis by sequencing of induced mutations (Wienholds et al., 2003). This approach has recently 
been able to identify mutations in 3,188 zebrafish genes that are orthologous to some of the 
5,494 human genes currently associated with human diseases (Kettleborough et al., 2013). 
More recently a wide array of engineered nucleases including ZFN (Zinc Finger Nucleases), TALENs 
(Transcription Activator-Like Effector Nucleases) and CRISPR-Cas (Clustered Regulatory 
Interspaced Short Palindromic Repeats) have emerged as more refined tools for genome-editing 
in zebrafish (Maeder et al., 2008; Sander et al., 2011; Hwang et al., 2013). These tools contain a 
specific DNA binding domain fused to a non-specific DNA cleavage domain that induces double-
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strand breaks (DBS), stimulating NHEJ (Non-Homologous End Joining) DNA repair mechanisms in 
the cell and promoting introduction of deletions, insertions or substitutions at target loci, as 
reviewed in (Gaj et al., 2013). ZFNickases (Zinc Finger Nickases) have been introduced as powerful 
alternatives to avoid unwanted indels caused by error-prone NHEJ repair of DBS (Kim et al., 2012; 
Ramirez et al., 2012). They create single-strand breaks or nicks and trigger DNA repair by the 
homologous directed repair pathway, reducing the mutagenesis rate of classical ZFNs. The 
application of these tools to the field of transcriptional regulation could be revolutionary, as it will 
allow dissection of the structure of CREs by disrupting potentially relevant motifs with high 
precision. Along these lines, a recent study has proven that a cancer-associated enhancer lost its 
function following deletion of a 7-bp motif using TALEN nucleases (Webster et al., 2014). As a 
result of the genetic lesion, the MET gene enhancer could no longer interact with its cognate 
promoter and gene regulation was altered, demonstrating the importance of a single TFBS.  
1.7 Transgenesis in zebrafish for the study of transcriptional regulation 
Transgenesis is the most effective method for assess the potential of putative regulatory elements 
in vivo. In these assays constructs containing the region to be tested are linked to a reporter gene, 
the activity of which can be accurately measured when introduced into the cells of the animal 
model. If the element to be tested is an enhancer, a construct is produced so that the enhancer is 
placed upstream of a weak promoter and a reporter gene, typically fluorescent proteins, as 
reviewed in (Narlikar and Ovcharenko, 2009). Transgenesis techniques have been described in 
several animal models such as mouse, Xenopus and zebrafish (Stuart et al., 1990; Khokha and 
Loots, 2005; Fisher et al., 2006b; Pennacchio et al., 2006). These methods require the injection of 
the vector into fertilized eggs. The vector is randomly integrated in the host genome and tissue 
specific activity is evaluated by assessing the in vivo expression pattern of the injected embryos. 
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Zebrafish has proven to be unique in its capacity for transgenesis screens due to the low cost of 
transgenesis and the availability of high throughput approaches. The production of around two 
hundred eggs per female per week makes it an ideal model for the injection and screening of 
large number of transient transgenic embryos. In addition to this, the short generation time (3 
months) permits generation of stable transgenic lines. Establishment of transgenic lines is more 
time-consuming and lower-throughput. Although transient transgenics allow for high-throughput 
screens, one main limitation is the high mosaicism between embryos. Mosaicism complicates the 
identification and analysis of transgene activities in small tissue domains (Pashos et al., 2008). 
Nevertheless, transient transgenic embryos can be used, where each injected embryo represents 
a different integration site. Thus, position effects can be statistically eliminated by observing 
common patterns in a large number of embryos (Muller et al., 1997; Muller et al., 1999; Dickmeis 
et al., 2004; Gehrig et al., 2009). In transgenesis assays it is also common to find that reporter 
constructs drive expression in unexpected cells or tissues, referred to as “ectopic expression” 
(Summerbell et al., 2000; Adachi et al., 2003; Chao et al., 2010) or at a stage that does not match 
temporally that of the tested gene, known as “heterochronic expression” (Lin et al., 2010), 
hindering the analysis of the CRE of interest.  
1.7.1 Zebrafish tests of human cis-regulatory elements 
Zebrafish has been successfully used to test fish and human candidate regulatory regions using 
transient and stable transgenic assays (de la Calle-Mustienes et al., 2005; Woolfe et al., 2005; 
Abbasi et al., 2007; Navratilova et al., 2009; Li et al., 2010b; Narlikar et al., 2010; Ritter et al., 
2010; Rada-Iglesias et al., 2011; Gorkin et al., 2012; Ritter et al., 2012; Bhatia et al., 2013; Ravi et 
al., 2013). Most of these studies tested conserved non-coding regulatory regions among 
evolutionary distant species, such as human and zebrafish or Fugu, and confirmed that CNEs are 
good indicators of putative enhancers that function in vivo. Although some studies have 
addressed in detail how well enhancer function is conserved across species, particularly between 
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human and zebrafish (Navratilova et al., 2009; Ritter et al., 2010), the test of enhancers predicted 
in a tissue-specific fashion by novel genome-wide methods has not been explored in depth. 
1.7.2 Transgenesis methods in zebrafish 
Several protocols exist for the creation of stable transgenic lines in zebrafish, but two basic 
approaches have been employed to analyse CREs by transgenesis: naked DNA microinjections and 
transposon-mediated transgenesis. 
The first experiments to create transgenic zebrafish embryos used linearized plasmid DNA 
containing cis-regulatory elements (Stuart et al., 1988; Stuart et al., 1990; Westerfield et al., 
1992). The injected linear plasmid is first replicated during cleavage stages before being mostly 
degraded during gastrulation. The vast majority of replicated DNA is not stably integrated but 
lives in an extra-chromosomal state, which results in a highly mosaic individual. The mosaicism is 
most likely caused both by late integration into the genomic DNA (prompted by the rapid 15-
minutes cleavages), uneven distribution of the exogenous DNA in the embryo, and/or tissue-
specific activation of the transgene (Stuart et al., 1988; Stuart et al., 1990; Westerfield et al., 
1992). These and other experiments proved that mosaic analysis of transient transgenic zebrafish 
provides a rapid method for the dissection of the activity of cis-regulatory elements, either by 
injecting promoters alone or by co-injecting enhancer and promoter fragments (Muller et al., 
1997; Woolfe et al., 2005; Allende et al., 2006). Only about 5% of the mosaic injected fish in these 
experiments carry germline integration of the transgene (Stuart et al., 1988; Stuart et al., 1990; 
Amsterdam et al., 1999) Nevertheless, germline transmission rates can be improved with the use 
of transposons.  
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1.7.3 Use of transposons for random integration of transgenes 
Transposons or DNA-based transposable elements are mobile DNA segments. In their simplest 
form they consist of a genetic sequence flanked by short terminal repeats and the encoded 
transposase enzyme, which triggers the replicative spread through the genome by recognising 
target DNA sequences and mediating integration by cutting, exchanging and fusing DNA strands 
(Plasterk, 1993). Autonomous transposons carry the transposase gene whilst non-autonomous 
transposons depend on an external enzyme for their mobilization in the genome (Cui et al., 2002). 
Transposon-mediated transgenesis represents an advantage over naked DNA microinjection, as 
reviewed in (Kawakami, 2005), particularly with regards to germline transmission rates, which 
increase from around 5% to 12.5%, or even 50% (Kawakami et al., 2000; Kawakami et al., 2004).  
1.7.3.1 Sleeping Beauty 
Sleeping Beauty (SB) is a synthetic transposon generated from a consensus sequence of the 
salmonoid Tc1-like elements. The system consists of a synthetic gene encoding the transposase 
and a cloned Tc1-like element containing the inverted repeats needed for transposition (Ivics et 
al., 1997). It is very active in higher vertebrates (including fish, mouse and human) and 
preferentially integrates one copy in sequences flanking TA dinucleotides (Ivics et al., 1997). In 
zebrafish, SB is a valuable tool for transgenesis: it enhances the expression rates of transgenes 
from 5% to 31% over standard plasmid injection and exhibits a germline transmission efficiency of 
around 10% of multiple single-copies of transgenes (Davidson et al., 2003). However, this two-
component system has a limited cargo carrying capacity (up to 7Kb for efficient transposition 
rates in human cells) and lowered transposition activity at high SB doses (Geurts et al., 2003; 
Balciunas et al., 2006).  
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1.7.3.2 Tol2 transposon 
Tol2 belongs to the hAT family of transposons and was isolated from the tyrosinase gene locus of 
the Medaka fish Oryzias latipes (Koga et al., 1996). Koga and collaborators identified a 4.7 Kb 
insertion on the 5th exon of i4 allele displaying "cut and paste" transposon features: it was present 
in multiple copies in the host genome and was flanked by short inverted terminal repeats (Koga et 
al., 1996). In order to determine whether the Tol2 element was autonomous and active in 
zebrafish, a construct harbouring the Tol2 element was injected into zebrafish eggs. Analysis by 
PCR of the injected embryos showed that Tol2 was excised from the plasmid leaving small 
deletions and insertions at the excision sites, which is characteristic of transposons (Kawakami et 
al., 1998). In addition, when mRNA transcribed in vitro was injected in embryos, Tol2 produced a 
functional transposase capable of catalysing transposition in the zebrafish germline (Kawakami et 
al., 2000). These results indicated that Tol2 was an autonomous element and, more importantly, 
that it was active in zebrafish. 
The minimal sequence required for transposition was identified from the Tol2 element, indicating 
that 200 bp from the left end and 150 bp from the right end were sufficient for Tol2-mediated 
transposition (Urasaki et al., 2006). Subsequently, constructs containing miniTol2 versions were 
designed (Balciunas et al., 2006; Urasaki et al., 2006). These vectors offered the additional 
advantage of being able to carry efficiently DNA elements larger than 10 Kb between the left and 
right Tol2 ends (Balciunas et al., 2006; Urasaki et al., 2006), and even Bacterial Artificial 
Chromosome (BAC) transgenes (Suster et al., 2009). 
Several features such as high rates of germline transmission (around 50%), single copy transgene 
insertions, an average of 5-6 insertions, clean integrations in the genome, and the passage of 
transgenes through generations make Tol2 an ideal system for creating transgenic zebrafish 
(Kawakami et al., 2000; Kawakami et al., 2004). 
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1.7.4 Zebrafish as a model for studying cis-regulation of vertebrate pancreas 
development and function 
1.7.4.1 Zebrafish shares a common pancreas structure and function with mammals 
In this thesis, pancreas specific human enhancers will be tested by transgenesis in zebrafish. 
Zebrafish has become a popular model for studying development and the fact that the zebrafish 
pancreas shares a common basic structure and cellular composition with mammals, implies that 
the lessons we can learn from zebrafish will be broadly applicable (Kinkel and Prince, 2009). 
Pancreas is a vital organ controlling glucose homeostasis, food digestion and nutrition, and 
consists of both endocrine and exocrine compartments. In adult mammals the endocrine 
pancreas represents 1-2% of the total mass of the organ and is embedded within the exocrine 
pancreas, as reviewed in (Slack, 1995).The exocrine component is a lobulated gland consisting of 
acinar and ductal cells. Acinar cells are arranged into spherical structures called acini that produce 
and secrete digestive enzymes (zymogens) from their apical surface including proteases, 
amylases, lipases and nucleases. Ductal cells form a network that allows the transport of 
zymogens into the intestine (Wang et al., 2011b). The endocrine pancreas consists of islets that 
contain four different cell types secreting hormones into the bloodstream: insulin producing β-
cells, glucagon producing α-cells, somatostatin producing δ-cells, and pancreatic polypeptide 
producing PP-cells. The pancreatic islet is organized in a mantle-core structure, with the most 
abundant β-cells in a central core surrounded by non β-cells at the periphery (Montague, 1983). It 
has been shown in most species that during development and early post-natal period there is a 
unique fifth type of endocrine cells: ghrelin producing ε-cells (Heller, 2010). In humans, the islets 
of Langerhans are organized as several mantle-core subunits. The adult endocrine pancreas 
contains approximately one million islets of Langerhans embedded in exocrine tissue (Li et al., 
2009). This description of the human pancreas is broadly applicable to reptiles, amphibia, birds 
and some fishes. 
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1.7.4.2 Zebrafish pancreas development 
At early larval stages, the zebrafish pancreas consists of exocrine tissue surrounding a single 
principal islet. The islet is composed of a core of β-cells, enclosed by an outer layer of δ-, α- and ε-
cells. Whether PP-cells form part of the zebrafish embryonic islet remains unclear, with some 
authors claiming that PP cells can only be detected in the adult pancreas (Argenton et al., 1999). 
The endocrine and exocrine compartments originate from two contiguous areas in the gut that 
bud at two different times during development (Figure 1.7): the anteroventral bud will give rise to 
the endocrine pancreas, while the posterodorsal bud will form the exocrine pancreas and a supply 
of endocrine cells (Field et al., 2003).  
The first pancreatic bud forms from two sets of endodermal cells that originate at both sides of 
the gastrula and merge at the midline by the 12-somite stage. These cells express pdx1, a 
pancreatic and duodenal homeobox gene, which is an early pancreatic and gut marker (Biemar et 
al., 2001). These cells bud off dorsally from the gut before 24 hpf. The posterodorsal bud gives 
rise to endocrine tissue expressing the main pancreatic hormones. Due to the rotation of the gut 
between 24-48 hpf, the dorsal bud is dislocated to the right side of the gut.  
 
Figure 1.7 Schematic diagram of the development of zebrafish pancreas. 
Relevant genes in pancreas morphogenesis are labelled in green, blue and magenta. L=liver, 
G=gut, S=swim bladder. All images are dorsal view with anterior at the top. Adapted from (Tiso et 
al., 2009) 
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By 48 hpf the first islet can be detected and it is organized like a mammalian one with a core of β-
cells surrounded by α- and δ-cells (Tiso et al., 2009). Ghrelin cells are not detected in the zebrafish 
pancreas, but have been found in catfish (Heller, 2010). The anteroventral bud emerges at 40 hpf 
from the ventral portion of the gut, anterior to the first islet. It can be detected by the expression 
of the exocrine marker ptf1a (Lin et al., 2004). This second bud will grow towards the posterior 
end of the gut, enveloping the islet. By 5 dpf the pancreas lies on the right side of the gut and 
consists of a head, where the principal islet and nkx2.2 -expressing extra-pancreatic ducts are, and 
a tail, which is posterior to the head and consists of exocrine pancreas (Parsons et al., 2009). The 
exocrine pancreas of a 5 dpf larvae contains approximately 260 cells (Jiang et al., 2008). 
While the embryonic and larval zebrafish pancreas consists of a single principal islet, the pancreas 
in the adult zebrafish is organized as a large principal islet located at the head of the pancreas and 
several secondary islets within the tail of the pancreas (Tiso et al., 2009). The cells that form the 
secondary islets do not appear during the first 6 days of development, but are established during 
the first three weeks of larval life and are embedded in exocrine tissue and scattered along the 
gut (Parsons et al., 2009). Their formation can be explained by two alternative hypothetical 
models. The first implies the replication and migration along the gut tube of existing β-cells from 
the primary islet. The second model proposes the differentiation of nkx2.2a-expressing ductal 
precursor cells. A paper published by (Wang et al., 2011b) confirmed this second hypothesis. 
There are two differentiated cell populations in the anteroventral bud: a ptf1a expressing domain 
and a Notch-responsive domain. The Notch responsive pluripotent cells align along the ducts and 
differentiate during development to form ductal and centroacinar cells and the insulin producing 
cells that will eventually form the secondary islets. 
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1.8 Aims of this thesis 
In the post-genomic era, international efforts have been devoted to design strategies that can 
identify CREs on a genome-wide scale. However, the vast majority of the putative enhancers have 
not been experimentally characterized in vivo and their contribution to disease is unclear. 
Therefore there is a demand for an animal model that can be used in validation assays with the 
capacity to be upscaled. Zebrafish has been used to study transcriptional regulation before but its 
relevance as an evolutionarily distant model for the functional test of mammalian cis-regulatory 
elements remains poorly understood. Therefore, I aimed to investigate the utility of the 
transgenic zebrafish embryo to study the function of candidate human enhancers identified by 
several prediction methods. I also aimed to develop a robust transgenesis method that would 
permit the detection of subtle quantitative changes in enhancer function caused by disease-
associated SNPs. 
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Chapter Two: MATERIAL AND METHODS 
2.1 Materials 
All the chemicals used were molecular biology quality grade. Some commonly used chemicals, 
consumables and equipment are not listed here. 
2.1.1 Antibiotics 
Ampicillin sodium salt A9518 Sigma-Aldrich, UK 
Gentamicin sulfate BPE918-1 Fisher Bioreagents, UK 
Kanamycin sulfate from Streptomyces 
kanamyceticus 
K1377 Sigma-Aldrich, UK 
 
2.1.2 Bacterial strains 
Alpha-Select Silver Efficiency chemically competent 
cells 
BIO-85026 Bioline Ltd., UK 
Alpha-Select Bronze Efficiency chemically 
competent cells 
BIO-85025 Bioline Ltd., UK 
Alpha-Select Silver Efficiency electrocompetent cells BIO-85028 Bioline Ltd., UK 
Stellar™ Competent Cells 636763 Clontech, UK 
 
2.1.3 Chemical Reagents 
Agarose BIO-41025 Bioline Ltd., UK 
Albumin from bovine serum, further purified 
fraction V, 99% pure (BSA) 
A3059 Sigma-Aldrich, UK 
5-Bromo 4-chloro 3 indolyl phosphate (BCIP) 11383221001 Roche Diagnostics, UK 
Chloroform C2432 Sigma-Aldrich, UK 
CTP alpha-32P BLU008H001MC Perkin Elmer, UK 
Denhardt's Solution (50X) 750018 Invitrogen, UK 
Deoxyribonucleic acid from calf thymus D4522-1MG Sigma-Aldrich, UK 
dNTPs 10mM R0192 Thermo Scientific, UK 
Dynabeads® M-280 Streptavidin 11205D Invitrogen, UK 
Ethyl-3-aminobenzoate methanesulfonate 98% 
(MESAB/E-222/Tricaine) 
E10521 Sigma-Aldrich, UK 
Formamide (deionized) AM9342 Ambion, UK 
Gel Loading Dye, Blue 6X B7021S NEB, UK 
Glycerol G6279 Sigma-Aldrich, UK 
Heparin sodium salt H3393 Sigma-Aldrich, UK 
Human genomic DNA G3041 Promega, UK 
LB (Luria Bertani) Agar L2897 Sigma-Aldrich, UK 
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LB (Luria Bertani)Broth L3022 Sigma-Aldrich, UK 
New Born Calf Serum N4637 Sigma-Aldrich, UK 
N-Phenylthiourea Grade I (PTU) P7629 Sigma-Aldrich, UK 
Nitro blue tetrazolium (NBT) 11383213001 Roche Diagnostics, UK 
Paraformaldehyde (PFA) P6148 Sigma-Aldrich, UK 
Phenol:Chloroform 5:1, pH 4.7 P1944 Sigma-Aldrich, UK 
Phenol:Chloroform:Isoamyl Alcohol 25:24:1 
Saturated with 10 mM Tris, pH 8.0, 1 mM EDTA 
P3803 Sigma-Aldrich, UK 
Phenol solution Equilibrated with 10 mM Tris HCl, 
pH 8.0, 1 mM EDTA 
P4557 Sigma-Aldrich, UK 
Phenol red solution P0290 Sigma-Aldrich, UK 
Ready-To-Go DNA Labelling Beads (-dCTP) 27924001 GE Life Sciences, UK 
SSC buffer substance 85639 Sigma-Aldrich, UK 
Sheep anti-digoxigenin-AP Fab fragments 1093274 Roche Diagnostics, UK 
Sheep serum 013000121 Interchim, US 
tRNA from wheat germ type V, lyophilized powder R7876 Sigma-Aldrich, UK 
Tween-20 P1379 Sigma-Aldrich, UK 
UltraPure™ 1M Tris-HCI, pH 8.0 15568-025 Invitrogen, UK 
1 kb DNA Ladder N3232S NEB, UK 
100 bp DNA Ladder N3231S NEB, UK 
 
2.1.4 Consumables 
Borosilicate glass capillaries (OD 1mm, ID 0.78mm) BF100-7810 Warner Instruments, USA 
Electroporation cuvettes 1 mm EP-01 Geneflow, UK 
GeneScreen Plus transfer membrane NEF987001PK Perkin Elmer, US 
Illustra MicroSpin G25 Columns 27532501 GE Life Sciences, UK 
Illustra ProbeQuant G-50 Micro Columns 28903408 GE Life Sciences, UK 
MicroAmp Optical 96-well Reaction Plates N8010560 Applied Biosystems, UK 
Microcon-30kDa Centrifugal Filter Unit with 
Ultracel-30 membrane 
MRCF0R030 Millipore, UK 
 
2.1.5 Enzymes 
Cloned Pfu DNA Polymerase 600353 Agilent Technologies, UK 
Gateway BP Clonase™ II Enzyme Mix 11789-100 Invitrogen, UK 
Gateway LR Clonase™ II Enzyme Mix 11791-020 Invitrogen, UK 
GoTaq® Hot Start Polymerase M5006 Promega, UK 
Herculase Hotstart DNA Polymerase 600310 Agilent Technologies, UK 
In-Fusion® HD Cloning Kit 639643 Clontech, UK 
PCR Extender System 2200500 5Prime, UK 
Protease from Streptomyces griseus Type XIV 
(Pronase) 
P5147 Sigma-Aldrich, UK 
Proteinase K from Tritirachium album P4850 Sigma-Aldrich, UK 
Ribonuclease A from bovine pancreas (RNase) R4642 Sigma-Aldrich, UK 
Restriction Enzymes various NEB, UK 
T4 DNA ligase M1801 Promega, UK 
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2.1.6 Kits 
DAB Peroxidase Substrate Kit SK4100 Vector Laboratories, UK 
DIG RNA Labelling Kit SP6/T7 11175025910 Roche Diagnostics, UK 
NucleoSpin Gel and PCR Clean-up Kit NZ74060950 Macherey-Nagel, UK 
NucleoSpin Plasmid Kit NZ74058850 Macherey-Nagel, UK 
NucleoBond Xtra Midi Kit NZ74041010 Macherey-Nagel, UK 
mMESSAGE mMACHINE® Kit AM1340 Ambion, UK 
 
2.1.7 Oligonucleotides 
All oligonucleotides described in this thesis were designed with Primer 3 software version 4.0 
(Untergasser et al., 2012) and were purchased from Sigma-Aldrich, UK. 
2.1.8 Buffers and solutions 
-2X BW Buffer: 2M NaCl, 10mM Tris-HCl (pH 7.5), 1 mM EDTA  
- 4% Paraformaldehyde (PFA): PFA was dissolved in sterile PBS at 60° with constant stirring. 
- E3 Medium: 0.5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4. 
- Mammalian lysis buffer: 10 mM Tris-HCI (pH 8.0), 0.1 M EDTA (pH 8.0), 0.5% (w/v) SDS, 20 μg/ml 
of DNase-free Ribonuclease A from bovine pancreas. 
-PBST: PBS, 0.1% Tween-20. 
-Southern Blot hybridization buffer: 6× SSC, 0.5% SDS, 5× Denhardt's solution, 10 mg/ml of 
denatured calf thymus genomic DNA  
-WISH Blocking Solution: 1x PBST, 2% sheep serum (vol/vol), 2 mg/ml BSA 
-WISH Hybridization Buffer (+):50% deionized formamide, 5X SSC, 0.1% Tween-20, 50 μg/ml of 
heparin bile salts, 500 μg/ml of extracted RNase-free tRNA adjusted to pH 6.0 by adding citric acid 
(460 μl of 1 M citric acid solution per 50 ml of hybridization buffer). 
WISH Hybridization Buffer (-):50% deionized formamide, 5X SSC, 0.1% Tween-20 
-WISH Staining Buffer: 1 M Tris-HCl, adjusted to pH9.5, 50 mM MgCl2, 100 mM NaCl, 0.1% Tween-
20. 
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-WISH Staining Solution: Dilute 225 μl of 50 mg/ml NBT and 175μl of 50 mg/ml BCIP with 50 ml of 
WISH Staining Buffer (Light sensitive). 
-WISH Stop solution: PBS pH 5.5, 1 mM EDTA, 0.1% Tween-20. 
-Antibody staining blocking buffer: 10% NBCS in PBST. 
2.1.9 Zebrafish strains 
Wild-type embryos used are derived from AB and AB* strains. For pancreas co-localization 
experiments the following stable transgenic lines were used: Tg (ins-mCherry)jh2 (Pisharath et al., 
2007). 
2.1.10 Equipment 
Digital microINJECTOR System MINJ-1 Tritech Research, US 
Flaming Brown micropipette puller P-97 Sutter Instruments, USA 
Heraeus Function line incubator B6 Thermo Scientific, UK 
Leica TCS LSI zoom confocal microscope LSI6000 Leica, UK 
MicroPulser Electroporation Apparatus 165-2000 BIO-RAD, UK 
NanoDrop ND-1000 Spectophotometer ND-1000 NanoDrop Technologies 
Scan^R High-Content Screening Station for Life 
Science 
scan^r Olympus, Germany 
Sensoquest Thermocycler 613-3908 GeneFlow, UK 
Stereoscopic Zoom microscope  SMZ1500 Nikon, UK 
Storage Phosphor Screen 28956474 GE Life Sciences, UK 
Stratalinker UV crosslinker 400075 Stratagene, US 
Stuart Scientific tube rotator SB3 VWR, UK 
Typhoon 9200 Variable Mode Imager 375-635 GE Life Sciences, UK 
Zoom stereomicroscope SMZ645 Nikon, UK 
6-Tube Magnetic Separation Rack S1506S New England Biolabs, UK 
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2.2 Molecular Biology Methods 
2.2.1 Phenol-chloroform extraction of nucleic acids 
Phenol-chloroform extraction is a widely used molecular biology method designed for the 
purification of nucleic acids (Chomczynski and Sacchi, 1987). One volume of Tris-HCl buffer 
saturated-phenol was added to the aqueous solution containing nucleic acid and proteins, 
forming two immiscible layers: an upper aqueous phase and a heavy phenolic phase. The two 
phases were mixed and separated by centrifugation at 10,000 rpm for 10 minutes at room 
temperature (RT). The upper aqueous phase containing nucleic acids was transferred to a fresh 
tube. One volume of chloroform was added, mixed briefly and centrifuged at 10,000 rpm for 10 
minutes at RT. The aqueous phase was transferred to a fresh tube for precipitation. 
2.2.2 Precipitation of nucleic acids 
DNA was precipitated by adding 0.2 volumes of 3M Na-acetate and 2 volumes of 100% ethanol. 
RNA was precipitated by adding one volume of isopropanol and 1/10 volumes of 10M ammonium 
acetate. Solutions were incubated at least for 1 hour at -20°C and centrifuged at 4°C for at least 
30 minutes. The precipitate was washed with 70-80% ethanol and pelleted at 10,000 rpm for 5-10 
minutes. The pellet was air-dried and resuspended in nuclease-free water. DNA was stored at -
20°C.  
2.2.3 Isolation of plasmid DNA 
Isolation of plasmid DNA was carried out using commercially available kits from Macherey Nagel, 
UK. These kits are based on the alkaline lysis extraction protocol described by (Birnboim and Doly, 
1979). Bacteria from liquid cultures are harvested by centrifugation and plasmid DNA liberated by 
alkaline-SDS lysis. The lysate is neutralised and plasmid DNA containing solution is applied to silica 
or anion-exchange membrane column. Genomic DNA, proteins and cell debris are removed by 
centrifugation. Other contaminants, like salts and metabolites, are removed by washing with 
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ethanolic buffers. Purified plasmid DNA is eluted under low ionic strength conditions with alkaline 
TE buffer or nuclease-free water. 
2.2.3.1 Miniprep of plasmid DNA 
Bacterial plasmids were purified using NucleoSpin Plasmid Kit (Macherey-Nagel, UK) following 
manufacturer’s instructions, which are described briefly below. Firstly, 5 ml LB cultures 
supplemented with the appropriate antibiotic were inoculated with a single colony picked from 
streaked agar plates and were incubated with constant shaking (200-250 rpm) overnight at 37°C. 
Cells were pelleted in a standard benchtop microcentrifuge for 30 seconds at 11,000 g. After 
discarding the supernatant, 250 µl of A1 Buffer supplemented with RNase A was added to 
resuspend the cell pellet. 250 µl of A2 Buffer was then added to lyse the cells and the tube was 
inverted 6-8 times carefully to avoid shearing of bacterial genomic DNA. After 5 minutes of 
incubation of the lysate, 300 µl of A3 Buffer were added to neutralize the reaction. The lysate was 
clarified by centrifugation at 11,000 g for 5 minutes. The supernatant was loaded onto a 
NucleoSpin Plasmid QuickPure Column and was centrifuged for 1 min at 11,000 g so that the DNA 
could bind to the silica membrane of the column. 450 µl of A4 Buffer supplemented with 100% 
ethanol were added to wash the column and after 1 minute of centrifugation at 11,000 g the 
flow-through was carefully discarded. An additional centrifugation step at 11,000 g for 2 minutes 
was performed to ensure that the silica membrane was dry. The bacterial plasmid was eluted by 
adding 30 µl of nuclease-free water to the column, incubating for 1 min and centrifuging for 1 min 
at 11,000 g. The flow-through was collected in a fresh tube. 
2.2.3.2 Midiprep of plasmid DNA 
High-quality bacterial plasmid DNA was prepared using NucleoBond Xtra Midi (Macherey-Nagel, 
UK) following manufacturer’s instructions, which are described briefly below. A 200 ml LB culture 
containing the appropriate selective antibiotic was grown overnight at 37°C and 200 rpm. Cells 
52 
 
were harvested by centrifugation at 6,000 g for 10 min at 4°C. After discarding the supernatant, 
the cell pellet was resuspended with 8 ml of Resuspension Buffer supplemented with RNase A. 
Then 8 ml of Lysis Buffer were added to the suspension, which was inverted 5 times carefully and 
incubated for 5 minutes at RT. The reaction was neutralised by adding 8 ml of Neutralization 
Buffer. The tube was inverted 10 times and the lysate was loaded into a NucleoBond Xtra Column 
filter previously equilibrated with 12 ml of Equilibration Buffer. After allowing the column to 
empty by gravity flow, 5 ml of Equilibration Buffer was added to the column to wash out the 
remaining lysate from the filter. The column filter was discarded and the column was washed with 
8 ml of Wash Buffer. Plasmid DNA was eluted with 5 ml of Elution Buffer and collected in a fresh 
50 ml centrifuge tube. To precipitate the DNA, 3.5 ml of isopropanol at RT were added to the 
tube. After vortexing, the precipitate was centrifuged at 10,000 g for 30 minutes at 4°C. The 
supernatant was removed and the pellet washed with 2 ml of 70% room-temperature ethanol by 
centrifuging at 15,000 g for 5 min. The DNA pellet was dried at RT and reconstituted with 100-300 
µl of nuclease-free water. 
2.2.3.3 Isolation of high molecular weight genomic DNA 
Genomic DNA was isolated according to the standard protocol described by (Sambrook and 
Russell, 2006). Snap-frozen zebrafish embryos were thawed on ice and homogenised using a clean 
pestle. One ml of Mammalian Cell Lysis Buffer (recipe in section 2.1.8 above) was added to the 
samples, and the solution was incubated for 1 hour at 37°C. Proteinase K was added to the lysate 
to a final concentration of 100 μg/ml and the mixture was incubated from 3h to overnight in a 
water bath at 50°C at 50-60 rpm. After cooling the solution at RT, phenol extraction was carried 
out twice. Phases were mixed by rotating the tubes in an end-over-end rotator at 2 rpm for 1 hour 
and separated by centrifugation at low speed to avoid breaking the DNA molecule (5,000 g for 20 
minutes at RT). A wide-bore pipette was used to transfer the viscous aqueous phase to a fresh 
centrifuge tube and a phenol-chloroform-isoamylalcohol (25:24:1) extraction was performed. 
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DNA was precipitated by adding 0.2 volumes of 10 M ammonium acetate and 2 volumes of 100% 
ethanol at RT. The sample was rotated for 15 minutes in an end-over-end rotor at 2 rpm. The 
precipitated DNA was removed in one piece with a sterile crook and transferred to a solution of 
70% ethanol. DNA was washed again in 70% ethanol and was dried at RT on a crook. When the 
precipitated DNA turned transparent, it was resuspended in 300 μl of Tris- buffer (pH 8.0) and was 
dissolved by gently rotating the solution overnight. 
2.2.4 Quantification of nucleic acids 
Nucleic acids yield and purity were assessed by UV spectrophotometry using a NanoDrop ND 1000 
Spectrophotometer (Thermo Scientific, UK). The concentration (ng/µl) is based on the 260λ 
absorbance. The purity of DNA and RNA was assessed by evaluating the 260/280λ ratio of the 
sample’s absorbance. A ratio of 1.8 was accepted as pure for DNA and a ratio of 2.0 was accepted 
as pure for RNA. The 260/230λ absorbance ratio was used as a second measurement of the 
nucleic acids purity (absence of co-purified contaminants). A ratio in the range of 1.8 – 2-2 was 
considered as pure. 
2.2.5 Polymerase Chain Reaction (PCR) 
Amplification of DNA sequences was performed by PCR using a Sensoquest Thermocycler 
(GeneFlow, UK). For cloning purposes, the proofreading PCR Extender System (Primer5, UK) for 
high fidelity amplifications was used. This system combines a blend of highly thermostable DNA 
Polymerases with high processivity that enable amplification of fragments up to 40 kb with 
minimal error rate. When high-fidelity was not needed, ie, when testing colonies after ligation 
reactions, a Taq Polymerase without proofreading capability was used (GoTaq® Hot Start 
Polymerase, Promega, UK). Reactions were assembled following manufacturer’s instructions. 
Annealing temperatures and extension times were adjusted depending on primer and template 
conditions. Typically, a standard PCR cycle consists on a hot-start step of 95°C for 5 minutes, 
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followed by 35-40 cycles of denaturing, annealing and extension, and a final extension step at 72 
°C for 7 minutes. 
2.2.6 Agarose Gel electrophoresis 
The size and specificity of PCR products, or digested DNA was assessed in agarose gels by 
electrophoresis. Gels were prepared by dissolving agarose in Tris-borate-EDTA (TBE) buffer to a 
final concentration ranging from 0.8 to 1.5% depending on the fragment size. To allow 
visualization of DNA under UV light 10ng/ml of ethidium bromide was added to the gels. The 
ladders commonly used were either 100 bp DNA Ladder or 1 Kb DNA Ladder from NEB UK, 
depending on the size of the fragments to be analyzed. Gels were run in TBE 1X electrophoresis 
buffer at 90 V for a minimum of 40 minutes or until proper separation of the bands was achieved. 
2.2.7 Purification of DNA from agarose gels 
PCR products were purified to remove remaining primers and other PCR components for 
downstream procedures. Also DNA products were excised and extracted from agarose gels when 
unspecific bands were present. Digested plasmid DNA was purified in order to ensure a higher 
quality for further procedures (usually ligation or recombination reactions) using the NucleoSpin 
Gel and PCR Clean-up Kit from Macherey-Nagel, UK. 
Gel purification was carried out by loading DNA samples into an agarose gel and the fragment of 
interest was excised using a clean scalpel under UV light. UV exposure was minimized to avoid 
damaging the DNA. The gel slice was purified following manufacturer’s instructions. For each 100 
mg of agarose 200 µl of NT Buffer was added. The sample was incubated at 50°C for 10 minutes. 
In the case of PCR clean-up, the volume of the PCR reaction was adjusted to 100 µl and 200 µl of 
Buffer NT were added. The sample was loaded into a NucleoSpin Column attached to a collection 
tube and centrifuged at 11,000 g for 1 minute. The flow-through was discarded and 700 µl of NT3 
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Buffer supplemented with ethanol were added to wash the silica membrane of the column. This 
was centrifuged for 1 minute at 11,000 g and after removal of the flow-through the column was 
centrifuged again for 2 minutes at maximum speed to remove residual ethanol. DNA was eluted 
by adding 15-50 µl of nuclease-free water into the column and centrifuging for 1 minute at 11,000 
g. The eluate was collected into a fresh tube. 
2.2.8 Molecular cloning 
Molecular cloning refers to the construction of plasmids made by directional ligation of DNA 
fragments flanked by complementary cohesive ends created by endonuclease restriction digest. 
Inserts coming from PCR products were amplified using primers containing restriction sites.  
2.2.8.1 Restriction digest of DNA 
Around 10 µg of vector and insert DNA were digested using appropriate Restriction Endonuclease 
enzymes from New England Biolabs, UK. Reactions were set up in a total volume of either 50 or 20 
µl, by adding suitable amounts of DNA, 2 to 10-fold excess of restriction enzyme (2-10 units per 
µg of DNA), appropriate NEBuffer (10X) and BSA to a final concentration of 100 ng/µl. Unless 
stated by the manufacturer, the reaction was incubated at 37°C for 2-3h.  
2.2.8.2 Ligation of DNA fragments 
T4 DNA ligase was chosen to catalyze the ligation of DNA fragments containing cohesive ends 
generated by restriction digest. Ligation reactions were assembled using a 1:3 vector:insert molar 
ratio, 1 μL of T4 DNA ligase and 2 μL of 10X Ligase Buffer in a total volume of 20 μL. The reaction 
was incubated at RT overnight and then 10 µl of this reaction was used to transform an aliquot of 
50µl of DH5α cells as described in section 2.3.1 below. 
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2.2.9 Gateway Cloning  
Expression vectors containing a human putative enhancer linked to a zebrafish promoter and 
fluorescent reporter gene were cloned using the Multisite Gateway Cloning System by Invitrogen, 
UK. The Gateway strategy is based on phage lambda site-specific recombination in vitro between 
PCR products and vectors containing attB and attP recombination sites (Roure et al., 2007). 
Expression Vectors are created through two recombination steps. The BP reaction is a 
recombination reaction between an attB-site flanked PCR product (either a human enhancer or 
zebrafish promoter PCR product) and a donor vector that generates a “shuttle vector” or Entry 
Vector. These entry vectors are recombined with a variety of Destination Vectors to create a final 
Expression (Figure 2.1). 
 
 
Figure 2.1. Schematic representacion of Gateway Cloning Technology: from attB-flanked PCR 
products to the generation of an Expression Clone.  
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2.2.9.1 Production of attB-flanked PCR products 
Human enhancers and zebrafish promoters were amplified using the proofreading PCR Extender 
System for high fidelity amplifications. Human genomic DNA containing disease-linked SNPs or 
mutations for amplification was provided by our collaborators. 
Two rounds of PCR were carried out to produce a final product flanked by attB recombination 
sites (29bp). In the first round the 12bp most 3’-prime to the gene-specific sequence was added 
by the adaptor primers. In the second round, the whole 29 bp attB tail was reconstructed by 
primers containing the complete attB site (Table 2.1): attB3 and attB5 sites were used to flank 
enhancers while attB1 and attB2 sites were flanking promoters.  
Table 2.1 Primers used to amplify attB-flanked products for Gateway Cloning 
Oligo Name Sequence (5' to 3') 
attB1-primer ggggacaagtttgtacaAAAAAGCAGGCT 
attB2-primer ggggaccactttgtacaAGAAAGCTGGGT 
attB3-primer ggggacaagtttgtataATAAAGTAGGCT 
attB5 –primer ggggaccactttgtataCAAAAGTTGGGT 
After assembling a high-fidelity PCR reaction (section 2.2.5 above) and assessing the size and 
specificity of the PCR product by electrophoresis, the PCR product was cleaned-up or gel 
extracted as described in section 2.2.7 above. Purification of the PCR product was carried out to 
remove attB primers and any attB primer-dimers, which could clone efficiently into the Entry 
Vector. 
2.2.9.2 Creation of Entry Clones via BP Reaction 
By the BP reaction attB-flanked PCR products were transferred as a unit into a Donor Vector 
(pDONR221) to create Entry Clones. Two separate BP reactions were needed to create promoter 
and enhancer containing Entry Clones.   
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The BP Reaction was assembled at room temperature as follows: 
 Negative Control Sample 
Component Tube 1 Tube 2 
attB PCR product (use 50 fmol*) ---- 1-10 µl 
pDONR221 Vector (150 ng/ml) 2 µl 2 µl 
BP Clonase Enzyme Mix 2 µl 2 µl 
TE buffer 10 µl To 10 µl 
 
The BP reaction was incubated at 25°C for 1 hour. To stop the reaction 2 µl of Proteinase K were 
added and incubated for 15 minutes at 37°C. Five µl of BP Reaction were transformed into an 
aliquot of 50 µl DH5α chemically competent cells, as described in section 2.3.1. The next day, 
single colonies were picked from LB Agar plates and colony PCR using M13 forward and reverse 
primers (flanking recombination sites) were used for testing positive Entry Clones. Positive Entry 
Clones were isolated by minipreps (see section 2.2.3.1 above) and sent for sequencing (see 
section 2.2.11 below). 
2.2.9.3 Creating Expression Vectors via LR Reaction 
From the Entry Clones, the non-coding sequences were shuttled by LR recombination to the 
Gateway Destination Vector pSP1.72BSSPE-R3-R5-RFA-Venus Tol2 (Roure et al., 2007). This vector 
contains two Tol2 arms which are recognized by Tol2 transposase, enabling single copy 
integration of the construct into the genome by co-injection with Tol2 mRNA. LR Reactions were 
assembled at room temperature as follows: 
Component  Negative Control Sample 
Enhancer containing Entry Clones  ---- 100 femtomoles 
Promoter containing Entry Clone  100 femtomoles 
Destination Vector 100 femtomoles 100 femtomoles 
LR Clonase Enzyme Mix 2 µl 2 µl 
TE Up to 10 µl Up to 10 µl 
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The LR reaction was incubated overnight at RT. To stop the reaction 2 µl of Proteinase K was 
added and incubated for 15 minutes at 37°C. For multisite LR cloning, 10 µl of the LR Reaction was 
transformed into 40 µl electrocompetent E. coli DH5α cells by electroporation, as described in 
section 2.3.2. To screen for positive colonies attB3 forward primer and the Venus reverse primers 
(5’-AACTCCAGCAGGACCATGT-3’) were used. Positive Expression Clones were isolated using 
NucleoBond Xtra Midi Kit, as per manufacturer’s instructions. All final Expression vectors were 
sent for sequencing. 
2.2.10 In-fusion cloning 
In-Fusion® HD Cloning Kit system allows directional cloning of one or many DNA fragments into a 
vector, using only one restriction site. Clontech´s In-fusion enzyme can efficiently fuse DNA 
fragments that share a 15 bp homology region at both ends. This technology was used when only 
one restriction site was available within a vector, and directional cloning of the insert was 
required. Manufacturer´s instructions were followed. 
2.2.10.1 Design of primers for PCR 
Primers were designed so that the 5’end would contain a 15 bp fragment overlapping with the 
end of the linearized vector where it was going to be cloned, and the 3´end would contain 18 to 
25 bp specific to the target gene. The 3´end region of the oligonucleotide was designed using 
Primer3 software. For the final primer design an online tool by Clontech was used: 
http://bioinfo.clontech.com/infusion/. 
2.2.10.2 Preparation of linearized vector and insert 
The vector was linearized using one or two restriction enzymes as described and it was gel 
extracted using Macherey Nagel Gel and PCR Clean-up Kit. The PCR fragment was amplified using 
the proofreading hot-start Polymerase provided by the Kit: CloneAmp™ HiFi PCR Premix.   
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The PCR reaction was assembled as follows: 
Component Volume 
CloneAmp™ HiFi PCR Premix 0.2 μL (1 unit) 
Template DNA 30-100 ng 
dNTPs (10 mM) 0.4 µl  
Primers containing 15 bp tail (10 μM) 0.5 µl/each 
Nuclease-free water up to 20 μL 
The specificity and size of the amplified fragment was checked by agarose gel electrophoresis and 
then the PCR fragment was purified by gel extraction. 
2.2.10.3 In-fusion cloning reaction 
Following manufacturer´s recommendations between 50-200 ng of both insert and vector were 
used to obtain good cloning efficiencies. For inserts smaller than 0.5 Kb, less than 50 ng were used 
and for vectors larger than 10 Kb more than 200 ng were used. The cloning reaction was 
assembled as follows: 
Component  Negative Control Sample 
Purified PCR fragment (insert) ---- 10-200 ng 
Linearized vector 50-200 ng 50-200 ng 
5X Fusion HD Enzyme Premix 2 µl 2 µl 
Nuclease-free water Up to 10 µl Up to 10 µl 
This reaction was incubated at 50°C for 15 minutes and then placed on ice. Then 2.5 µl of the 
reaction was used for transformation. 
2.2.10.4 Transformation using Stellar™ Competent Cells 
An aliquot of 50 µl of Stellar™ Competent Cells was used to transform 2.5 µl of the cloning 
reaction. After thawing the cells, the mixture was incubated on ice for 30 minutes. Then, the cells 
were heat-shocked for 45 seconds in a 42°C water bath and placed on ice for 3 minutes. Cells 
were diluted in 500 µl of pre-warmed SOC Medium and then recovered for one hour at 37°C in a 
shaker at ~250 rpm. 1/10th, 1/25th and the remaining transformation volume were used to streak 
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LB Agar plates containing the appropriate selective antibiotic. Colony PCR was performed the next 
day to screen for positive colonies. 
2.2.11 Sequencing 
To ensure no mutations were introduced during PCR reactions or after cloning, all plasmids 
produced and critical PCR products were sequenced by an external service (Beckman Coulter 
Genomics, UK). For each sequencing reaction, 1.5µg of each plasmid DNA or 250 ng of a purified 
PCR product together with 10 µl of appropriate primers (5 mM) were barcoded and sent for Quick 
Lane Express Sequencing to Beckman Coulter Genomics (Takeley, UK). 
2.2.12 Site-directed mutagenesis 
Site-directed mutagenesis by PCR was used in order to generate a PROX1 putative human 
enhancer carrying the non-common variant of rs3242786 SNP (G>A). This point mutation was 
generated following Higuchi's method (Higuchi et al., 1988) using PROX1 element Entry Clone as a 
template. Higuchi's method is based on two PCR rounds: in the first round two overlapping DNA 
fragments carrying the desired mutation are produced (Figure 2.2) using primers specified in 
Table 2.2. Mutations are introduced via primer mismatch. Then, products from the first round 
serve as a template for the second round and produce a duplex fragment that can be extended by 
a standard DNA polymerase after denaturation and renaturation.  
Table 2.2 Primers used to create a single site mutation in PROX1 element 
Primer name Sequence (5’ to 3’)  PCR Round 
PROX1-pF1 GCAAAAATGAACTTGAGAAATCC First round: PCR product A PROX1-G>A-pR TGATTACAAAGATGATAATTTATGACTGACATAC 
PROX1-G>A-pF TCATAAATTATCATCTTTGTAATCATTAAGGATC First round: PCR product B PROX1-pR1 CATTCCCTTTAATATCCCATGC 
PROX1-pF2 GCAAAAATGAACTTGAGAAATCC Second round PROX1-pR2 CATTCCCTTTAATATCCCATGC 
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For the first round of PCR, the following conditions were used: 
95°C 95°C 60°C 72°C 95°C 65°C 72°C 72°C 
2 min 20s 20s 30s 30s 15s 30s 5 min 
 Repeat 10 times Repeat 20 times  
Products A and B from the first round were purified from an agarose gel as described above. For 
the second round of PCR 7.5 µl of the purified A and B products were mixed and serve as template 
after denaturalization for 95 ºC for 10 minutes. The following conditions were used: 
95°C 95°C 50°C 72°C 95°C 65°C 72°C 72°C 
2 min 30s 30s 50s 30s 10s 30s 5 min 
 Repeat 10 times Repeat 20 times  
The final PCR product bearing the mutation was sequenced and was used to create a Gateway 
Expression Vector following the protocol detailed in section 2.2.9.3 above. 
 
Figure 2.2. Schematic representation of Higuchi´s Method used for site-directed mutagenesis. 
Adapted from (Hadzhiev, 2007)  
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2.2.13 Extension primer tag selection linker-mediated PCR (EPTS-LMPCR) 
In order to map the genomic insertion site of a transgene in several zebrafish transgenic lines 
generated in the lab, I used a modified linker-mediated PCR protocol adapted from (Yergeau et 
al., 2007). In standard linker-mediated PCR (LMPCR) protocols, genomic DNA is digested by 
restriction enzymes and linkers are ligated to the DNA fragments. PCR is then carried out using 
primers specific to the adaptors and to the terminal ends of the transposon. A variation of LMPCR 
is Extension Primer Tag Selection (EPTS)-LMPCR, where the fragmented genomic DNA regions 
containing the transgene are purified from the rest of genomic DNA fragments using a 
biotinylated primer specific to the transposon arms (Figure 2.3). Briefly, genomic DNA is digested 
with a restriction enzyme that does not cut in the transposon terminal end. A transposon-specific 
biotinylated primer is added and DNA is extended using a DNA polymerase that generated 
biotinylated products, which can be specifically purified by streptavidin beads. Genomic DNA 
fragments that do not contain the transposon are therefore removed. Through several steps, 
excess adaptors are washed away and the purified biotinylated product is used as a template for 
one or two rounds of PCR that used transposon and linker specific primers. The resultant 
product(s) are sequenced or subcloned in order to identify the genomic DNA sequences flanking 
the transposon integration site. 
The following protocol was followed: two μg of high-quality genomic DNA from the zebrafish 
transgenic lines of interest were digested at 37°C overnight with either AluI (for mapping the 3' 
end of Tol2 transgene) or DpnII (to map the 5'end). 1/10th of 3M sodium acetate and 3 volumes of 
100% ethanol were added and the samples were incubated on dry ice for 30 minutes. Samples 
were centrifuged at 16,000g for 10 minutes at RT and all liquid was removed and DNA pellet was 
air-dried. 
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Figure 2.3. Overview of EPTS-LMPCR protocol. 
After digesting genomic DNA with restriction enzymes (RE), a biotinylated primer (black circle) 
annealing the Tol2 inverse repeats (TIR) is used to extend DNA fragments containing the 
transgene insertion. These products are purified using streptavidin beads (red circle), adaptors are 
linked (grey lines), and amplification using oligos specific to TIRs and linkers takes place (black 
triangles). Resultant PCR products are either sequenced or subcloned to identify the genomic 
sequence flanking the transposon integration site. Figure adapted from (Yergeau et al., 2007).  
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The primer extension reaction was set up on ice as follows: 
Component Volume 
10X Pfu DNA Polymerase reaction buffer 5 µL 
dNTPs (10 mM) 1 µL 
Biotinylated Tol2 primer (0.125 µM) 2 µL (250 µM) 
Cloned Pfu DNA Polymerase  1 µL (2.5 units) 
Nuclease-free water 41 µL 
DNA pellet was resuspended in 50 μl of primer extension mix and carefully mixed. Each DNA and 
primer extension mix was transferred to a thin-walled 200 μl PCR tube and it was incubated in a 
thermocycler using the following parameters: 98°C for 3 minutes, 68°C for 30 minutes and 72°C 
for 30 minutes. 450 μl of nuclease-free water was added to each tube and the extended products 
were purified using a Millipore Microcon-30 spin column. Briefly, samples were spun for 12 
minutes at 12,000 g at RT to remove excess of primers and enzymes. In the elution step, the 
column insert was inverted and inserted in a fresh tube. A small concentrated volume ranging 
from 5 to 20 μl was visible after spinning for 3 minutes at 1,000 g at RT. Forty μl of nuclease-free 
water were added to each sample and they were kept at RT while streptavidin beads were 
processed. 
For each reaction 200 μg of beads were used. The amount of beads required to process all 
reactions was transferred to a fresh 1.5 ml eppendorf tube and it was placed on a magnetic 
holder for 1 minute. All liquid was removed with a pipette tip and the tubes were removed from 
the magnet holder. An equal volume of 2X BW buffer was added, mixed and placed in the 
magnet. Beads were washed this way for a total of 3 times. After the third was, beads were 
resuspended at a concentration of 200 μg per 40 μl of 2X BW buffer. 
Forty μl of streptavidin beads (Dynabeads® M-280) were mixed with 40 μl of the primer extension 
product and the mixture was rotated in an end-to-end rotator for at least 30 minutes at RT, 
followed by 30 minutes of shaking at approximately 200 rpm. 
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The beads were washed twice with 100 μl of nuclease-free water using the magnetic holder in 
order to remove genomic DNA fragments not containing the transgene, and therefore, were not 
bound by streptavidin beads. After the second wash, beads were resuspended in 10 μl of ligation 
mix, which was prepared as follows: 
Component Volume 
10X T4 DNA ligase buffer 1 µL 
50 pmol/l of annealed linker cassette 2 µL 
T4 DNA ligase  2 µL (6 units) 
Nuclease-free water 5 µL (final volume of 10 µL) 
Ligation reaction was incubated overnight at 16°C. The following morning beads were washed 
twice with 100 µL of nuclease-free water using magnetic holder as described. After the second 
wash, magnetic beads were resuspended in 10 µL of nuclease-free water and the first round of 
PCR was set up as follows: 
Component Volume 
Resuspended magnetic beads 1 µL 
dNTPs (10 mM) 1 µL 
OCI primer 2 µL (500 mM) 
Tol2 5N1 primer 2 µL (500 mM) 
10X Herculase Hot Start Polymerase buffer 5 µL 
Herculase Hot Start Polymerase  0.5 µL (2.5 units) 
Nuclease-free water 38.5 µL 
The following thermocyler program was used to amplify the product: 
Cycle number Denature Anneal Extend 
1 92°C for 2 min --- --- 
2-11 94°C for 30 sec 50°C for 30 sec 72°C for 2 min 
12-31 94°C for 30 sec 50°C for 30 sec 72°C for 2 min plus 10 sec per cycle 
32   72°C for 5 min 
 
After amplification 15 µL were run on a 1.25% agarose gel in 1X TAE. If products were visible, all 
bands from each sample were purified, as described above. If no products were visible or present 
at very low concentrations, a nested PCR was carried out using the following components: 
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Component Volume 
Primary PCR product 1 µL 
dNTPs (10 mM) 1 µL 
OCII primer 2 µL (500 mM) 
Tol2 5N2 primer 2 µL (500 mM) 
10X Herculase Hot Start Polymerase buffer 5 µL 
Herculase Hot Start Polymerase  0.5 µL (2.5 units) 
Nuclease-free water 38.5 µL 
Nested PCR was carried out using the following thermocyler program: 
Cycle number Denature Anneal Extend 
1 92°C for 2 min --- --- 
2-11 94°C for 30 sec 48°C for 30 sec 72°C for 2 min 
12-31 94°C for 30 sec 48°C for 30 sec 72°C for 2 min plus 10 sec per cycle 
32   72°C for 5 min 
The oligonucleotides used in this protocol are listed in Table 2.3. 
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Table 2.3 Primers used in EPTS-LMPCR protocol. 
Oligo name Sequence (5´-3´) Modification Description 
BIO-Tol2-3'end AAACTGGGCATCAGCGCAATTCAAT 5´ biotinylation Used for primer extension reaction of Tol2 3'end 
BIO-Tol2-5'end ATTCCATGGATATCAAGCTTAAACA 5´ biotinylation Used for primer extension reaction of Tol2 5'end 
NZ117 GACCCGGGAGATCTGAATTCAGTGGCACAGCAGTTAGG None Linker primer 
NZ118-P CCTAACTGCTGTGCCACTGAATTCAGATCTCCC 5´phosphorylation Linker primer phosphorylated on the 5'end to ligate extended fragments 
Tol2-N1-3'end CGCAATTCAATTGGTTTGG None Primer specific to Tol2 5'end (used in primary PCR) 
Tol2-N3-5'end aAGCTTAAACAAGAATCTC None Primer specific to Tol2 3'end (used in primary PCR) 
OCI GACCCGGGAGATCTGAATTC None Primer specific to linker sequence (used in primary PCR) 
Tol2-N2-3'end-nested GCAAGGGAAAATAGAATGAAG None Primer specific to Tol2 5'end (used in nested PCR) 
Tol2-N4-5'end-nested TCTTTCTTGCTTTTACTTTTA None Primer specific to Tol2 3'end (used in nested PCR) 
OCII-nested AGTGGCACAGCAGTTAGG None Primer specific to linker sequence (used in nested PCR) 
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2.2.14 Capped mRNA in vitro transcription 
Tol2, CFP and PhiC31 integrase mRNA for microinjections were in vitro transcribed from pCS2+-
Tol2, pCS2+-CFP and pCS2+PhiC31 plasmids respectively using mMESSAGE mMACHINE® Kit from 
Ambion, UK. Linearized plasmid DNA was used as a template for transcription. Digestion of pCS2+ 
plasmids was carried out with an appropriate digestion enzyme cutting downstream of the polyA 
of the insert to be transcribed (NotI). After linearization the plasmid DNA was purified using 
phenol-chloroform extraction, as described in section 2.2.1 above), and precipitated with 3M Na 
acetate and ethanol and resuspended in nuclease-free water. The capped transcription reaction 
was assembled at room temperature as follows: 
Component Volume 
2X NTP/CAP 10 µl 
10X Reaction Buffer 2 μl 
Purified linear plasmid DNA 100ng-1 μg 
Enzyme Mix 2 μL 
Nuclease-free water up to 20 μL 
The reaction was mixed thoroughly and incubated for 2-4 hours at 37°C. To remove plasmid DNA 
template, 1 µl of Turbo DNase was added and it was incubated for 15 minutes at 37°C. To remove 
the enzymes as well as unincorporated nucleotides, transcribed RNA was further purified by 
phenol-chloroform extraction, as described. First, 115 µl of nuclease-free water and 15 µl of 
Ammonium Acetate Stop Solution were added to the reaction and were thoroughly mixed. RNA 
was extracted with 1 volume of 5:1 phenol: chloroform equilibrated with citric acid (pH= 3.8). RNA 
was precipitated by adding isopropanol and RNA was eluted in nuclease-free water. RNA correct 
size and purity was checked by agarose electrophoresis and spectophotometry. 
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2.3 General microbiological methods 
2.3.1 Transformation using chemically competent cells 
Retransformation of existing plasmids was performed using an aliquot of 30 µl Alpha-Select 
Bronze Efficiency DH5α chemically competent cells. Transformation of ligation reactions was 
performed using an aliquot of 50μl of Alpha -Select Silver Efficiency DH5α chemically competent 
cells or 100μl of Stellar™ Competent Cells following manufacturer’s instructions. 
Between 10 and 50 ng of DNA or 2.5-10 μl of ligation reactions were incubated on ice for 30 
minutes, heat-shocked in a 42°C water bath for 45 seconds and placed on ice for 3 minutes. Cells 
were recovered with 1 ml of LB Broth 1X and incubated at 37°C for at least 1 hour in a shaker at 
approximately 300 rpm. 100-500 µl of cell transformation mixture was plated by spreading on 
fresh LB Agar plates containing the appropriate selective antibiotic. Plates were incubated 
overnight at 37°C. 
2.3.2 Transformation of electrocompetent cells 
For multisite LR cloning DH5α electrocompetent cells were used. Ten µl of the LR Reaction were 
transformed into an aliquot of 40 µl cells. The mixture was incubated on ice for 15 minutes in a 
0.1 cm cuvette and was electroporated using a voltage of 1.8kV in a BIO-RAD Micropulser. Cells 
were recovered with 1 ml of LB Broth 1X and incubated at 37°C for at least 1 hour in a shaker at 
~200 rpm. All the cells were plated by spreading onto fresh LB Agar plates the appropriate 
selective antibiotic. Plates were incubated overnight at 37°C. 
2.4 Fish husbandry and embryo methods 
2.4.1 Zebrafish husbandry 
Zebrafish were kept in the BMSU according to Home Office Regulations. Seven to fifteen pairs of 
adult zebrafish were maintained in 3.5 litre polycarbonate tanks in a ZebTEC recirculating housing 
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system (Tecniplast, UK) on a regular light-dark cycle, with 14 hours of light and 10 hours of 
darkness. Water temperature was kept at 26°C. Adults were fed three times a day combining ZM 
Medium Premium Granular dry food and hatched brine shrimp cysts (ZMSystems, UK). 
2.4.2 Production of zebrafish embryos and eggs 
Crosses of adult zebrafish were carried out in 1 litre breeding cages containing an inlay with a 
bottom mesh, which allowed for embryo collection and prevented the adult fish from eating their 
eggs. In the evening, one female and one male were placed in a crossing cage separated by a 
divider and left overnight. Fertilized eggs were collected by filtering the water in each crossing 
cage with a net. 
2.4.3 Raising zebrafish larvae 
Zebrafish embryos were kept in 90 cm Petri dishes in E3 Medium supplemented with gentamicin 
(0,01%) in an incubator at 28.5 ºC for 5 days after fertilization (Westerfield, 1993). Medium was 
changed every day and dead embryos were removed to avoid bacterial infections. PTU was added 
to E3 Medium (0, 03%) in embryos older than 24 hpf, when removal of pigment was necessary to 
allow visualisation. 
2.4.4 Dechorionation 
Embryos were dechorionated before 48 hpf by adding 1 ml of Pronase stock solution (10 mg/ml) 
to 10 ml of E3 medium. After swirling the plate, the enzymatic reaction was carefully controlled 
under the microscope. When 2/3 of the embryos were out of the chorion, they were washed at 
least three times with fish water to remove all traces of the enzyme and placed in fresh plates 
with E3 Medium supplemented with gentamicin. Alternatively, embryos older than 24 hpf were 
dechorionated manually using fine and sharp forceps. 
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2.4.5 Microinjections 
Fertilized embryos were microinjected using an analogue pressure-controlled microinjector from 
Tritech Research, US. Needles for microinjection were pulled using a Flaming Brown needle puller. 
Microinjection solutions contained 15 ng/µl of high-quality plasmid DNA, 30 ng/µl of CFP mRNA 
(when appropriate), 15 ng/µl of Tol2 mRNA or 15 ng/µl of PhiC31 integrase mRNA (unless 
otherwise indicated), filtered phenol red solution (0,2%) and nuclease-free water up to 10 µl. 
Embryos within 10 minutes of fertilization were collected in Petri dishes and water was removed, 
so that just a fine layer of water was covering the eggs. Under the control of the 
stereomicroscope eggs were injected through the chorion with approximately 1 nl of 
microinjection solution. Successful microinjections were visible due to phenol red solution. 
Immediately after injections, embryos were transferred to a dish containing E3 Medium and 
gentamicin and were incubated at 28,5 ºC for a maximum of 5 days. Embryos expressing high 
levels of CFP mRNA at 24 hpf were considered correctly injected and further analyzed. 
2.4.6 Generation of stable transgenic lines 
Injected embryos were returned to the fish facility and raised as a stock to screen for germline 
transmission of the transgenes. Approximately 100 embryos injected with each construct were 
raised to create stable transgenic lines. Larvae and young adults were maintained in breeding 
cages for the first 3 weeks and fed at least three times a day with fry diets (ZM-000, ZM-100 and 
ZM-200; ZMSystems, UK), in combination with live food (paramecia, ZMSystems, UK). After three 
weeks, fish were moved to regular 3.5 tanks in a regular recirculating housing system (ZebTEC, 
Tecniplast). 
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2.5 Whole-mount in situ hybridization (WISH) 
Whole-mount in situ hybridization (WISH) is a widely used technique to describe the pattern of 
expression of developmental genes in preserved organisms (Herrmann, 1991; Schulte-Merker et 
al., 1992). It allows the detection of mRNA in whole embryos by using an antisense RNA probe, 
which is synthesized in vitro and labelled with digoxygenin-UTP. After permeabilization of the 
embryos and hybridization of the probe, the transcript of interest is visualized by an anti-
digoxygenin antibody conjugated to alkaline phosphatase, which catalyzes a chromogenic 
reaction. WISH was carried out following the protocol described by (Thisse and Thisse, 2008). 
2.5.1 WISH RNA probe synthesis 
Antisense RNA probes were labelled with digoxigenin-UTP by in vitro transcription with SP6 or T7 
polymerases using a DIG RNA labelling kit from Roche Diagnostics. As a template, constructs that 
contained SP6 or T7 promoters downstream the DNA to be transcribed were used. Vectors were 
linearized with a suitable enzyme and the RNA polymerases were used to produce a run-off 
transcript. Labelling reaction was assembled as follows: 
Component Volume 
10X dNTP labelling mixture 2μl 
10X transcription buffer 2μl 
RNase inhibitor 1μl 
SP6/T7 RNA Polymerases 2μl 
Linearized purified DNA template 1 μg 
 
These components were mixed and incubated at 37 °C for 2 hours. DNA template was removed by 
incubating the sample with 2 μl of RNase-free DNase I for 15 min at 37 °C. This reaction was 
stopped by adding 2 μl of 0.2 M EDTA (pH 8.0). The DIG-labelled probe was further purified by 
filtering it through resin based Illustra MicroSpin G25 Columns. Probes were quantified and their 
size and quality were checked by agarose electrophoresis. 
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2.5.2 Fixation of embryos 
Dechorionated embryos of the appropriate developmental stages were fixed in 4% 
paraformaldehyde diluted in PBS overnight at 4°C. The next day, embryos were dehydrated by 
replacing PBS with methanol. Washes of 75%, 50% and 25% PBS-Methanol were performed for 5 
minutes each. Embryos were washed twice in 100% methanol and stored at -20°C. 
2.5.3 Permeabilization of embryos 
Embryos were rehydrated in successive dilutions of methanol in PBST (75%, 50%, 25% methanol-
PBST). Washes were performed at RT for 5 minutes each with gentle agitation (40 rpm). Embryos 
were washed 4 times in PBST, 5 minutes per wash. Embryos were permeabilized by digestion with 
proteinase K (10 μg/ml) at RT for 10 minutes if they were 24 hpf and for 30 minutes if they were 
older than 24 hpf. 
2.5.4 Hybridization of embryos 
Digestion was stopped by incubating the embryos for 20 minutes in 4% PFA. Residual fixative was 
removed by washing 4 times in PBST. Embryos were pre-hybridized in 700 μl of hybridization 
buffer for 2-5 h in a 70°C water bath. Embryos were hybridized overnight at 70°C, in 200 μl of 
hybridization mix containing 50-100 ng of DIG-labelled RNA probe (for recipe see section 2.1.8 
above). 
2.5.5 Washes and incubation with anti-DIG antibody 
The next day, hybridization buffer was replaced with 2X SSC through a series of 10 minutes 
washes at 70°C with hybridization buffer (-) diluted in 2X SSC with gentle agitation (for recipe see 
section 2.1.8 above). Embryos were washed twice in 0.2X SSC at 70°C for 30 minutes. Next, 0.2 X 
SSC was replaced with PBST through a series of 10 minutes washes at RT with 0.2X SSC diluted in 
PBST. In order to prevent non-specific binding of the antibody, embryos were incubated in 
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blocking buffer for 3-4 hours at RT with gentle agitation. Anti-DIG antibody was diluted at 1:4000 
with blocking buffer and incubated overnight at 4°C on a horizontal orbital shaker. 
2.5.6 Washes and staining 
The antibody solution was discarded and embryos washed with gentle agitation in PBST 4 times, 
for 30 minutes each wash. Embryos were washed twice with staining buffer for 5 minutes. In 
order to stain the embryos, they were transferred to a 24-well plate and staining buffer was 
replaced with 1 ml of fresh staining solution. The colorimetric reaction was monitored closely 
under the microscope and embryos were kept in the dark between checks.  
When the staining intensity and pattern desired was reached, the reaction was stopped by adding 
stop solution for 3 minutes. Embryos were washed 3 times in PBST and then fixed in PFA 4% for 
30 minutes at 4°C and dehydrated through a series of washes with methanol diluted in PBST. 
2.5.7 Embryo mounting 
Dehydrated embryos were mounted in 100% glycerol. Methanol was replaced with glycerol 
through a series of washes with glycerol diluted in water. Washes were performed at RT for 10 
minutes with gentle agitation. For imaging, embryos were placed in a small glycerol drop on glass 
slide, covered with a glass coverslip and oriented accordingly.  
2.6 Antibody staining 
Embryos were fixed, dehydrated and permeabilized as described above. After proteinase K 
digestion, embryos were washed 4 times in PBST for 30 minutes with gentle agitation and then 
embryos were blocked for at least 1 hour in blocking buffer (for recipe see section 2.1.8 above). 
The primary antibody was added and incubated overnight at 4°C with gentle agitation. For vasa 
staining 1:500 dilution of anti-vasa antibody was used, a kind gift of Holger Knaut (Knaut et al., 
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2000). The following day, the primary antibody was removed and embryos were washed 4 times 
in PBST for 30 minutes with gentle agitation. Embryos were blocked for at least 1 hour in blocking 
buffer, and then incubated at 4°C with the secondary antibody overnight. The embryos were 
washed 4 times in PBST for 30 minutes. For secondary antibodies conjugated with HRP, detection 
was carried out with DAB Staining Kit, following manufacturer’s instructions. Embryos were briefly 
incubated in DAB staining solution in the dark. The reaction was carefully monitored under the 
brightfield microscope and was stopped by washing the embryos twice with PBST. For long-term 
storage, embryos were then fixed in PFA 4% and dehydrated in methanol as described above. 
2.7 Southern blotting  
Southern blot was carried out with invaluable technical help of Elizabeth Marsh (University of 
Birmingham, UK) following the protocol described in (Wilson et al., 2007). Briefly, 5 µg of high-
quality genomic DNA from clutches of GFP-positive and GFP-negative 5 dpf embryos from an F3 
outcross of F3 Tg(Xla.crygc:attP-GFP)uobL6 and Tg(Xla.crygc:attP-GFP)uobL12 lines were digested 
with an excess of the appropriate enzymes at 37°C overnight. To control for copy number 
integration, the plasmid used to generate these lines: pTol2/Xla.crygc:attP-GFP (pDB896) vector 
(Roberts et al., 2014) was spiked in WT genomic DNA and digested in parallel to the samples. 
Digested DNA was separated on 0.8% agarose gel at 45 V overnight and visualized quickly the 
morning after. The gel was then washed twice for 20 minutes in 0.25M HCl, and twice for 30 
minutes in 0.4 M of NaOH with gentle shaking. DNA was transferred to a GeneScreen™ nylon 
membrane (PerkinElmer, MA) by capillarity overnight in 0.4 NaOH solution. The membrane was 
washed twice in 2X SSC and DNA was crosslinked to the nylon membrane using a Stratalinker® UV 
crosslinker (Stratagene, US). The membrane was blocked with 5 ml of hybridization buffer (recipe 
in section 2.1.8 above) containing 10 mg/ml of denatured calf thymus genomic DNA for a 
minimum of 60 minutes in a rotating oven at 42°C. 
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The probe containing attP-GFP and Tol2 3’arm was generated by digesting pTol2/Xla.crygc:attP-
GFP (pDB896) vector with ApaI and BamHI enzymes and purified as described in section 2.2.7. 
Fifty ng of the probe was labelled with [α-32P]-CTP (Perkin Elmer, UK) using Ready-To-Go DNA 
Labelling Beads (GE Life Sciences, UK) and purified using Illustra ProbeQuant G-50 Micro Columns 
(GE Life Sciences, UK). The labelled probe was denatured and added to the hybridization buffer. 
The membrane was incubated with the radiolabelled probe at 42°C overnight. The following 
morning, it was washed at RT for 15 minutes in 2X SSC/0.1% SDS and then with 0.1X SSC/0.1%  to 
remove excess background. Finally, it was wrapped in plastic film and exposed to autoradiograph 
film for at least 16 hours. To analyze the copy number of the transgenic recipient lines, the nylon 
membrane was blocked by light for 30 minutes and transferred to a Storage Phosphor Screen 
(Molecular Dynamics, UK). It was scanned on a Typhoon 9200 Variable Mode Imager (Amersham 
Biosciences, UK) with Typhoon Scanner Control software (v5.0) and analyzed using ImageQuant 
5.1. 
2.8 Fluorescence imaging methods 
Injected embryos were individually screened for transgenic expression using a Nikon SMZ1500 
epifluorescence microscope. Agarose coated plates were used for orienting anaesthetised 
embryos. Relevant expression patterns were documented using NIS Elements imaging software.  
For high resolution imaging of mosaic or stable transgenic expression Olympus ScanR high content 
screening microscope was used. A brass template adapted for 96-well plate was employed to 
orient and image 24-72 hpf embryos (Peravali et al., 2011). 96-well plates were coated by 60 µl of 
1.5% liquid agarose. The level was made even by adding 20 µl of 100% ethanol. The brass 
template was placed and agarose was allowed to set for around 30 minutes. After cooling down, 
template was removed and ethanol was washed away by rinsing the plate several times with tap 
water. Individual anesthetized embryos in 0.03% MESAB were then pipetted into each well with a 
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cut yellow tip in a volume of 100 µl of medium. They were oriented with a bent 19 G hypodermic 
needle attached to a plastic Pasteur pipette under the stereomicroscope. 
Stacks containing 100 slices of 4 µm thickness were taken in both fluorescence and brightfield 
channels. For fluorescence channels, out of focus slices were manually removed and maximum 
projections were made using an extended depth of field plug-in for ImageJ software (Forster et 
al., 2004). Brightfield images were processed using Photoshop CS6 (Adobe). For high resolution 
imaging of whole embryos six overlapping stacks were taken. Each stack was processed separately 
and afterwards reconstructed using a "Grid and Stitch" plug-in for Image J software (Preibisch et 
al., 2009). Contrast and brightness was adjusted linearly afterwards using Photoshop CS6 (Adobe). 
2.9 Statistical analysis 
Statistical analyses were carried out using GraphPad Instat Software version 3.05 for Windows 
(GraphPad Software, US). Chi-square test or Fisher’s exact test where used to compare rates of 
expression patterns between injection groups. P values smaller than 0.05 were considered to be 
statistically significant. 
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Chapter Three: FUNCTION OF ISLET-SPECIFIC HUMAN CANDIDATE 
ENHANCERS IN ZEBRAFISH 
Foreword:  
The results presented in this chapter have been partially published in (Pasquali et al., 2014). 
This project is the result of a collaboration with Lorenzo Pasquali and Jorge Ferrer, affiliated to 
IDIBAPS (Spain) and Imperial College London (UK), and was funded by Marie Curie BOLD ITN. 
The computational analysis was carried out by Lorenzo Pasquali. 
  
 80 
 
3.1 INTRODUCTION 
3.1.1 Type-two diabetes as a disease model  
Type 2 diabetes (T2D) is a complex metabolic disorder that accounts for approximately 90% of all 
cases of diabetes and affects hundreds of millions of people worldwide (Stitzel et al., 2010). It is 
characterized by hyperglycaemia (elevated blood sugar) and insulin resistance. Insulin is the key 
hormone for regulation of blood glucose levels. It is secreted by β-cells of the pancreatic islets, 
which take glucose from blood and metabolize it to produce energy (Figure 3.1, (Stumvoll et al., 
2005)). Normally, the pancreatic β-cells can adapt to changes in insulin by up-regulating the levels 
of secretion. However, when the insulin production by β-cells is unable to meet the metabolic 
demand of peripheral tissues diabetes occurs (Oliver-Krasinski and Stoffers, 2008). Type-one 
diabetes is characterized by the autoimmune attack of beta cells by auto-reactive T cells, resulting 
in deficient insulin production and a severely reduced β-cell mass (Stankov et al., 2013). Type-two 
diabetes on the other hand is characterized by insulin resistance, which implies a reduced ability 
 
Figure 3.1 Regulation of insulin secretion in a pancreatic beta cell.  
Beta cells sense concentration of glucose and regulate insulin secretion. In the resting state, the 
ATP-sensitive KATP channel is open, the beta-cell membrane is hyperpolarized and the voltage-
gated calcium channel is closed. Upon ingestion of food, the serum glucose levels are elevated 
and glucose enters the beta cell through a non-insulin dependent GLUT2 transporter and 
becomes phosphorylated by the glucokinase enzyme. Further glucose metabolism in the 
mitochondria produces ATP, which is involved in membrane depolarisation and closure of the 
potassium channel. The change in ADP/ATP ratio induces the closure of the K+ channel. This 
depolarizes the beta-cell membrane, opening the Calcium channel, and triggering the exocytosis 
of insulin. Image adapted from (Sperling, 2005).  
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of the beta cells to respond to insulin, and which leads to disruption of function and to a modest 
beta cell mass loss (Mastracci and Sussel, 2012). 
3.1.2 Type 2 diabetes as a disease model to unravel cis-regulatory networks 
Unravelling the mechanisms that govern tissue-specific cis-regulation is essential to understand 
development and disease. In the case of endocrine pancreas and beta cell function, the 
motivation is underlined by the fact that epidemic diabetes is becoming a global health challenge. 
The prevalence of diabetes mellitus has more than doubled over the last 30 years, accounting in 
2010 for more than 285 million affected people worldwide, 90% of whom suffer from type-two 
diabetes (Chen et al., 2012). Type-two diabetes (T2D) is a complex multifactorial metabolic 
disorder that results from the interplay between genetic, environmental and behavioural factors, 
such as smoking, obesity, sleeping disorders and depression (Chen et al., 2012). Around 60 T2D 
susceptibility loci have been identified so far (Morris et al., 2012), however it is calculated that 
this susceptibility can only explain between 5 and 10% of the risk (Bramswig and Kaestner, 2014). 
3.1.3 Transcriptional regulation in the pancreatic islet 
There are several key transcription factors that control both pancreas development and β-cell 
specification. Some of them, including PDX1, PTF1A, PAX6, and NKX2.2 are also conserved in 
zebrafish (Biemar et al., 2001). PDX1 or Pancreas Duodenum Homeobox-1 is a marker of 
pancreatic progenitors essential for pancreas development and β-cell differentiation and it is 
conserved from human to zebrafish (Milewski et al., 1998). Pdx1 regulates the expression of 
several key genes in the beta-cell such as insulin and glucagon by binding directly to their 
promoters (Leonard et al., 1993; Petersen et al., 1994). Deletion of Pdx1 in mouse causes 
pancreatic agenesis (Jonsson et al., 1994) and heterozygous or homozygous mutations in PDX1 
gene can lead to permanent neonatal diabetes (Stoffers et al., 1997b; Schwitzgebel et al., 2003; 
Thomas et al., 2009) or monogenic diabetes (MODY, maturity-onset diabetes of the young, 
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(Stoffers et al., 1997a). Pdx1 is initially expressed in the pancreatic progenitors and later restricted 
to the insulin producing β-cells and more scarcely in somatostatin-producing δ cells (Ohlsson et 
al., 1993). Precisely, it is the combined expression of Pdx1 and Ptf1a (Pancreas-specific 
Transcription Factor) that specifies pancreatic commitment from multipotent progenitors cells, 
which can give rise to endocrine, exocrine or ductal lineages (Kawaguchi et al., 2002; Burlison et 
al., 2008). Other important transcription factors involved in pancreas development are FoxA gene 
family. It has been shown that Foxa1 and Foxa2 can regulate Pdx1 expression by specifically 
binding to conserved enhancer sequences located around 6 kb upstream of Pdx1 TSS. Moreover, 
deletion of Foxa1 and Foxa2 in mice causes pancreatic hypoplasia and loss of Pdx1 expression. 
(Gao et al., 2008). 
Nk homeodomain factors Nkx2.2 and Nkx6.1 are also essential for pancreas development and β-
cell differentiation. Both TFs are expressed in the pancreatic buds but Nkx6.1 becomes restricted 
to the β-cells in adults, similarly to Pdx1, while Nkx2.2 is expressed in α, β and PP cells of the 
mature pancreas (Sussel et al., 1998). In mice lacking Nkx2.2 TF β-cells fail to differentiate, they 
develop severe hyperglycaemia and die shortly after birth (Sussel et al., 1998). Interestingly, the 
phenotypes displayed by Nkx6.1/Nkx2.2 double mutant mice is identical to the Nkx2.2 mouse, 
implying that Nkx6.1 is downstream of Nkx2.2 in β-cell differentiation pathway (Sander et al., 
2000). 
3.1.4 Chromatin profiling in the pancreatic islet: how much do we know 
Despite the fast development in the field of epigenetics and the global prevalence of diabetes, the 
pancreas epigenome has not been systematically assessed. The first attempt to map genome wide 
regulatory regions in purified human islets used a technique called FAIRE-Seq, that is, 
Formaldehyde-Assisted Isolation of Regulatory Elements, coupled with NGS (Gaulton et al., 2010). 
The authors found that open chromatin sites defined by FAIRE were not isolated, but clustered in 
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the genome in what they termed COREs (Clusters of Regulatory Elements). These clusters are in 
average 25 kb in size and are usually linked to single islet-specific genes such as PDX1 or NKX6.1 
(Gaulton et al., 2010). The first study that profiled chromatin in human pancreatic islets mapped 
several histone modification marks by ChIP-Seq (H3K4me1-3 and H3K27me3). They found that 
insulin and glucagon promoters were sparsely enriched in H3K4 methylation and also made global 
predictions of which described T2D-associated polymorphisms were overlapping with H3K4me1 
enriched regions and therefore could be functional (Bhandare et al., 2010). However, this study 
lacked functional validations. Following a similar strategy, around 18,000 putative promoters and 
34,000 distal elements were found when profiling chromatin in pancreatic islets by a combination 
of DNase I-Seq and ChIP-Seq on CTCF and H3K4me3, H3K4me1 and H3K79me2 (Stitzel et al., 
2010). Upon validation of some of the putative enhancers in a murine islet cell line they found 
that 4 out of the 12 enhancers that worked in vitro harboured T2D-associated SNPs (Stitzel et al., 
2010). Other studies have focused on master regulators of the pancreas. Khoo and colleagues 
investigated PDX1 occupancy and targets both in human and mouse islets to find that binding 
sites are not generally conserved; whereas in mouse islets PDX1 is enriched in promoter regions, 
in humans it is preferentially bound to intragenic regions (Khoo et al., 2012). Nevertheless, what 
most of these studies have in common is the lack of functional validation of predicted CREs in the 
context of a complex organism. 
3.1.5 Preliminary data leading to the project 
In an effort to elucidate the linkage between transcriptional regulation and epigenetics, our 
collaborators decided to profile islet-specific transcription factor binding sites and several key 
regulatory histone modification marks, which together with expression data would help to 
understand pancreas cis-regulation in humans.  
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Genome-wide integrated maps of key pancreatic transcription factors, including PDX1, NKX6.1, 
NKX2.2, FOXA2 and MAFB and active chromatin marks including H3K4me1, H3K4me3 and H327ac, 
were generated by Lorenzo Pasquali (IDIBAPS, Barcelona) using purified human islets as starting 
material. Bioinformatic analysis revealed ~95,000 “open” chromatin regions in human islets 
marked either by FAIRE-Seq or by H2A.Z enrichment. Among these sites, discrete subclasses of 
open chromatin regions can be distinguished that correlate with distinct CRE categories (Figure 
3.2). The cluster termed “C1” contained ~14,000 regions that showed strong H3K4me3-
enrichment, a typical promoter chromatin signature. ”C2“ regions (~30,000) resembled inactive or 
“poised” enhancers (unimodal H3K4me1-enrichment lacking H3K27ac (Creyghton et al., 2010; 
Rada-Iglesias et al., 2011), and “C3” regions (~31,000) had a typical active transcriptional 
enhancer signature (strong bimodal enrichment in H3K4me1 and H3K27ac but not H3K4me3. 
Among remaining open chromatin sites, ~8,900 (C4) were enriched in CCCTC-binding factor, while 
~9,600 (C5) lacked active histone modifications. 
 
Figure 3.2 Clustering of~95,000 open chromatin regions based on active histone modifications 
revealed 5 distinct epigenetic classes. 
Clusters of open chromatin sites (C1-C5) defined by H2AZ or FAIRE (top). Transcription factor 
distribution in each cluster is depicted (bottom). Figure adapted from (Pasquali et al., 2014).  
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3.1.6 Aims: 
These initial observations led to the hypothesis that regions within C3 cluster could act as 
developmental islet enhancers, since they were open chromatin sites enriched in H3K27ac and 
H3K4me1. Harnessing the advantages of zebrafish as an effective transgenesis model, we 
proposed the use of zebrafish as a tool to test pancreatic-specific CREs. Our main motivations 
included the exploitation of easy transgenesis screens, the conservation of the expression and 
function of pancreas-specific transcriptional network between mammals and zebrafish and a 
shared anatomical structure of the pancreas. 
In order to test the function of putative CREs, several candidate regions conserved at the 
sequence level between human and fish were selected for transgenesis assays. In addition, 
regions within C2 and C5 clusters were used as control regions to evaluate the accuracy of the 
enhancer selection process. Within this global aim, several specific objectives were set: 
• To test the potential of these regions to direct tissue-specific activity in the transient 
transgenic zebrafish embryo. 
• To verify autonomous independent activity of the human candidate enhancers. 
• To verify whether the transient patterns were valid in stable transgenic lines and to 
evaluate how faithful are transient transgenic assays to fully recapitulate the expression 
pattern of a human CRE. 
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3.2 METHODS 
Putative human elements were cloned into 2 different contexts: linked to hsp70 zebrafish 
promoter using Multisite Gateway Cloning, and linked to gata2 promoter using T4 ligation-
mediated cloning.  
3.2.1 Multisite-Gateway Cloning of Entry Clones and Expression Vectors 
Expression vectors containing a human putative enhancer linked to hsp70 zebrafish promoter and 
reporter gene (Venus fluorescent protein) were cloned using the Multisite Gateway Cloning 
System by Invitrogen, following manufacturer’s instructions. Selected human putative enhancers 
were amplified from human genomic DNA provided by our collaborators using the primers listed 
in Table 3.1. In order to control zebrafish promoter functionality, a non-conserved region from 
Fugu rubripes showing no regulatory activity (fr2(assembly 2004) chrUn:54,537,362-54,537,937) 
was used (Sanges et al., 2006). As additional negative controls, two genomic regions from C2 and 
C5 clusters were also cloned (Table 3.1). Final expression vectors were generated through LR 
recombination reactions between Entry Clones and pSP1.72BSSPE-R3-R5-hsp70-Venus 
Destination Vector, as described (Roure et al., 2007). These vectors contained Tol2 transposase 
arms to facilitate single-copy genome integration of the construct into the host genome by co- 
injection with Tol2 transposase mRNA (Figure 3.3). 
3.2.2 Molecular cloning of putative human enhancers in a different construct 
In order to test the autonomous capacity of candidate enhancers to drive tissue-specific 
expression, the pDB896-hsp70-mCherry vector available in the lab, a kind gift from Darius 
Balciunas (Balciunas et al., 2006), was modified to contain a multicloning site where the human 
element of interest, zebrafish gata2 promoter and a reporter protein (YFP) could be inserted 
using T4 ligation-mediated cloning. The three elements were flanked by restriction sites, which 
allows for an easy exchange of both reporter genes and cis-regulatory elements. The resulting 
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vector was named pDB896-gata2-YFP. Zebrafish promoters can be cloned using AgeI and XhoI 
sites, and the reporter proteins using XhoI and SnaBI sites. The putative elements were cloned 
using the primers described in Table 3.1 adding EcoRV and SpeI tails to the forward and reverse 
primers respectively. 
 
 
 
 
Figure 3.3 Schematic representation of the vectors cloned for each human element. 
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Table 3.1 Primers used to amplify human putative enhancers and zebrafish promoters from genomic DNA 
CRE  Genomic coordinates (Hg18 or Zv9) Forward primer (5’-3’) Reverse primer (5’-3’) 
Product size 
(bp) 
C3-1 chr4:85339334-85339883 TGCAGTCACATGCACAAAG AGAAACTAGGGCTGTGTTTA 550 
C3-3 chr5:51786984-51788169 TTAAGGTCCCTCTGCCATGT AACTCTTCCCAAGCCTCATT 1186 
C3-4 chr1:212242123-212243697 AATTTTCTTCCTCCGCTTTC CATTCCCTTTAATATCCCATGC 1575 
C3-5 chr19:6066434-6067353 GAAAAGCGCTCCAGAAATTG AGTTCCCTTTGCACTTGTT 920 
C3-6 chr10:114736989-114737824 CCAAGGCTTGAAAATGGATG AGAGCTTTTTCTAGGCCTCC 836 
C2-11 chr1:244375378-244375874 AGGCATCTGAGCTTCACTGG AGTCAGACAGACCTGGAATA 491 
C5-14 chr4:139712081-139712568 ACGCATATGGTCGGATATGA AAGGCCTGTAGAGAAAGAAT 488 
hsp70 zebrafish promoter chr3:26911324-26911472 TTGATTGGTCGAACATGCTGG CAGTCCGCTCGCTGTCTCGCT 149 
gata2 zebrafish promoter chr11:3,922,100-3,923,130 ATTCATTAATAGAATAGAGGCATT CTCAAGTGTCCGCGCTTA 1031 
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3.3 RESULTS 
3.3.1 Selection of candidate islet-specific human enhancers based on epigenetic marks 
and sequence conservation analysis 
Based on the epigenetic clusters uncovered by our collaborators, we decided to test whether 
human putative enhancers, predicted by the presence of a strong bimodal enrichment in 
H3K4me1 and H3K27ac in the human islet, could function as developmental enhancers in the 
zebrafish pancreas. We selected 5 enhancer candidates from cluster C3 based on human-
zebrafish conservation (>70% sequence identity over 100 nt, hg18 vs DanRer7). Tested fragments 
were around 1 kb in size around the central point of FAIRE or H2AZ. Element boundaries were 
determined manually by examining epigenetic enrichment profiles. In parallel, we also checked as 
a proof of principle two additional regions that belonged to C2 cluster, resembling inactive 
enhancers and C5 cluster lacking histone modification marks (Table 3.1). 
3.3.2 Functional testing of putative islet-specific developmental enhancers using the 
zebrafish embryo 
Zebrafish transient transgenesis assays have been successfully applied in the past to functionally 
uncover long-range acting cis-regulatory elements (Muller et al., 1997; Muller et al., 1999; 
Dickmeis et al., 2004; Woolfe et al., 2005). To investigate the function of human putative 
enhancers in vivo, selected candidates were linked to zebrafish hsp70 promoter and YFP reporter 
gene and were injected in zebrafish embryos as described (Gehrig et al., 2009). Reporter gene 
expression pattern was assessed during the first 5 days of development and all tissues of 
expression from at least three experimental replicates were annotated (Table 3.2). 
Representative patterns of expression were documented at 72 hpf, as the zebrafish pancreas has 
developed completely at this stage (Tiso et al., 2009). As a control a Fugu region with no enhancer 
activity linked to hsp70 minimal promoter was used (Sanges et al., 2006). 
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Table 3.2 Frequency of transgene expression in 3 dpf injected zebrafish embryos. 
 
 
Tested 
CRE 
Nearby gene upstream 
(kb from TSS) 
Nearby gene 
downstream (kb from 
TSS) 
Domains of expression at 72 hpf (%) No of 
injected 
embryos 
No of 
replicates  Lens Pancreatic islet Neurons Hindbrain Floor plate 
Pronephric 
duct 
C3-1 AGPAT9 (663) NKX6-1 (299) 49.9  0.0 18.6  0.0 0.0  0.0  746 4 
C3-3 ISL1 (1,108) PELO (296) 94.9  38.3  0.0  0.0  0.0  0.0 352 3 
C3-4 PROX1 (14) SMYD2 (277) 0.0 28.7  0.0 0.0 0.0 0.0 230 3 
C3-5 LOC100128568 (88) RFX2 (43) 0.0 32.9 0.0 94.7  86.8  44.7 228 3 
C3-6 TCF7L2 (27) HABP2 (573) 41.3 0.0 46.6 0.0 0.0  0.0 496 4 
C2-11 KIF26B (990) SMYD3 (271) 0.0 0.0 0.0 0.0 0.0 0.0 466 4 
C5-14 LINC00499 (481) CCRN4L (224) 0.0 0.0 0.0 0.0  0.0 0.0  407 4 
Fugu n/a n/a 0.0 0.0 0.0  0.0 0.0 0.0 217 3 
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Figure 3.4 C3 human active enhancer regions drove tissue-specific transient expression patterns 
in zebrafish.  
A. Merged images of YFP and brightfield channels for zebrafish embryos injected with C3 
candidate enhancers or a control construct containing the zebrafish hsp70 promoter linked to a 
region lacking enhancer function. B. Representative embryos injected with C2 and C5 regions. YFP 
expression is observed in the pancreatic islet (pi), neurons (ne), lens (lens), and floor plate (fp). 
Expression in the lens is ectopic activity from the hsp70 promoter (Blechinger et al., 2002). All 
embryos are 72 hpf, oriented dorsally anterior to the right. Scale bar indicates 100 µm. 
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The enhancer-less control and C2 and C5 sequences showed no YFP activity. In contrast, 5 
conserved elements tested from C3 cluster behaved as enhancers, as they were able to direct 
tissue-specific expression; and three of them, C3-3, C3-4 and C3-5, were active in the pancreatic 
islet (Figure 3.4, Table 3.2).  
3.3.2.1 C3-3 candidate enhancer 
C3-3 element contained a 1,185 bp fragment located in an intergenic region that is 1.1 Mb 
downstream of ISL1 and 300 kb upstream of PELO. It was in an open chromatin site, bound by 
PDX1, NKX6.1, FOXA2 and NKX2.2 TFs and showed a significant enrichment for H3K27ac and 
H3K4me1 epigenetic marks (Figure 3.5A). In transient transgenic assays C3-3 element linked to 
zebrafish hsp70 promoter could drive islet-specific expression in 38.4% of the injected embryos in 
all replicates (total number of injected embryos n=352). In contrast, none of the embryos injected 
with the control region could reproduce the pancreas expression pattern (n=217). Lens activity 
was shown by 94.9% (n=352) of the expressing embryos. Lens ectopic expression was caused by 
the endogenous promoter itself and not by the human element linked to it (Blechinger et al., 
2002). Islet-specific activity in transient transgenic assays was verified by injecting the putative 
enhancer-containing constructs into Tg(ins-mCherry)jh2 transgenic line (a kind gift from Elke Ober), 
which labels insulin-producing beta cells in red (Figure 3.5B). Co-localization experiments verified 
that C3-3-driven activity was specific to the endocrine pancreas. 
Given that enhancers can be very far away from their regulatory target, it is challenging to identify 
target genes (Krivega and Dean, 2012). Both in mammals and zebrafish, ISL1 gene is essential for 
the development of endocrine cells (Ahlgren et al., 1997; Wilfinger et al., 2013), while PELO gene 
is unrelated to pancreas or endodermal development (Shamsadin et al., 2000). Interestingly, 
chromosome capture conformation experiments carried out elsewhere demonstrated that there   
 93 
 
 
Figure 3.5 Intergenic enhancer located 1 Mb downstream of ISL1 can direct islet-specific 
expression in the zebrafish embryo. 
A. UCSC genome browser screenshot of C3-3 putative enhancer location and epigenomic 
landscape. Note that C3-3 (black rectangle) is in an open chromatin region 1.1 Mb downstream of 
ISL1 and 300 kb upstream of PELO. It is bound by NKX2.2, PDX1, NKX6.1 and FOXA2 TFs and shows 
a bimodal enrichment of H3K4me1 and H3K27ac, which are considered typical enhancer marks. B. 
C3-3 can drive robust expression in the pancreatic islet as demonstrated by co-localization assays 
in Tg(ins-mCherry)jh2 line. Embryos are 72 hpf oriented dorsally anterior to the right. Scale bar 
indicates 100 μm.  
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was a direct interaction between C3-3 tested enhancer and ISL1 promoter, which is located > 1 
Mb away (Pasquali et al., 2014), supporting the pancreas-specific activity. 
3.3.2.2 C3-4 candidate enhancer 
CRE3-4 is located on the second intron of PROX1 (1,574 bp) and could also drive pancreas-specific 
reporter expression in 28.7% (n=230) of the injected embryos. This region was also shown to be 
bound by pancreas-specific TFs, including NKX6.1, FOXA2, MAFB, NKX2.2. 
3.3.2.3 C3-1 and C3-6 candidate enhancers 
In contrast to the previous elements, which were active in the endocrine pancreas, neither a 
region of 835 bp in the second intron of TCF7L2 gene (C3-6) nor a 549 bp fragment upstream of 
the NKX6.1 gene (C3-1) showed islet-specific activity in four experimental replicates (Table 3.2). 
Both elements behaved as weak and broad neuronal enhancers in the zebrafish embryo (Figure 
3.4). 
3.3.2.4 C3-5 candidate enhancer 
A very interesting example among the elements tested is C3-5, a 919 bp region from the second 
intron of the RFX2 gene. When C3-5 was cloned upstream of the zebrafish hsp70 promoter, it 
could drive hindbrain, floor plate and pronephric duct expression at 3 dpf, recapitulating almost 
completely the endogenous pattern of rfx2 zebrafish gene (Figure 3.6) consistently among the 
experimental replicates. 
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Figure 3.6 C3-5 candidate human enhancer recapitulates activity domains of zebrafish rfx2 
gene.  
Zebrafish mosaic embryos injected with C3-5 human enhancer linked to hsp70 promoter and YFP 
reporter gene protein (right panels) recapitulated broadly zebrafish rfx2 endogenous expression 
patterns as demonstrated by rfx2 WISH (left panels, taken from www.zfin.org). Expression 
domains include forebrain, dorsal hindbrain, cerebellum, cephalic floor plate and pronephric 
ducts. Lens expression is driven by hsp70 promoter. Scale bar indicates 100 µm. 
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3.3.2.5 Validation of control regions 
In order to test the hypothesis that only regions showing enhancer-associated epigenetic marks 
would be able to drive tissue-specific activity, two regions from C2 and C5 clusters (Figure 3.2), 
bound by PDX1 but devoid of active epigenetic marks were tested by transient transgenesis. 
These regions could not direct tissue-specific expression on zebrafish embryos during the first 
days of development (Table 3.2, Figure 3.4), suggesting that epigenetic marks are indeed 
predictive of enhancer function. 
3.3.3 Enhancer-promoter interactions in vivo. 
In order to test whether C3 candidate enhancers were autonomously capable of driving 
expression in the endocrine pancreas, C3 candidates were tested with a second independent 
minimal promoter and compared their activity to hsp70 promoter. Candidates were cloned into a 
pD896 vector containing mini Tol2 arms (Balciunas et al., 2006), YFP reporter gene and gata2 
promoter, which had been successfully used to validate enhancers in zebrafish (Bessa et al., 2009; 
Navratilova et al., 2009; Royo et al., 2012). 
All human enhancers from cluster C3 could activate gata2 promoter with similar frequencies and 
patterns except for C3-5. Interestingly, when C3-5 (located on the second intron of RFX2 gene) 
was linked to gata2 zebrafish promoter, it was able to activate reporter expression in the 
endocrine pancreas as an additional expression domain (Figure 3.7) in 32.9% of injected embryos 
(n=228, Table 3.2). This domain had not been detected in embryos injected with hsp70-containing 
construct (n= 278, Figure 3.6) and underlined the importance of selecting an appropriate 
promoter for validations as well as the specificity enhancer-promoter interactions occurring in 
vitro. These differences were also prevalent in the transgenic lines established from both 
constructs, which will be discussed below. 
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Figure 3.7 Specificity of enhancer promoter interactions in vivo using C3-5 human enhancer. 
Representative images of 72 hpf embryos injected with constructs containing C3-5 human enhancer linked to zebrafish gata2 promoter (C3-5:gata2:YFP, 
top) or C3-5 enhancer linked to hsp70 promoter (C3-5:hsp70:YFP, bottom). Note how gata2 promoter is overall more sensitive to regulatory input from 
the enhancer and can drive an additional domain of expression in the pancreatic islet. Scale bar indicates 250 µm. 
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3.3.4 Verification of enhancer activity detected in mosaic transient transgenics by the 
establishment of stable transgenic lines 
In order to verify the pancreas-specific activity shown by transient transgenic embryos I decided 
to establish transgenic lines for all the enhancers that were active in the pancreatic islet (C3-3, C3-
4 and C3-5). Injected embryos showing reporter gene expression were raised to sexual maturity 
and outcrossed with wild type fish. The offspring of these outcrosses was screened during the first 
3 dpf (Table 3.3). The expression patterns of the transgenic lines were documented using 
Olympus ScanR microscope and representative images are shown in Figure 3.8 and Figure 3.9.  
I identified three adult founders containing C3-3 CRE linked to hsp70 promoter whose offspring 
was positive for reporter gene expression (Table 3.3). Two of them displayed specific expression 
in the pancreatic islet and the third one showed an additional domain of expression, the spinal 
cord, which had not been seen in transient transgenic assays but is a sub-expression domain of 
the isl1 gene (Figure 3.5). Expression in the lens was considered as ectopic activity from the hsp70 
promoter (Blechinger et al., 2002). One positive founder containing C3-4 candidate enhancer gave 
rise to positive progeny expressing in the pancreatic islet and in a specific group of midbrain 
neurons, reproducing the specific expression in the islet cells seen in transient embryos. Because 
different activities were displayed by C3-5 human enhancer when linked to different zebrafish 
promoters, I decided to establish transgenic lines using both constructs. Two lines established 
using C3-5 linked to hsp70 promoter (C3-5 L1 and L2) showed expression in forebrain, hindbrain, 
spinal cord and pronephric duct, reproducing endogenous pattern of rfx2 and the activity seen in 
transient transgenic assays (Figure 3.9). In contrast, the 3 lines established with a construct 
containing C3-5 linked to gata2 promoter (C3-5 L3, L4 and L5) were active in all of the 
aforementioned rfx2 endogenous domains plus the pancreatic islet (Figure 3.8). It is interesting to 
note how transgenic lines containing C3-5 and hsp70 minimal promoter failed to activate the 
pancreas domain, resembling mosaic injected embryos. Slight differences between C3-5 lines 
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might be attributed to position effects caused by Tol2-mediated transgenesis. Nevertheless, it 
needs to be noted that the additional domains, namely olfactory bulb and ventricular zone, are 
also rfx2 endogenous domains. 
Islet-specific expression of the transgenic lines was verified by out-crossing the adult transgenic 
founders with individuals from the Tg (ins-mCherry)jh2 line (Figure 3.10), confirming activity in the 
zebrafish endocrine pancreas. Taken together these results suggest that the transgenic lines 
validate the tissue-specific patterns seen in the transient transgenic embryos. 
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Table 3.3 Analysis of the offspring of C3 human enhancer-derived transgenic lines 
  
Transgenic line name 
No. of 
screened 
founders 
No. of 
positive 
founders 
Germline 
transmission 
rate (%) 
Line ID Domains of expression 
No. of 
embryos 
analysed 
Transmission 
rate per 
pattern (%) 
Tg(hs-PELO-0.1dr-hsp70-pr:YFP) 8 2 25.0 
C3-3-L1 Pancreatic islet, lens 107 57.9 
C3-3-L2 Pancreatic islet, lens 
173 
75.7 
C3-3-L3 Pancreatic islet, floor plate, lens 24.3 
Tg(1.5hs-PROX1-0.1dr-hsp70-pr:YFP) 10 1 10.0 C3-4-L1 Pancreatic islet, midbrain neurons  63 34.9 
Tg(hs-RFX2-0.1dr-hsp70-pr:YFP) 4 2 50.0 
C3-5-L1 
Forebrain, dorsal hindbrain, cephalic 
floor plate, hindbrain, pronephric 
duct, lens 
252 45.2 
C3-5-L2 
Forebrain, dorsal hindbrain, cephalic 
floor plate, hindbrain, pronephric 
duct, lens 
190 42.1 
Tg(hs-RFX2-1.0dr-gata2-pr:YFP) 7 3 42.9 
C3-5-L3 Olfactory bulb, hindbrain, floor plate,  pronephric duct, islet 378 3.9 
C3-5-L4 Forebrain, hindbrain, floor plate, pronephric duct, islet 51 23.5 
C3-5-L5 Forebrain, hindbrain, floor plate, pronephros, islet 153 47.1 
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Figure 3.8 Stable transgenic lines derived from predicted enhancers recapitulate transient patterns.  
Three stable transgenic lines derived from C3-3 element (C3-3 L1-3), one line derived from C3-4 (C3-4 L1) and three lines derived from C3-5 (C3-5 L1-3) 
confirm pancreas specific activity (arrow) displayed by mosaic transgenic embryos. Additional domains of expression include lens, fp=floor plate, 
pro=pronephros, hin=hindbrain, ne=neurons, ob=olfactory bulb, ven=ventricular zone All embryos are 72 hpf oriented anterior to the right. One dorsal 
and one lateral brightfield and YFP images are shown.  
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Figure 3.9 Transgenic lines from C3-5 element linked to hsp70 promoter fail to activate the islet. 
Two transgenic lines established with a construct containing C3-5 human enhancer linked to 
hsp70 promoter displayed expression domains that broadly overlap rfx2 endogenous pattern, 
similarly to our observations in transient transgenic assays (Figure 3.6). YFP domains include 
hin=hindbrain, lens, tel=telencephalon and ven=ventricular zone. Embryos are 72 hpf oriented 
anterior to the right. Scale bar is 100 µm.  
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Figure 3.10 C3-3,4,5 derived stable transgenic lines show pancreas-specific activity when 
outcrossed with Tg(ins-mCherry)jh2 line. 
One representative founder is shown per CRE tested. Note the overlap between insulin producing 
beta cells in red and enhancer driven activity in green. Additional domains of expression include 
cfp=cephalic floor plate, hin=hindbrain, ne=neurons, ob=olfactory bulb and pro=pronephros. All 
embryos are 72 hpf oriented anterior to the left. 
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3.4 DISCUSSION 
In this chapter, I studied the function of several human putative enhancers selected through a 
combination of transcription factor binding events and the presence of key epigenetic marks to 
address the utility of the zebrafish as a validation model for human enhancers. I demonstrated 
that all 5 human predicted human enhancers can drive tissue-specific reporter activity in zebrafish 
embryo. From these elements, 3 are active in the zebrafish embryonic islet (C3-3, C3-4 and C3-5), 
while the remaining 2 were broad neuronal enhancers (C3-1 and C3-6). Additionally, two control 
regions devoid of epigenetic marks failed to drive any tissue-specific expression. These results 
were verified not only in transient transgenesis assays, where a high percentage of injected 
mosaic embryos were displaying very reproducible and specific patterns beyond background, but 
also in stable transgenic lines. Taking into account the negligible background level of our 
enhancer-less construct we can conclude that the specific expression patterns are attributable to 
the human elements tested. This argues for the specificity of the enhancer selection process and 
leaves 3 out of 5 enhancers behaving as predicted by their epigenetic marks.  
A challenge in enhancer tests is the unambiguous identification of the target gene. In the case of 
the three tested human enhancers active in the pancreatic islet, the expression patterns 
reproduced broadly the endogenous activity of the predicted target gene. As a general rule, we 
associated the enhancer to the closest coding gene. C3-4 which was located on an intronic region 
of PROX1 proved to be a very specific pancreatic enhancer in zebrafish, and indeed the endocrine 
pancreas is included among the expression domains of PROX1, a master regulator during 
embryogenesis (Sosa-Pineda et al., 2000; Burke and Oliver, 2002; Wang et al., 2005; Pistocchi et 
al., 2008). C3-5 located in the second intron of RFX2 reproduced most of the endogenous domains 
of activity of zebrafish rfx2, including ventral floor plate, dorsal hindbrain and pronephric duct. 
Interestingly, only when C3-5 was paired with gata2 endogenous promoter an additional domain 
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in the pancreatic islet was active. This result, which was consistent, both in transient and stable 
transgenic assays, argues for in vivo evidence of enhancer-promoter interactions and underlines 
the importance of promoter choice in enhancer validation assays. In the case of C3-3, an element 
located in an intergenic region 1Mb away from ISL1 and 400 Mb away from PELO, it was 
demonstrated a very strong and reproducible expression in the endocrine pancreas, which is an 
active domain of ISL1 gene in human and zebrafish. Additionally, 4C experiments carried out 
elsewhere demonstrated that the tested enhancer was directly interacting with ISL1 promoter 
(Pasquali et al., 2014).  
Even though a higher number of tested elements would be necessary to establish a statistically 
significant correlation, in our hands 60% of the predicted human islet enhancers showing 
sequence conservation with zebrafish were interpreted accurately by the zebrafish embryo. This 
figure is similar to the rates shown in the literature of conserved human elements directing tissue-
specific expression in fish: 58% out of 24 candidate enhancers (Ritter et al., 2012), 34.5% out of 
113 sequences tested (Royo et al., 2011), 47% out of 34 enhancers tested (Punnamoottil et al., 
2010) and 77% out of 31 tested candidates (Ritter et al., 2010), among others. 
It is difficult to predict why some of these human enhancers could not drive specific enhancer 
activity in the pancreas, despite showing similar levels of sequence conservation, strength and 
enrichment of histone modification marks and transcription factor occupancy. Statistical analysis 
on any of these parameters would require a higher number of elements to be tested in vivo, 
however, imposing the sequence conservation filter drastically reduces the number of human 
candidates that can be validated. Nevertheless, it needs to be noted that the neuronal expression 
pattern displayed by some candidates is not completely unexpected. The neuroendocrine nature 
of islet cells has been recognized: endocrine cells are electrically excitable and share the 
expression of a large battery of genes with neurons (Atouf et al., 1997). In fact, the expression 
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profile of pancreatic endocrine cells is more similar to ectoderm-derived neuronal tissues than to 
tissues such as liver or lung, which share a common endodermal origin (van Arensbergen et al., 
2010). 
Recently, several studies have highlighted the benefits of applying the knowledge derived from 
genome-wide analyses of epigenetic marks to the vertebrate embryo (Rada-Iglesias et al., 2011; 
Bernstein et al., 2012). Nevertheless, this is the first study where an isolated tissue from human 
donors was interrogated and predicted pancreas enhancers were tested using an embryonic 
model. Most publications have based their validations on cell lines, which cannot reproduce the 
complexity of an organism (Gaulton et al., 2010; Stitzel et al., 2010). A recent study based on the 
profiling of the chromatin and transcriptome in human islets, has also identified chromatin states 
that could overlap with enhancers, promoters and insulators (Parker et al., 2013). Based on this 
chromatin segmentation, 2 predicted enhancers were tested in vivo, demonstrating tissue-specific 
activity in the pancreas primordium of mouse embryos (Parker et al., 2013). Interestingly, the 
predicted pancreatic enhancers appear clustered contiguously along regions larger than 3 kb, 
what was termed “stretch enhancers”, similarly to the clustered C3 elements described by 
(Pasquali et al., 2014). 
Our set of validations, together with previous studies testing human pancreas-specific enhancers 
in zebrafish (Ragvin et al., 2010) argue that despite over 460 million years of evolutionary 
divergence between human and teleosts (Meyer and Schartl, 1999), the zebrafish can interpret 
functionally certain conserved pancreatic enhancers maintaining the tissue-specificity; 
demonstrating conserved regulatory codes acting in vertebrate endocrine pancreas during 
development.  
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Chapter Four: ANALYSIS OF NON-CODING SEQUENCE VARIANTS 
DOWNSTREAM OF PTF1A RELATED TO PANCREAS AGENESIS 
FOREWORD 
Within the BOLD Network, we initiated a collaboration with Andrew Hattersley and Michael 
Weedon, from the University of Exeter Medical School (UK), with the common aim of testing 
disease-associated variants in human enhancers. This led to the design of functional experiments 
in zebrafish where I tested the function of a candidate enhancer associated with pancreas 
agenesis.  
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4.1 INTRODUCTION 
4.1.1 Genetic basis of pancreatic agenesis 
Pancreatic agenesis is a rare condition resulting from a developmental abnormality of the 
pancreas that causes permanent neonatal diabetes mellitus and exocrine insufficiency (Winter et 
al., 1986). There are 2 forms of neonatal diabetes mellitus: transient and permanent. Transient 
neonatal diabetes mellitus (TND) is resolved by 18 months of age and predisposes to adult T2D 
(Greeley et al., 2011). The main cause for TND is abnormalities chromosome 6q24 including 
overexpression of paternally imprinted genes, methylation defects or uniparental chromosome 
disomy (Temple et al., 1996; Gardner et al., 2000; Temple et al., 2000; Mackay et al., 2008). The 
permanent form of neonatal diabetes mellitus (PND) is mainly caused by activating mutations of 
the KATP channel (KCNJ11 gene) or heterozygous mutations in the insulin gene (INS) but can also 
be caused by pancreas agenesis or hypoplasia (Gloyn et al., 2004). There are less than 50 
examples of permanent neonatal diabetes mellitus caused by pancreatic agenesis described in the 
literature and the genetic basis is mostly unknown; only in a few cases mutations in the coding 
regions of pancreas-specific transcription factors, such as PDX1, PTF1A or GATA6 have been found 
(Stoffers et al., 1997b; Schwitzgebel et al., 2003; Sellick et al., 2004; Thomas et al., 2009; Al-
Shammari et al., 2011; Allen et al., 2012; De Franco et al., 2013). 
Stoffers and colleagues showed a case of pancreatic agenesis caused by a homozygous single 
point deletion within codon 63 of the PDX1 gene. This mutation caused a frame shift in the C-
terminal end of the PDX1 protein, which leads to the translation of 59 novel codons before 
termination, altering the transactivation domain of PDX1 that is essential for DNA-binding 
(Stoffers et al., 1997b). Another case of neonatal diabetes caused by a homozygous mutation of 
the same gene was also described recently by (Thomas et al., 2009). In the case reported by 
(Schwitzgebel et al., 2003) a compound heterozygous mutation in two highly conserved sites of 
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helix 1 and 2 of PDX1 homeodomain caused a decreased half-life form of PDX1 protein, which 
subsequently led to pancreas agenesis and neonatal diabetes mellitus. Several other studies also 
identified a couple of mutations (705insG and C886T) and a homozygous deletion (c.437-460del) 
in PTF1A transcription factor gene in patients presenting permanent neonatal diabetes mellitus 
accompanied by pancreatic and cerebellar agenesis (Sellick et al., 2004; Al-Shammari et al., 2011). 
More recently, Allen and colleagues showed that GATA6 was a common cause of syndromic 
pancreatic agenesis (Allen et al., 2012), which was later confirmed in a larger cohort of 795 
individuals (De Franco et al., 2013). 
However, in around 30% of described cases of PND caused by pancreatic agenesis, the genetic 
cause remains to be elucidated (Greeley et al., 2011). Interestingly, most papers that could not 
find a genetic cause excluded the presence of mutations in the coding sequence of several TFs 
involved in pancreas development or differentiation, such as PDX1, PTF1A, SOX9, SOX17, HNF6 or 
HLXB9 (Chen et al., 2008; Balasubramanian et al., 2010; Salina et al., 2010). Indeed, in all of the 
PND case reports described above the causal mutations were affecting the coding gene sequence 
or intron-exon boundaries. However, there is now ample evidence describing human disorders 
caused by non-coding sequence variations (Kleinjan and van Heyningen, 2005; Epstein, 2009; Lee 
and Young, 2013). Suspecting that non-coding variants could be responsible for several cases of 
pancreatic agenesis, we established a collaboration with Michael Weedon and Andrew Hattersley, 
partners of the BOLD Network, in order to carry out some functional analysis of a potential cis-
regulatory element. 
4.1.2 Preliminary data leading to the project 
Weedon and colleagues had found 6 subjects with isolated non-syndromic pancreatic agenesis 
coming from 3 unrelated consanguineous families. Initially they performed whole-genome 
sequencing and linkage analysis to look for causative homozygous mutations. Homozygosity 
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mapping in the families revealed an inherited 25-100 Mb region in chromosome 10, which 
included PTF1A candidate gene. However, coding mutations in PTF1A and 24 other genes from 
this region were excluded by Sanger Sequencing. Whole-exome sequencing did not reveal either a 
potential causative homozygous coding mutation. After filtering common variants, they found 7 
variants overlapping with putative regulatory elements and particularly 1 variant that was shared 
by 2 consanguineous and unrelated individuals, overlapped with the shared region on chr10 
previously identified by homozygosity mapping. This conserved region comprised 485 bp, was 
located 25 Kb downstream of the PTF1A gene and was conserved between human and zebra 
finch, but not with zebrafish.  
4.1.3 PTF1A transcription factor has a conserved role in specification of pancreatic fate 
PTF1A (previously called PTF1-p48) encodes for a pancreas-specific basic helix-loop-helix DNA-
binding subunit of the Pancreas Transcription Factor-1 PTF1 complex (Krapp et al., 1996). In adults 
it is restricted to the acinar compartment of the exocrine pancreas (Rose et al., 2001) but during 
development Ptf1a is essential for both endocrine and exocrine pancreas formation: lineage-
tracing experiments indicate that Ptf1a is expressed in the progenitors of acinar, endocrine and 
exocrine cells, contributing to acquisition of lineage identity (Kawaguchi et al., 2002). Consistent 
with this role in cell commitment, in Ptf1a-/- embryos the exocrine pancreas is absent and cells 
with endocrine functions relocate to the spleen (Krapp et al., 1998). Additionally Ptf1a contributes 
to neurogenesis: Ptf1a mRNA can be detected in E9.5 in neural tube and myelencephalon, and is 
further expressed in the central nervous system including medulla oblongata, cerebellum and the 
spinal cord until E12.5 (Obata et al., 2001).  
In zebrafish ptf1a is an early marker of the anteroventral bud that will give rise to the exocrine 
pancreas (Zecchin et al., 2004). Its mRNA is first detected at 12-somite stage, when it is expressed 
in the developing hindbrain (Zecchin et al., 2004) and by 32 hpf it is already expressed in the 
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ventrolateral endoderm sharing the domain of Pdx1 positive cells (Lin et al., 2004). The neural 
expression pattern peaks at 2 dpf in the hindbrain, retinal anlagen and the rhombic lip and is 
undetectable by 72 hpf, mimicking the transient neural pattern observed in mice (Obata et al., 
2001). At 48 hpf ptf1a is additionally expressed in the exocrine bud surrounding insulin positive 
cells, where it will be restricted to from this moment on in development, reproducing the 
distribution of exocrine tissue (Biemar et al., 2001). While Ptf1a is essential for the formation of 
the endocrine pancreas in mouse (Krapp 1998), morpholino knock-down experiments in zebrafish 
cause the loss of exocrine pancreas but do not affect the formation or the spatial organization of 
the endocrine islet (Lin et al., 2004). 
4.1.4 Aims: 
Given the conserved evolutionary role of PTF1A in human and zebrafish pancreas development 
and suspecting that the inherited region downstream of PTF1A in patients with pancreas agenesis 
could be a long-range acting cis-regulatory element, I set out to use the zebrafish embryo to 
determine whether this human putative regulatory region located 25 kb downstream of PTF1A 
gene held regulatory potential. Also, I wanted to investigate whether the genomic variants found 
in the consanguineous probands suffering from pancreatic agenesis could affect the regulatory 
activity of PTF1A putative enhancer by transient transgenesis assays.  
  
 112 
 
4.2 METHODS 
Genomic DNA from patients containing recessive mutations in homozygosis in the putative 
enhancer element was provided by our collaborators at the University of Exeter: alongside with 
the wild-type gDNA, one sample containing a homozygous g.23508363A>G mutation and a third 
sample containing a homozygous g.23508305A>G mutation were used for all experiments. 
A short 485pb region from chromosome 10 encompassing the variants from the three patients 
(Table 4.1) was cloned into a Gateway multisite destination vector provided by Darius Balciunas 
that contained miniTol2 arms (Balciunas et al., 2006), hsp70 zebrafish promoter and mCherry 
reporter gene (pDB896_GWB3B5_HSP70-PRM_mCherry).  
A large region encompassing a vertebrate conservation block of 1445 bp was also amplified from 
the patient gDNA using oligos described in Table 4.1. Due to technical problems previously 
encountered when trying to clone enhancer fragments larger than 1 Kb using Gateway 
Technology, two additional Tol2-based constructs containing zebrafish hsp70 or gata2 promoters 
linked to mCherry were also designed, where the enhancer and its variants could be introduced 
by cloning. For this purpose, mCherry reporter gene was purified from pCS2+-mCherry and cloned 
into pDB896_HSP70-PRM_YFP construct (Chapter 3) using XhoI and SnaBI sites. The resulting 
vector was named pDB896_HSP70-PRM_mCherry. Zebrafish gata2 promoter was amplified from 
zebrafish genomic DNA and cloned into this vector using AgeI and XhoI sites. The resulting vector 
was named pDB896_GATA2-PRM_mCherry. In order to control zebrafish promoter functionality, a 
non-conserved region from Fugu rubripes showing no regulatory activity (fr2(assembly 2004) 
chrUn:54,537,362-54,537,937) was used (Sanges et al., 2006), as discussed in Chapter 3. A total of 
9 vectors containing variations of the putative human enhancer and minimal promoters and two 
additional control-containing constructs were sequenced and subsequently used for functional 
validations (Table 4.1). 
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Table 4.1 Constructs generated to test PTF1A enhancer variants in zebrafish transgenesis assays 
Construct 
Putative 
enhancer 
size (bp) 
Putative enhancer 
coordinates (hg19) Forward primer (5' to 3') Reverse primer (5' to 3') 
Tails used 
for cloning 
gDNA sample 
used 
Zebrafish 
Promoter 
pDB896_Hs.PTF1A-short-WT:Dr.hsp70:mCherry 
485bp chr10:23,508,102-23,508,586 ATCACCCCCTGGATGATTCT GGTGCATGCAACATAGAAAG attB3/attB5  
WT 
hsp70 pDB896_Hs.PTF1A-short-305:Dr.hsp70:mCherry 23508305A>G 
pDB896_Hs.PTF1A-large-363:Dr.hsp70:mCherry 23508363A>G 
pDB896_Hs.PTF1A-large-WT-:Dr.hsp70:mCherry 
1445bp chr10:23,507,374-23,508,818 GCCCCAGGTTTTAATTTATCA CAGCCTCCTCTGCTTCTTTA 
EcoRV/SpeI WT 
hsp70 pDB896_Hs.PTF1A-large-305:Dr.hsp70:mCherry HindIII/EcoRI  23508305A>G 
pDB896_Hs.PTF1A-large-363:Dr.hsp70:mCherry HindIII/EcoRI 23508363A>G 
pDB896-PTF1A-large-WT:Dr.gata2:mCherry 
1445bp chr10:23,507,374-23,508,818 GCCCCAGGTTTTAATTTATCA CAGCCTCCTCTGCTTCTTTA 
EcoRV/SpeI WT 
gata2 pDB896-PTF1A-large-305:Dr.gata2:mCherry HindIII/EcoRI  23508305A>G 
pDB896-PTF1A-large-363:Dr.gata2:mCherry HindIII/EcoRI 23508363A>G 
pDB896_Fugu-control:Dr.hsp70:mCherry n/a chrUn:54,537,362-
54,537,937 
GTGTGTCATCCTCATCCACG 
 
CCATGATGGTGCTCTGCC 
 
attB3/attB5 
Fugu gDNA 
hsp70 
pDB896-Fugu-control:Dr.gata2:mCherry n/a EcoRV/SpeI gata2 
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4.3 RESULTS 
4.3.1 Transient transgenesis assays to test PTF1A putative human enhancer 
In order to test the regulatory potential of the non-conserved element located 25 Kb 
downstream of PTF1A, I initially verified the pattern of ptf1a gene in zebrafish and whether it 
was also expressed in the pancreas. The endogenous pattern of ptf1a in zebrafish is very 
similar to mouse (Obata et al., 2001), being expressed temporally in the central nervous 
system, in the pancreas primordium and later in the acini of the exocrine pancreas (Lin et al., 
2004; Zecchin et al., 2004). The Tg(ptf1a:EGFP)jh1, a transgenic line created by replacing the 
coding sequence of ptf1a gene by eGFP in a genomic BAC (kindly provided by Elke Ober) 
reproduced ptf1a expression pattern and provided an appropriate anatomical marker and 
potential co-localization tool (Godinho et al., 2005). 
In order to determine whether PTF1A putative enhancer could function as a regulatory 
element in zebrafish and whether the variants found in patients could affect the regulatory 
potential of this element, the 485bp conserved region from chromosome 10 and its mutations 
(Figure 4.1A) were tested in Tol2-based transient transgenesis assays in zebrafish embryos. 
For functional tests, two promoters that had previously worked in combination with human 
enhancers were chosen: hsp70 and gata2 promoter. Zebrafish hsp70 promoter was chosen 
because it drove minimal background and had a general capacity of interacting with 
enhancers (Gehrig et al., 2009); zebrafish gata2 promoter was selected because it was highly 
sensitive in recapitulating expression in the pancreas driven by human enhancers (see 
Chapter 3). As a control region, a non-conserved region from Fugu rubripes showing no 
regulatory activity was used (Sanges et al., 2006). These elements were placed upstream of a 
red fluorescent protein (mCherry) that would potentially allow for co-localization studies 
using Tg(ptf1a:EGFP)jh1 transgenic line.  
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Initially three vectors containing the WT sequence and two mutated variants of the inherited 
485 bp region from human chromosome 10 linked to zebrafish hsp70 minimal promoter were 
tested in transient transgenic assays; but no tissue-specific activity was detected during the 
first 5 dpf. The putative pathogenic variants did not show any reporter expression either, 
being comparable to the WT sequence or to the control construct (Table 4.2).  
Given the lack of activity shown by the 485 bp candidate enhancer I decided to amplify a 
region of 1,445 bp encompassing the vertebrate conservation block between human and 
zebra finch (Figure 4.1B), with the expectation that a larger fragment could represent the full 
functional element required for autonomous enhancer activity, and thus could be easily 
interpreted by our evolutionarily distant model despite the lack of sequence conservation. 
This large fragment containing variants was cloned upstream of the hsp70 minimal promoter 
and the more sensitive gata2 promoter and injected in zebrafish embryos (Table 4.1). 
However, no regulatory activity driven by the candidate enhancer could be detected when we 
compared embryos injected with the enhancer-containing constructs and promoter only 
controls (Table 4.2). Taken together, the above results showed that neither variant nor the 
WT candidate PTF1A enhancer could direct detectable activity in the transient transgenic 
zebrafish embryo when linked to two zebrafish promoters, suggesting lack of functionality in 
zebrafish. 
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Figure 4.1 USCS screenshot showing the location of putative PTF1A regulatory region. 
A. The region of 485 bp identified by whole exome sequencing is located 25 Kb downstream of 
the PTF1A coding gene (red ellipse). B. Putative enhancer regions used for zebrafish transgenesis 
assays are depicted by black rectangles. The large PTF1A putative element encompassing 1,445 bp 
and the vertebrate conservation block is labelled with a dashed red rectangle. 
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Table 4.2 Summary of transient transgenesis assays performed using PTF1A putative human enhancers 
Construct Variant tested Putative enhancer size 
Number of 
injected embryos  
Number of 
expressing embryos 
(%) 
Number of 
replicates 
pDB896_Hs.PTF1A-short-WT:Dr.hsp70:mCherry WT 
485 bp 
310 0 (0) 2 
pDB896_Hs.PTF1A-short-305:Dr.hsp70:mCherry 23508305A>G 419 0 (0) 2 
pDB896_Hs.PTF1A-large-363:Dr.hsp70:mCherry 23508363A>G 183 0 (0) 2 
pDB896_Hs.PTF1A-large-WT-:Dr.hsp70:mCherry WT 
1445 bp 
253 0 (0) 2 
pDB896_Hs.PTF1A-large-305:Dr.hsp70:mCherry 23508305A>G 212 0 (0) 2 
pDB896_Hs.PTF1A-large-363:Dr.hsp70:mCherry 23508363A>G 182 0 (0) 2 
pDB896-PTF1A-large-WT:Dr.gata2:mCherry WT 
1445 bp 
184 0 (0) 2 
pDB896-PTF1A-large-305:Dr.gata2:mCherry 23508305A>G 228 0 (0) 2 
pDB896-PTF1A-large-363:Dr.gata2:mCherry 23508363A>G 230 0 (0) 2 
pDB896_Fugu-control:Dr.hsp70:mCherry 
Fugu gDNA n/a 
217 0 (0) 2 
pDB896-Fugu-control:Dr.gata2:mCherry 205 0 (0) 2 
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4.4 DISCUSSION 
In this chapter, I aimed to test the regulatory potential of a region downstream of PTF1A 
containing variants inherited in unrelated patients suffering from pancreatic agenesis by zebrafish 
transient transgenesis assays. However, none of the nine constructs made to test the candidate 
enhancer with various combinations of length, linked to two different minimal promoters could 
show enhancer effect in zebrafish. Moreover, neither the wild type sequence nor the element 
containing potentially pathogenic variants could drive any tissue-specific activity in transient 
transgenic assays.  
The role of cis-regulatory variants in disease is still not very well understood and finding the 
functional causing variant is still a challenge. We and others have proposed to use the zebrafish 
model as a tool to validate the function of human enhancers (Ishibashi et al., 2013), and the 
variants within. Because sequencing of all these constructs was carried out before the reporter 
expression assays took place, we can exclude the possibility that mutations introduced during 
cloning are responsible for the lack of activity. In the same line, both the Gateway Expression 
Vectors and the classical screening vectors used to validate PTF1A putative enhancers had been 
previously used by us to test the activity of human enhancers (as discussed in Chapters 3 and 5), 
with reliable detection of function. 
From these results we can propose that either lack of sufficient degree of sequence conservation, 
lack of enhancer-promoter interaction, or lack of enhancer function in vivo, could be the reason 
for the lack of reporter activity in zebrafish. 3C analysis showed that the candidate enhancer is 
interacting with PTF1A promoter in human pancreatic progenitor cells (Weedon et al., 2014). To 
test in zebrafish whether the specificity of the enhancer-promoter interaction is the reason for 
the lack of function, the human putative enhancer would have to be cloned upstream of the 
endogenous ptf1a zebrafish promoter. Nevertheless, the promoters used for the assays: hsp70 
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and gata2, have been shown to have a general ability to interact with enhancers (Gehrig et al., 
2009) and had been active in combination with several pancreas-specific human enhancers before 
(as discussed in Chapter 3). Moreover, zebrafish gata2 promoter has been routinely used by us 
and others in similar enhancer tests and has proven very sensitive to unravel the full regulatory 
potential of human CREs (Bessa et al., 2009; Navratilova et al., 2009; Ragvin et al., 2010; Royo et 
al., 2012). 
Despite evidence demonstrating that zebrafish can recapitulate regulatory function in the lack of 
sequence conservation (Fisher et al., 2006a; McGaughey et al., 2009), our experience with testing 
a limited set is that non-conserved elements are less likely to work than conserved elements. 
PTF1A putative enhancer shares no sequence similarity to the zebrafish genome (0% sequence 
alignment), therefore we could attribute the lack of activity to the lack of conservation. 
One piece of evidence that suggests that the negative results from zebrafish assays might not be 
necessarily due to the large evolutionary distance between human and zebrafish, is provided by 
additional functional assays carried out with human cells lines and mouse embryos. In parallel to 
the zebrafish assays, Jorge Ferrer´s lab tested the functionality of PTF1A element using luciferase 
assays in progenitor and adult pancreas cell lines. Their results, which have been published in 
(Weedon et al., 2014), argue that the 485 bp element is active at low levels in pancreatic 
progenitor cells (not in adult exocrine cell lines) and that the 23508363A>G variant abolishes 
enhancer activity through the disruption of a FOXA2 binding site, while the 23508305A>G variant 
disrupts the binding of a non-identified protein as demonstrated by EMSA (Electrophoretic 
Mobility Shift Assay). Furthermore, the putative PTF1A enhancer region is enriched in typical 
enhancer marks such as H3K27ac or H3K4me1 in hESCs derived from pancreatic progenitors, 
although at very low levels (Weedon et al., 2014). 
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In zebrafish, pancreatic progenitors giving rise to the anteroventral and dorsolateral buds appear 
at the 12-somite stage, express pdx1 and are located at both sides of the midline (Argenton et al., 
1999; Biemar et al., 2001), while ptf1a expressing cells appear first at 32 hpf (Lin et al., 2004). We 
could therefore argue that our Tol2-based transgenesis system was not sensitive enough to 
detect such small cell numbers or even the stage at which embryos were analysed might not have 
been suitable.  
Interestingly, when Weedon’s collaborators tested PTF1A putative enhancer in vivo by 
transgenesis assays in mice using a construct where PTF1A enhancer was linked to a minimal viral 
promoter and GFP, E9.5-E.10-5 embryos did not show enhancer-driven reporter gene expression; 
not even when they tried to amplify the signal using immunofluorescence techniques (Inês 
Cebola, personal communication).  
Conflicting results between in vitro and in vivo data in two species could be attributed to a 
suboptimal genomic environment of the isolated enhancer. The fact that certain isolated 
enhancer sequences can function in transgenesis assays does not mean that all are able to 
function independently outside of their regulatory context; and therefore, might require 
interactions with other cis-regulatory elements to regulate transcription (Frankel, 2012). Such 
physical interactions have been described during digit development in mouse, where several 
enhancer elements spread in a gene desert forming a "regulatory archipelago" contribute 
quantitatively or qualitatively to full transcriptional response of HoxD genes (Montavon et al., 
2011). 
Epigenetic silencing of the transgene might also be a potential cause for lack of in vivo function. 
The lab of Mary Goll has reported transgenerational epigenetic silencing of integrated transgenes 
mediated by DNA methylation, where transgene reactivation was possible but occurred in a cell-
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specific manner (Goll et al., 2009). We could hypothesize that instead of transgenerational 
inactivation, our transgene is being silenced through cell differentiation, which could point to an 
inherent property of certain enhancers. Testing the enhancer in its endogenous regulatory 
context would require the development of more elaborate loss of function assays mediated by 
genome editing tools such as CRISPR (Shen et al., 2014).  
Attributing the lack of PTF1A activity in zebrafish to lack of enhancer function is thus partially 
refuted by the work of Weedon and colleagues. On one hand the region is enriched in typical 
enhancer marks such as H3K27ac or H3K4me1 in hESCs derived from pancreatic progenitors, 
although at very low levels. The putative CRE acts as a developmental enhancer in cell culture 
assays but does not function in vivo either in mouse or in zebrafish transgenesis experiments. 
Taken together, conflicting functional results suggest that this enhancer could be very stage-
specific and possibly have a very weak transcriptional effect. We can conclude that the lack of 
activity of this region could be explained by either lack of enhancer conservation at the sequence 
level, by lack of enhancer-promoter interaction, by the lack of a sensitive transgenesis system able 
to detect subtle activity in early development affecting a few number of cells; or because it is not 
an autonomous enhancer and it is only able to function on transient cell culture assays in a 
context dependent fashion. 
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Chapter Five: VALIDATION OF BIDIRECTIONALLY TRANSCRIBED 
HUMAN ENHANCERS 
FOREWORD 
The results presented in this chapter have been partially published in (Andersson et al., 2014). 
This project is the result of a collaboration between our lab and Robin Andersson and Albin 
Sandelin from the University of Copenhagen (Denmark), members of the FANTOM5 International 
Consortium. They provided all the computational data presented in this chapter, which formed 
the basis of in vivo functional analysis of predicted human enhancers.  
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5.1 INTRODUCTION 
5.1.1 Limitations of current approaches for enhancer prediction 
Genome-wide strategies for enhancer prediction have been based on the use of multiple layers of 
information that include comparative genomics, searching for open chromatin sites and/or 
profiling of tissue-specific TFs, general co-factors and histone modification marks (Visel et al., 
2009a; Zinzen et al., 2009; Rada-Iglesias et al., 2011; Bernstein et al., 2012; Rada-Iglesias et al., 
2012). Nevertheless, there are limitations to all of these approaches. Conservation is not always 
indicative of function and there are subsets of functional enhancers that are not bound by general 
co-factors. Furthermore, ChIP-Seq, which is frequently used to map protein-DNA interactions, has 
technical limitations (Furey, 2012). Restrictions include the lack of appropriate antibodies 
(particularly in zebrafish) and the large numbers of cells required per experiment (in the order of 
tens of millions); factors that represent a challenge when dealing with small cell-numbered 
organisms or cells isolated from a tissue. Therefore, there is an opportunity for the 
implementation of a complementary strategy to predict enhancers. 
5.1.2 Enhancers produce transcripts 
Multiple lines of evidence have recently indicated that transcription from enhancers is a general 
property (Kim et al., 2010; Melgar et al., 2011; Wang et al., 2011a; Djebali et al., 2012). Initial 
studies demonstrated that mouse neuronal enhancers marked by H3K4me1 and CBP co-activator 
binding can recruit PolII and transcribe bidirectionally a novel class of RNA, which was then 
termed enhancer RNA (eRNA, (Kim et al., 2010)). Subsequent RNA-Seq analysis excluded the 
possibility that PolII was in fact associated to the promoter and had been crosslinked to the 
enhancer during ChIP experiments, and it clearly revealed bidirectional transcription towards 
H3K4me1 enriched nucleosomes (Kim et al., 2010). This reported phenomenon was then used for 
modelling a strategy to predict enhancer-associated bidirectional expression of short transcripts 
 124 
 
in a single cell line (Melgar et al., 2011). This study showed that there is widespread bidirectional 
transcription not associated with promoters and co-occurring in open chromatin regions enriched 
in H3K27ac and H3K18ac (potentially marking active enhancers), while lacking H3K27me3 and 
H3K9me3 repressive marks. These observations allowed the authors to use the bidirectional 
signature of transcription as a genome-wide enhancer predictive tool (Melgar et al., 2011). Global 
run-on sequence analysis (GRO-Seq, which maps the position, amount and orientation of 
transcriptionally engaged PolII genome-wide, (Core et al., 2008) also confirmed that active 
enhancers in human prostate adenocarcinoma cells produce non-coding eRNAs (Wang et al., 
2011a). 
The fact that both gene-rich and gene-poor regions are pervasively transcribed was already hinted 
by the first phase of the ENCODE Project, which analysed 1% of the human genome (Birney et al., 
2007). The second phase of the Project interrogated the human transcriptome genome-wide and 
showed that in one of their cell lines there was a significant overlap of CAGE tags with ENCODE-
predicted enhancers (Djebali et al., 2012). These tags extended a few kb and could be seen in 
both polyadenylated and non-polyadeylated RNA fractions. The enhancer regions showing 
transcription also displayed a different chromatin signature than non-transcribed enhancers, 
consisting of a high enrichment of H3K4 methylation, H3K27 acetylation as well as high levels of 
PolII recruitment (Djebali et al., 2012). What these studies left unanswered is whether 
bidirectional transcription could be used as a novel enhancer predictive tool and whether 
predicted enhancers would be functional in the context of a vertebrate organism. 
5.1.3 Preliminary data leading to the project 
FANTOM (Functional ANnoTation Of the Mammalian genome) is an international consortium 
established by Dr. Hayashizaki at RIKEN (Japan) that aims to assign functional annotations to 
mammalian genomes. FANTOM5 Project has aimed to generate a map of human promoters and 
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enhancers through the generation of a TSS atlas that includes 432 human primary cell types and 
135 human tissue samples (FANTOM Consortium, 2014) using single molecule CAGE (Kanamori-
Katayama et al., 2011). 
Andersson and colleagues found that there was bidirectional transcription of short RNAs at 
enhancer locations and they used this signature to systematically predict active enhancers and 
characterize their usage across the FANTOM5 tissue atlas, which covers the majority of human 
cell types and tissues. Enhancer locations were defined by the co-occurrence of P300, H3K27ac 
and H3K4me1 marks. When this data was overlaid with CAGE tags, they could identify a genome-
wide bidirectional transcription pattern where tags would extends away from the enhancer 
centre, flanked by H3K27ac and H3K4me1 ChIP signals (Figure 5.1).  
These initial observations proved to be valid with well-known enhancers from VISTA and were 
confirmed as a general feature across the FANTOM5 CAGE atlas, proceeding to identify more than 
43,000 enhancer candidates in 808 human CAGE libraries. The RNA produced by enhancers is 
approximately 350 bp in length, capped, unspliced, contains termination sequences and is rapidly 
targeted by the exosome. Most of the transcripts are nuclear and non-polyadenylated. In 
contrast, mRNA produced from promoters are in average 1246 bp in size, are biased towards the 
sense direction and contain splice sites. 
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Figure 5.1 Bidirectional transcription is a signature of active enhancers across the human body. 
Overlay of enhancer sites identified by the presence of H3K4me1 and H3K27ac (bottom), with 
CAGE tags showing a bimodal distribution relative to the P300 centre point (top). This figure was 
produced by Robin Andersson and has been adapted from (Andersson et al., 2014). 
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5.1.4 Aims: 
To address whether candidate enhancers predicted by the presence of bidirectional transcription 
were able to drive tissue-specific expression in the complexity of the whole organism, I decided to 
carry out transient and stable transgenic assays using the zebrafish embryo. Within this global 
aim, the following objectives were also set: 
• To investigate whether bidirectionally transcribed sequences, predicted as enhancers, are 
active in zebrafish. 
• Determine whether enhancers recapitulate human or zebrafish endogenous expression 
patterns. 
• Evaluate if ubiquitously transcribed candidate enhancers show activity in the zebrafish 
embryo. 
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5.2 RESULTS 
5.2.1 Selection of bidirectionally transcribed human putative enhancers based on 
sequence conservation. 
To ask whether human enhancers could function in a living organism, we selected bidirectionally 
transcribed enhancers that were only expressed in a subset of tissues or cells from the FANTOM5 
CAGE Atlas. Selection was based on human-zebrafish conservation (>70% sequence identity over 
100 nt, hg19 vs DanRer7), in order to take into account the large evolutionary separation between 
the two species. We prioritized candidates that had zebrafish orthologous target genes with 
known endogenous patterns (www.zfin.org), so as to be able to compare potential reporter 
activity to both human and zebrafish patterns. Enhancer candidates that were active in human 
tissues with no zebrafish correspondence, such as lungs or trachea, were excluded. Epigenetic 
marks including histone modifications or DHS sites were not taken into consideration during the 
selection process, so as to rely only on the prediction power of the transcriptional mark. Three 
control regions were also chosen randomly from the human genome with the following 
constraints: low sequence conservation with zebrafish and no other enhancer-selective feature, 
that is, no DNase hypersensitivity, no H3K4me1 or H3K27ac signals and CAGE signal only at noise 
levels. The enhancer candidates selected for zebrafish validations are listed in Table 5.1. 
5.2.2 Transient transgenesis assays of bidirectionally transcribed human enhancers 
To test if candidate enhancers could drive tissue-specific expression in the complexity of the 
whole organism, I tested evolutionarily conserved CAGE-defined human enhancers by Tol2-
mediated transgenesis in zebrafish embryos. I cloned ~1kb regions surrounding the cis-regulatory 
element centre point into a pDB896 vector containing gata2 zebrafish promoter and YFP reporter 
gene (Table 5.2). Zebrafish gata2 promoter was used because previous enhancer screens carried 
out in the lab showed that it is more sensitive than core promoters such as hsp70 (see Chapter 3).  
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Table 5.1 Tissue specificity of selected human enhancers  and control regions based on CAGE expression atlas and zebrafish counterparts 
Cis-regulatory 
element ID 
Nearest human coding 
gene(s) 
Human tissue expression 
(FANTOM 5 Atlas) 
Zebrafish orthologous gene expression  
(www.zfin.org) 
CRE1 TMEM161b and MEF2C Fetal brain, neurons, optic nerve Branchial arches, myotome boundaries, pectoral fin muscles, posterior hypaxial muscles 
CRE2 POU3F2 Brain specific Central nervous system 
CRE3 SOX7 Endothelial cells, salivary gland, pineal gland and aorta  Vasculature, endoderm, ysl, rhombomeres 
CRE4 PAX6 and RCN1 Retina, heart and brain Retina, pancreas and brain 
CRE5 DLX1 and DLX2 Brain  Brain 
CRE6 HNF1B Liver Liver 
CRE7 TBR1 and PSMD14 Brain specific Olfactory bulb and telencephalon 
CRE8 PTPRN2 Brain specific Central nervous system 
Control region 1 C11orf74 No expression Not spatially restricted 
Control region 2 DSCAM No expression Central nervous system and eye 
Control region 3 PBX1 No expression Central nervous system and posterior branchial arches 
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Table 5.2. Selected human Cis-Regulatory Elements (CRE) and control regions used in zebrafish transient reporter assays. 
 
Cis-regulatory element ID Nearest human gene(s) Coordinates (Hg19 or Zv7) Size (bp) Forward primer (5' to 3') Reverse primer (5' to 3') 5' Tail  3' Tail  
CRE5 DLX1 and DLX2 chr2:172958266-172959477 1211 CCAGACCCATCCTCCTATCTTGA GCGGTAGAGACAAAAGAAGAGCC HindIII  EcoRI 
CRE4 PAX6 and RCN1 chr11:31840987-31842070 1083 AGAAAAGAGGTTTCTTTCCCGCT GGGAGCTTTGGCTGAGAAGTTT EcoRV SpeI 
CRE3 SOX7 chr8:10573085-10574291 1206 CTTTGCTCTCATGCTGCTTGTCT AAGATGACACTGAAAAGGGGGAG EcoRV SpeI 
CRE2 POU3F2 chr6:99275060-99276226 1166 GTTTTCCCCTCACTCTTCTGAGC CTAGTACTTCGGTCTGGGGTGCT EcoRV SpeI 
CRE1 TMEM161b and MEF2C chr5:87692532-87693408 877 CCCAAGGGAAGTCACGTAAA TGAGCCTTGGGTTTTTGTTT EcoRV SpeI 
Control region 1 C11orf74 chr11:38087624-38088486 863 CATGGCAATCACCACTTCTG CCGACTGGGATGATTGATCT HindIII  EcoRI 
Control region 2 DSCAM chr21:41847729-41848678 950 GCCTGGGCAACAGAGTAAGA ATTTTTGAGCCCTTCCCATC EcoRV SpeI 
Control region 3 PBX1 chr1:163991571-163992470 900 CAGGCCTCAACCCATTTCTA AACAGGTGGCACTCCTATGG EcoRV SpeI 
Zebrafish gata2 promoter n/a chr11:3922100-3923130  1031 ATTCATTAATAGAATAGAGGCATT CTCAAGTGTCCGCGCTTA AgeI XhoI 
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CRE6-8 overlapped with highly repetitive genomic regions and could not be amplified, therefore, 
only 5 conserved elements (CRE1-5) were used for transgenesis assays. Additionally, three control 
regions were also cloned and analysed to check the specificity of the enhancer selection process. 
Constructs were injected at one-cell stage and reporter expression patterns were analysed at 
long-pec stage (48 hpf) by fluorescent microscopy (Table 5.3). The levels of expression are 
depicted as a percentage between the number of expressing embryos versus the total number of 
injected embryos. In order to control for overall background activity from the construct (i.e., 
promoter, backbone) an empty pDB896 vector containing the zebrafish gata2 promoter linked to 
YFP reporter gene but lacking an enhancer sequence was injected and analysed in parallel. Any 
tissue-specific enrichment shown by enhancer-containing vectors over the activity shown by the 
empty control vector (ectopic expression or background) was considered enhancer-specific. 
I observed tissue-specific enhancer activity with 3 out of 5 human CREs, which corresponded to 
the human enhancer tissue expression (Table 5.1). CRE1, which is located in an intronic region of 
the TMEM161b gene and is 450 Kb downstream of the MEF2C gene, was robustly expressed in 
the central nervous system (CNS) including the forebrain, midbrain, hindbrain and spinal cord 
regions, reproducing the activity found with the human enhancer in fetal brain and neurons 
(Figure 5.2A). Around 82% (n=202) of the expressing embryos showed this neural-specific 
expression pattern, with minimal background in the yolk syncytial layer (ysl, Table 5.3). 
CRE2, which is 7 Kb upstream of POU3F2 was weakly expressed in the floor plate of the zebrafish 
embryo, that is, the ventral section of the neural tube. The neuronal pattern matched the tissue-
specificity found in the human CAGE expression atlas, as it was active in human neuronal stem 
cells (Figure 5.2B). The resolution of this experiment did not allow us to address whether these 
are the same sets of neurons.  
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(See next page for figure legend)  
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Figure 5.2. Validations of in vivo activity of CAGE-defined human enhancers CRE1-3 in zebrafish 
embryos at long-pec stage. 
Representative YFP and brightfield images of embryos injected with human enhancer-containing 
constructs are shown. UCSC browser left sub-panels depict the human genomic landscape 
(including USCS gene track) around the validated enhancer (red arrow). Right sub-panels 
represent CAGE expression in human tissues or cell types for the enhancer, measured in 
Transcripts Per Million (TPM). Note the correspondence between zebrafish and human enhancer 
expression patterns. A. CRE1, ~230kb upstream of the MEFC2 gene, drives highly robust 
expression in the brain (brain) and neural tube (nt). Right panel shows zoom-in overlay image 
showing expression in the forebrain (fb), midbrain (mid), hindbrain (hin) and spinal cord (sp). B. 
CRE2, 5kb upstream of the POU3F2 gene, is active in the floor plate (fp). Right panel is a zoom-in 
overlay image. C. CRE3, 10kb upstream of the SOX7 gene TSS, shows specific expression in the 
vasculature, including intersegmental vessels (iv), dorsal vein (dv) and dorsal aorta (da). Detail is 
shown on the right panel. Muscle (mu) and yolk syncytial layer (ysl) activities are background 
expression coming from the gata2 promoter-containing reporter construct (Table 5.3). All 
embryos are 48 hpf oriented laterally with the head to the left.  
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Table 5.3 Quantitation of transient expression displayed by long-pec zebrafish embryos injected with selected human Cis-Regulatory Elements (CRE) 
and control regions. 
 
*Table legend: Transgene-driven reporter expression at 48 hpf is depicted as a ratio between the number of embryos showing tissue-specific activity 
versus the total number of embryos injected with the enhancer-containing construct or “enhancer-less” gata2 promoter-containing control vector. 
Merged numbers from 3 independent injection experiments are shown. Ectopic expression (background) includes all expression domains displayed by 
the control vector. Enhancer-specific expression includes tissue-specific enrichment beyond the activity shown by the control vector. 
CRE ID 
No. of 
injected 
embryo
s 
Ectopic expression (background, %) 
 
Enhancer driven specific 
expression (%) Total % of expressing 
embryos 
Unspecific 
expression 
(%) 
Specific 
expression 
(%) 
Non-
expressing 
embryos 
(%) Muscle  YSL Heart  Ubiquitous Combination of tissues 
 CNS Floor plate Vasculature 
CRE5 218 14.7 4.6 0.0 18.3 9.2  0.0 0.0 0.0 46.8 46.8 0.0 53.2 
CRE4 234 24.8 6.8 0.8 7.3 5. 6  0.0 0.0 0.0 45.3 45.3 0.0 54.7 
CRE3 162 0.0 17.5 0.0 0.0 25.0  0.0 0.0 12.5 55.0 42.5 12.5 45.0 
CRE2 160 10.0 6.2 0.0 0.0 5.6  0.0 7.5 0.0 29.4 21.9 7.5 70.6 
CRE1 202 0.0 0.5 0.0 0.0 0.0  81.2 0.0 0.0 81.7 0.5 81.2 18.3 
Control 1 198 19.7 14.1 0.0 4.5 3.5  0.0 0.0 0.0 41.9 41.9 0.0 58.1 
Control 2 187 17.7 9.6 0.0 5.5 7.5  0.0 0.0 0.0 40.1 40.1 0.0 59.9 
Control 3 205 25.4 6.8 0.5 5.4 4.9  0.0 0.0 0.0 42.9 42.9 0.0 57.1 
Promoter 
control 156 23.7 8.9 2.5 8.3 13.5  0.0 0.0 0.0 57.0 57.0 0.0 42.9 
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CRE3, which is 8Kb downstream of the 3´ end of the SOX7 gene, acted as a weak enhancer in the 
zebrafish vasculature, with expression in the intersegmental vessels, dorsal vein and dorsal aorta. 
This expression pattern partially resembled the human activity, since CRE3 showed expression in 
salivary gland and blood vessels in human tissues (Figure 5.2C). Notably, moderate to high levels 
of background in tissues such as ysl, muscle, heart (or a combination of them) were found in 
embryos injected with CRE2 and CRE3 (Table 5.3). Thus, we considered CRE2 and CRE3 to be weak 
enhancers, since there was tissue enrichment over the activity shown by the empty control 
vectors (7.5% (n=160) and 12.5% (n=162), respectively) but also ectopic background. This is 
depicted graphically in (Figure 5.3). 
CRE4 and CRE5 could not direct tissue-specific expression. Similarly, none of three control 
fragments without CAGE signal activated the gata2 promoter (Table 5.3). Taken together the 
above results showed that 3 candidate enhancers reproduced the activity displayed in the CAGE 
human tissue atlas, suggesting that bidirectional transcription could be used as a predictive 
enhancer tool. 
 
Figure 5.3 Tissue specificity of enhancer activity in mosaic transgenic zebrafish embryos  
Percentage of zebrafish injected embryos at 48 hpf showing tissue specific expression (driven by 
human CRE1-3, green bars) and unspecific expression coming from the enhancer-less gata2 
promoter containing vector (lilac bars). For detailed expression patterns refer to Table 5.3. 
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It has been reported that SINE B2 sequences in mice could actively repress cis-regulatory activity 
by harbouring CTCF binding sites that act as insulators (Schmidt et al., 2012). Although a genome-
wide enrichment of CTCF sites was not found in human SINE sequences, taking into account that 
CTCF binding events are more conserved than tissue-specific TFs, we wanted to test whether 
repetitive sequences were responsible for the weak activity of two of our enhancers. Thus, we 
decided to scan the candidate CREs and remove any SINE sequences, if found. Among CRE1-5, 
only CRE3 contained 168 bp SINE repetitive region on its 5´end (Figure 5.4) and was bound by 
CTCF in several ENCODE lines. Thus, the CRE3 element excluding the repetitive fragment was re-
amplified and its activity was re-evaluated in Tol2-based transient zebrafish assays. I found that in 
three experimental replicates where both the original element and the shortened CRE were 
injected in parallel under the same conditions, 6.6% (n=389) and 8.2% (n=365) of the total 
injected embryos respectively were active in the vasculature. Thus, reporter assays with the 
shortened 911 bp fragment did not show any statistically significant change in terms of either 
expression pattern or frequencies (p= 0.4876), suggesting that the low activity of this enhancer 
was not directly related to the presence of the SINE fragment and that the SINE element was not 
required either for autonomous activity of the enhancer. 
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Figure 5.4 UCSC screenshot depicting genomic location of CRE3 putative enhancer and SINE region 
CRE3 (depicted as a black horizontal bar) contained a SINE region located on the 5´end (labelled by a dashed red rectangle). A new fragment of 911 bp 
that excludes this repetitive region was tested (chr8:10,573,380-10,574,291). 
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5.2.3 Validation of transient transgenesis results by establishing stable transgenic lines 
In order to verify whether the patterns seen in transient transgenic embryos were confirmed in 
stable lines, I decided to grow up embryos injected with CRE1-3-containing constructs. Adults 
were bred to WT fish and analysis of their offspring led to the identification of 5 different 
transgenic lines containing CRE1 candidate enhancer (Table 5.4). All transgenic lines displayed a 
similar pattern to that seen in transient transgenic embryos (Figure 5.5). No positive founders 
containing CRE2 candidate enhancer could be identified, despite screening a comparable number 
of fish. The 2 founders with CRE3 displayed expression patterns that were not similar to the 
enhancer activity seen in transient transgenic embryos or that could be related to the zebrafish 
orthologous gene expression pattern, suggesting enhancer traps events (Figure 5.6). Taken 
together, stable transgenic lines allowed us to verify the activity of CRE1. More transgenic lines 
would be needed to conclude on the activity of CRE2 and CRE3 candidate enhancers. 
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Table 5.4 Analysis of the offspring of CRE1-3 containing founders 
Transgenic line name 
No. of 
screened 
founders 
No. of 
positive 
founders 
Germline 
transmission 
rate (%) 
Line ID No. of embryos analysed 
Transmission 
rate per 
pattern (%)  
Expression pattern 
Tg(hs-TMEM161-1.0dr-gata2-pr:YFP) 8 5 62.5 
CRE1-L1 57 26.3 Brain, neural tube 
CRE1-L2 106 3.8 Brain, neural tube 
CRE1-L3 275 8.7 Brain, neural tube 
CRE1-L10 140 8.6 Brain, neural tube 
CRE1-L30 68 17.6 Brain, neural tube 
Tg(hs-POU3F2-0.1dr-hsp70-pr:YFP) 22 0 0.0 n/a n/a n/a n/a 
 20 1 5.0 
CRE3-L1 
120 
10.8 Lens, tectum, neural tube, jaws 
Tg(hs-SOX7-0.1dr-hsp70-pr:YFP) CRE3-L2 5.8 Lens, neurons 
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Figure 5.5 Stable lines containing CRE1 recapitulated faithfully the expression pattern seen in 
transient transgenic zebrafish embryos 
A. Embryos injected transiently with CRE1 (left panel) displayed a very similar expression pattern 
to the established transgenic lines (right panel), recapitulating human tissue activity. B. Full 
expression pattern driven by CRE1-containing transgenic lines. All embryos are 48 hpf anterior to 
the left.  
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Figure 5.6 Stable lines containing CRE3 showed expression patterns not relevant to the human 
or zebrafish activities. 
Two transgenic lines displayed different expression patterns to one another that are not related 
to the human or zebrafish expected activities, suggesting position effects. Embryos are 42-48 hpf 
oriented anterior to the left. Scale bar indicates 100 µm.  
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5.2.4 Test of in vivo function of ubiquitously expressed candidate enhancers 
Aside from enhancer candidates that were expressed in specific human tissues or cell types, 
Andersson and colleagues identified sequences that were transcriptionally active in the majority 
of tissues and cell lines encompassing the CAGE-expression atlas. We asked whether these 
elements would be able to drive any expression in the zebrafish embryo. In a proof of principle 
experiment, we selected 3 candidates that were bidirectionally transcribed, conserved between 
human and fish and also had enhancer-associated histone modification marks, overlapped DHs 
and were bound by transcription factors (Table 5.5). I cloned the three candidates upstream of 
the zebrafish gata2 promoter linked to YFP, and co-injected the constructs with Tol2 mRNA in 
zebrafish one-cell stage embryos (Table 5.6). Analysis of the expression pattern during the first 5 
days of development showed that these elements were not active or tissue-specific, as they were 
not able to control any tissue-specific activity beyond promoter background (Table 5.7). 
 
Table 5.5 Tissue specificity of selected ubi-enhancers based on CAGE expression atlas and 
zebrafish counterparts 
CRE 
ID 
Nearest human 
coding gene(s) 
Human tissue 
expression (FANTOM 5 
Atlas) 
Zebrafish orthologous gene expression 
(www.zfin.org) 
ubi1 GTF2A Ubiquitous not spatially restricted 
ubi2 GPR84 Ubiquitous not spatially restricted 
ubi3 ZBTB16 Ubiquitous central nervous system, branchial arches, pectoral fin, pronephric ducts 
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 Table 5.6 Selected candidate enhancers ubiquitously expressed in human CAGE atlas. 
 
 
Table 5.7 Quantitation of transient expression displayed by high-pec zebrafish embryos injected with ubiquitously expressed candidate enhancers. 
CRE ID 
No. of 
injected 
embryos 
Ectopic expression (background, %) Enhancer- 
driven 
expression (%) 
Total % of 
expressing 
embryos 
Unspecific 
expression (%) 
Specific 
expression (%) 
Non-
expressing 
embryos (%) Muscle  YSL Heart  Ubiquitous 
Combination 
of tissues 
ubi1 253 14.2 5.5 2.8 7.9 9.9 0.0 40.3 40.3 0.0 59.7 
ubi2 257 16.7 4.3 1.9 9.7 8.6 0.0 41.2 41.2 0.0 58.8 
ubi3 273 17.6 6.6 2.9 11.0 11.7 0.0 49.8 49.8 0.0 50.2 
Promoter 
control 156 23.7 9.0 2.6 8.3 13.5 0.0 57.1 57.1 0.0 42.9 
 
Cis-regulatory element ID Coordinates (Hg19) Size (bp) Forward primer (5' to 3') Reverse primer (5' to 3') 5' Tail  3' Tail  
ubi1 chr14:81685343-81686243 901 ACCAAAACCAAGTCCTCTGC CAGTTCCTTCCGAATGGGTA HindIII  EcoRI 
ubi2 chr12:54752583-54753476 854 TGCCTTCCTTCTCTCCTCAA TCTCGGGATGTGTGTGTGTT HindIII  EcoRI 
ubi3 chr11:114033182-114034045 864 AGATGGCTTCCCCTCATCTT GTGAATCAGCAGCAGGGTTT HindIII  EcoRI 
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5.3 DISCUSSION 
In this study I tested whether predicted bidirectionally transcribed candidate enhancers were 
active in the context of a vertebrate embryo, based on the observations made by the FANTOM5 
Consortium. Out of 5 evolutionary conserved human enhancers, I observed tissue-specific activity 
driven by 3 CREs in zebrafish transient transgenesis assays, whereas none of the three control 
fragments without CAGE signal could function as enhancers, suggesting that bidirectional 
transcription is predictive of active enhancers. In contrast, none of the ubiquitously expressed 
enhancers displayed any activity in the zebrafish transgenic embryo, suggesting lack of 
functionality in zebrafish. 
Interestingly, the tissue-specific pattern displayed by the zebrafish embryos injected with the 3 
functional CREs corresponded to the human tissues where the putative enhancers were shown to 
be active in vitro and not to the zebrafish endogenous patterns (Table 5.1). However, the 
relatively small set of tested enhancers hindered a meaningful statistical analysis of this 
correlation.  
Recently, the prediction of enhancers has been based on the analysis of histone modification 
marks, nucleosome-depleted regions, the presence of transcription factor binding sites or a 
combination of these approaches (Rada-Iglesias et al., 2011; Djebali et al., 2012; Rada-Iglesias et 
al., 2012). However, although several studies had reported that enhancers could effectively bind 
to PolII and produce non-coding transcripts (Kim et al., 2010; Melgar et al., 2011), bidirectional 
transcription had never been used as a signature to predict active enhancers throughout the 
human body and to our knowledge this is the first study where bidirectionally transcribed 
enhancers has been functionally tested in vivo. 
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We decided to use transient transgenesis as these type of analyses have proven successful in the 
past to validate CREs (Navratilova et al., 2009; Narlikar et al., 2010), among others, arguing that 
reproducible expression patterns seen in hundreds of injected embryos can indicate enhancer 
function. The establishment of stable transgenic lines on the other hand has been used here to 
validate the expression patterns seen in transient transgenic assays. In this study, however, I 
could distinguish between two categories among the 3 functional human CREs. Transient 
transgenic assays demonstrated that CRE1 was a strong enhancer in the central nervous system of 
the zebrafish embryo and the expression pattern was validated in 5 independent transgenic lines. 
These lines showed an almost identical pattern to each other and to the injected embryos. In 
opposition to that, CRE2 and CRE3 could drive tissue-specific expression, in the floor plate and in 
the vasculature respectively, but also displayed ectopic expression domains in yolk syncytial layer, 
muscle, and other tissues that were present in embryos injected with the enhancer-less gata2 
promoter only. Consistent with this, we were unable to confirm these patterns in stable 
transgenic lines, obtaining offspring that exhibited activity in tissues that were irrelevant to 
activities expected from the human and zebrafish potential target genes. These results suggested 
position effects, which are caused by the random integration in the host genome of the transgene 
flanked by the transposase arms (Wilson et al., 1990; Rossant et al., 2011). Both position effects 
and partial recapitulation of the expression pattern displayed in transient transgenesis hindered 
the unambiguous identification of a CRE regulatory potential. In order to conclude better, a higher 
number of founders would have to be established. Nevertheless, a comparable number of adults 
were screened for all 3 elements, which suggests that an unknown inherent property of these 
weak enhancers might be responsible for the lack of reproducible gene expression. 
In order to investigate whether the presence of repetitive SINE sequences were responsible for 
the weak activity of CRE, a “SINE-less” CRE3 was cloned and tested. Nevertheless, the percentage 
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of tissue-specific activity obtained with the “SINE-less” fragment was not significantly different 
from the whole region, suggesting that this region was not related to the low activity of the 
human enhancer. As an alternative, lack of enhancer-promoter specificity could also be 
responsible for weak activity displayed by CRE2 and CRE3, which underlines the often 
underestimated importance of promoter selection in validation assays. 
Overall, although we have demonstrated that human enhancers recapitulate expression patterns 
relevant to the human activity in 3 tissue-specific CREs, higher-throughput analysis would be 
desirable to conclude statistically on the validation rates in zebrafish. Using sequence 
conservation as a filter significantly reduced the number of enhancer candidates suitable for 
zebrafish assays. As I will discuss throughout the Thesis, in our experience non-conserved human 
enhancers are not functional in zebrafish, so we believe that this filter, although restrictive is 
backed up by our results.  
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Chapter Six: DETECTION OF QUANTITATIVE DIFFERENCES CAUSED 
BY ENHANCER VARIANTS  
FOREWORD 
For my studies on developing a method to detect quantitative differences between enhancer 
variants we established a collaboration with Lorenzo Pasquali and Jorge Ferrer, affiliated to 
IDIBAPS (Spain) and Imperial College London (UK), and members of the Marie Curie BOLD 
Network.  
The computational analysis of epigenetic marks and selection of appropriate T2D-associated SNPs 
was carried out by Lorenzo Pasquali. 
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6.1 INTRODUCTION 
6.1.1 Genome-wide association studies as a source of non-coding variability 
Several publications have recently confirmed that functional cis-regulatory elements, particularly 
enhancers marked by DNase I hypersensitivity and histone modification marks, are enriched in 
disease-associated SNPs (Hindorff et al., 2009; Bernstein et al., 2012; Maurano et al., 2012; Lee 
and Young, 2013; Trynka et al., 2013).  
In the last ten years, the capacity to identify common variants has increased enormously thanks 
to Genome Wide Association Studies (GWAS), which nurtured from the sequencing of the Human 
Genome (Human Genome Sequencing Consortium, 2004) and from HapMap and 1000 Genomes 
Projects (HapMap Consortium, 2005; Frazer et al., 2007; Altshuler et al., 2010; Abecasis et al., 
2012). GWAS allow for millions of independent SNP association tests with a trait of interest 
without considering candidate genes, aiming to identify multiple variants that contribute with a 
small effect to the phenotype (Prokopenko et al., 2008). In contrast, linkage analysis and 
candidate gene approaches find rare loci that strongly influence a disease (Billings and Florez, 
2010).  
It is estimated that there are around 10 million common SNPs in the human genome, around one 
SNP every 300 nt, where the frequency of allelic variants is above 1% (HapMap Consortium, 
2003). Their analysis is facilitated by the presence of block-like structures of variants that are in 
linkage disequilibrium (LD). Two allelic variants are in LD when their genotypes are correlated and 
one SNP allele can predict the genotype of a closely positioned second variant (Mohlke and Scott, 
2012). The particular combination of allelic variants on a chromosome region that is co-inherited 
is termed haplotype (HapMap Consortium, 2005). LD is commonly measured by 2 parameters: 
D´and r2. D´ is a measure of the frequency of the haplotype and ranges from 0 (no LD) to 1 (LD is 
100%). New haplotypes can be generated by the occurrence of new mutations or by 
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chromosomal recombination events (HapMap Consortium, 2003), thus, the rate of recombination 
between the 2 allelic variants will directly influence the decrease of D´ value. The statistic r2 
measures the correlation coefficient between 2 SNPs, and ranges from 0 to 1, being 1 when the 
association between the two is not disrupted by recombination (HapMap Consortium, 2005). 
Although GWAS are a source of disease-associated SNPs, they usually point to associations with 
other correlated variants with which they are in LD but are not powerful enough to identify the 
variant that is causing the phenotype or disease (Cooper et al., 2010; Schaub et al., 2012). 
6.1.2 Common variants associated to disease lie on functional regulatory regions 
Several reports have confirmed that single base pair nucleotide variation in cis-regulatory regions 
can have phenotypic effects and increase the susceptibility to human disorders, mostly through 
the disruption or creation of TFBS (Pomerantz et al., 2009; Musunuru et al., 2010; Harismendy et 
al., 2011; Smemo et al., 2014). For example, the risk allele of a SNP present in the enhancer of 
Interferon Regulatory Factor 6 disrupts an AF2-α binding site and confers a higher risk to Van der 
Woude syndrome (Rahimov et al., 2008). A similar study has demonstrated that the SNP 
rs6983267, which has been strongly associated to colorectal cancer, lies on an intergenic region 
that behaves as an enhancer in vitro. Interestingly, the risk variant displays differential enhancer 
activity, and an increased capacity for TCF7L2 TF binding; uncovering a possible molecular 
mechanism for the increased risk to cancer pathogenesis (Pomerantz et al., 2009). Another 
example of a disease-associated SNP with clinical relevance is rs12740374, located on a 
chromosomal region linked to myocardial infarction in humans (Musunuru et al., 2010). The 
infrequent allelic variant of rs12740374 creates a novel binding site for the liver-specific TF CBPEA, 
influencing the expression of SORT1 in the liver. This in turn modulates hepatic secretion of low-
density lipoproteins and contributes to the altered phenotype (Musunuru et al., 2010).  
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Although most of these publications have not used in vivo models, a study has recently utilized 
zebrafish transgenesis to demonstrate differential activity of a SNP linked to Restless Leg 
Syndrome (Spieler et al., 2014). The authors showed that the risk allele, located in a highly 
conserved non-coding region within MEIS1 locus, could reduce significantly the enhancer activity 
in the brain and spinal cord (Spieler et al., 2014), demonstrating the utility of zebrafish in this type 
of assays. 
6.1.3 Type two diabetes associated polymorphisms identified by GWAS 
T2D is a complex disease caused by both genetic and environmental factors. The genetic basis of 
T2D has been widely studied through linkage analysis and association methods, reviewed in (Pal 
and McCarthy, 2013). GWAS have made progress towards understanding the inherited base of 
T2D by detecting more than 60 disease-associated DNA variants in European and Asian 
populations (Morris et al., 2012). Interestingly, out of the 18 most strongly T2D-associated SNPs, 
only 3 are mis-sense variants, while the rest are non-coding (Prokopenko 2008).  
One of the most interesting non-coding variants lies in TCF7L2, where the SNP rs7903146 has the 
strongest link effect to T2D demonstrated so far, in most, but not all ethnicities (Grant et al., 
2006; Cauchi et al., 2007; Guo et al., 2007; Helgason et al., 2007; Dupuis et al., 2010; Morris et al., 
2012). TCF7L2 encodes a high-mobility group TF involved in Wnt signalling pathway. Gaulton and 
colleagues demonstrated that the risk allele of the SNP s7903146 (C>T) showed greater enhancer 
activity in vitro than the common allelic variant (Gaulton et al., 2010). Nevertheless, only a subtle 
effect could be detected, and the question remained of whether it could lead to an alteration in 
the spatio-temporal control of gene expression in vivo. 
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6.1.4 Aims 
In this project, I asked whether quantitative differences in expression driven by candidate 
enhancer variants associated with T2D could be detected using zebrafish. Given that most studies 
to date had used luciferase assay in cell lines to show functionality (Gaulton et al., 2010; Stitzel et 
al., 2010), we argued that differential enhancer activity had to be verified in the context of a 
vertebrate organism that shared a common pancreas-specific transcriptional regulatory network 
and anatomical structure with humans, such as zebrafish. The following objectives were set: 
- To test in vivo the functionality candidate enhancers associated with T2D using Tol2-
based zebrafish transgenesis assays. 
- To develop a proof of principle method able to quantitate in vivo allelic differences from 
enhancer variants associated with T2D. 
 
6.2 METHODS 
Selected human putative enhancers with T2D-associated SNPs were amplified from human 
genomic DNA provided by our collaborators using the primers listed in Table 6.1. Due to the 
unavailability of human genomic DNA carrying the infrequent allelic variant of T2D-associated SNP 
rs3242786 on PROX1 intronic region, a point mutation was generated following Higuchi method 
(see Chapter 2 for primers and a detailed protocol). In order to control zebrafish promoter 
functionality, a non-conserved region from Fugu rubripes showing no regulatory activity 
(fr2(assembly 2004) chrUn:54,537,362-54,537,937) was used (Sanges et al., 2006). Final 
expression vectors were generated using pSP1.72BSSPE-R3-R5-R1-R2-Venus Destination Vector 
(Roure et al., 2007). These vectors contained Tol2 transposase arms to facilitate single-copy 
genome integration of the construct into the host genome by co-injection with Tol2 transposase 
mRNA. 
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Table 6.1 Primers used to amplify human putative enhancers and zebrafish promoters from genomic DNA 
CRE  
Genomic coordinates 
Forward primer (5’-3’) Reverse primer (5’-3’) Product size (bp) 
(Hg18 or Zv9) 
PROX1 chr1:212242977-212243697 GCAAAAATGAACTTGAGAAATCC CATTCCCTTTAATATCCCATGC 721 
TCF7L2 chr10:114748248-114748506 AATTCATGGGCTTTCTCTGC GTGAAGTGCCCAAGCTTCTC 239 
DGKB-TMEM195 chr7:15030251-15031281 AGTCTAATACCTCTCAGTGGATA TGGTTGATTGACAGAATTCATT 1031 
ADCY5 chr3:124547851-124549052 GATTCAGCCAGGGGCAGCCTT GAAGCAACACCAGCCGCTTTG 1202 
Zebrafish prox1 promoter chr17:33071557-33071979 TCCGCACAGAGAACGTATTG TGAGCTTCTTCGCGATAGTG 423 
Zebrafish tcf7l2 promoter chr12:32790190-32790830 TCAGCCTCTTCTGTTTTGAGCAG TTTAAGTTTAGGGACTCGCAGTGG 641 
Zebrafish hsp70 promoter chr3:26911324-26911472 TTGATTGGTCGAACATGCTGG CAGTCCGCTCGCTGTCTCGCT 149 
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6.3 RESULTS 
6.3.1 Selection of putative enhancers associated with T2D  
To ask whether T2D-associated variants were active in zebrafish, we initially selected four T2D-
associated SNPs uncovered by a global meta-analysis (Table 6.2, (Dupuis et al., 2010). The SNPs 
were located in or near ADCY5, PROX1, TCF7L2 and DGKB-TMEM195 loci and were significantly 
associated with elevated fasting glucose in non-diabetic individuals, which increased the risk to 
T2D (Dupuis et al., 2010). Next, candidate enhancer sequences harbouring these T2D-associated 
SNPs were identified by Lorenzo Pasquali. Candidate enhancers for in vivo assays were defined by 
the presence of open chromatin sites and/or enhancer-associated marks, including H3K4me1 or 
H3K27ac (Pasquali et al., 2014), and were approximately 1 kb in length (Table 6.1). 
Table 6.2 List of T2D SNPs selected for in vivo assays. 
T2D-associated SNP T2D-associated locus Location Allelic variants GWAS Reference 
rs4282786 PROX1 Intronic G>A (Dupuis et al., 2010) 
rs7903146 TCF7L2 Intronic C>T (Cauchi et al., 2007) 
rs2191349 DGKB-TMEM195 Intergenic G>T (Dupuis et al., 2010) 
rs11708067 ADCY5 Intronic A>G (Dupuis et al., 2010) 
 
6.3.2 Identification of zebrafish endogenous promoter using a CAGE dataset 
For reporter assays, we decided to use zebrafish endogenous promoters, as well as the 
heterologous hsp70 promoter. In order to identify the endogenous promoters of prox1 and tcf7l2 
genes in zebrafish, a CAGE dataset was utilized, which predicts promoters at a single nucleotide 
resolution in several embryonic developmental stages (Nepal et al., 2013).  
The transcription start site (TSS) of genes was determined by CAGE tag cluster distribution 
(depicted as blue peaks in Figure 6.1), where the peak represents the 5’ end position of aligned 
CAGE reads and its height is indicative of the enrichment of the aligned segments. 
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A region of 423 bp in length, surrounding the TSS of prox1 gene was identified as the minimal 
promoter and was amplified for cloning (Figure 6.1A) Approximately 50 bp downstream and 400 
bp upstream of the dominant CAGE-predicted TSS were used.  
Zebrafish tcf7l2 promoter was identified as a broad promoter due to the presence of two 
enrichment peaks (Figure 6.1B). The CAGE peak overlapping with the reference TSS was chosen as 
the main promoter as it was consistently supported by the highest number of tags at the zygotic 
stages of development. A region of 641 bp around the main TSS was used for cloning (Table 6.1). 
 
 
 
Figure 6.1 Identification of zebrafish prox1 and tcf7l2 endogenous promoters.  
UCSC Genome Browser screenshot displaying custom tracks of the fragments cloned, RefSeq 
genes, full length mRNAs, spliced EST and CAGE tag data for 24 hpf and 33 hpf developmental 
stages. The solid black box with arrowheads, which point the direction of transcription, in the 
"promoter fragment" track represents the region cloned for reporter assays. A. Identification of 
prox1 minimal promoter (423 bp around the main CAGE TSS). B. Identification of tcf7l2 minimal 
promoter (641 bp) around the main CAGE TSS.  
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6.3.3 In vivo testing of T2D-associated candidate enhancers by Tol2-based transient 
transgenic assays in zebrafish 
To determine whether predicted regulatory elements could function as enhancers, and whether 
disease-associated SNPs could result in differential enhancer activities in a vertebrate embryo 
model, Tol2-based transient transgenesis assays were carried out. For each T2D-associated locus 
three constructs were produced by linking the human enhancer variants to a zebrafish promoter 
and a reporter gene. In order to control zebrafish promoter functionality, a non-conserved region 
from Fugu rubripes showing no regulatory activity was used (as described in Chapter 3, see also 
Figure 3.3). These three expression vectors were injected in parallel into WT zebrafish fertilized 
eggs and reporter expression was assessed at protruding mouth stage (72 hpf) using fluorescence 
microscopy. All tissues of expression from three experimental replicates were annotated 
following the criteria set in previous chapters and representative patterns of expression were 
documented. The time point chosen was 72 hpf because the zebrafish pancreas has developed 
completely at this stage (Tiso et al., 2009). 
6.3.3.1 Validation of PROX1 putative human enhancer containing SNP rs4282786 
GWAS revealed that SNP rs340874, which was located 2kb upstream of PROX1 TSS, was 
significantly associated to T2D (Dupuis et al., 2010). However, rs340874 was neither conserved in 
zebrafish nor enriched in chromatin marks typically associated with enhancers. In contrast, 
intronic SNP rs4282786 (G>A) was in LD with T2D-associated rs340874, and was located in an 
evolutionary conserved region of PROX1 gene. Additionally, it was enriched in H3K4me1 and 
H3K27ac histone modification marks, suggesting that it could be a developmental enhancer 
(Figure 6.2A). Thus, we selected a 721 bp region harbouring SNP rs4282786 for functional analysis 
in zebrafish. Due to the unavailability of human genomic DNA carrying the infrequent variant in 
homozygosis, I used site directed mutagenesis by PCR to generate the infrequent A allele carried 
by the candidate enhancer associated to T2D (Figure 6.2B).  
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(See next page for figure legend)  
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Figure 6.2 Chromatin landscape and activity of putative human regulatory element PROX1.  
A. UCSC Genome Browser screenshot displaying custom tracks of FAIRE-Seq data, histone 
modifications and DNA sequence conservation. PROX1 putative element is depicted by a black 
solid line box. Screenshot is courtesy of Lorenzo Pasquali. B. Sequencing chromatograms of 
rs4282786 SNP within PROX1 putative element. Left panel shows the wild type sequence 
containing the common variant (G). Right panel shows the site-directed introduced mutation to 
mimic the infrequent allelic variant of the SNP (A). C. Transient expression pattern driven by 
PROX1 candidate enhancer. Representative dorsal and lateral view images of embryos injected 
with G (top) and A (bottom) variants of SNP rs4282786 are displayed. All embryos are 72 hpf 
oriented with anterior to the right. Scale bar indicates 100 µm.  
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In order to test the functionality of the conserved PROX1 putative regulatory element in zebrafish, 
this region was linked to the zebrafish prox1 endogenous minimal promoter (Figure 6.1) and 
Venus reporter gene and domains of expression were annotated at 3 dpf (Table 6.3, Figure 6.3). 
Constructs containing PROX1 putative enhancer variants could drive reporter gene expression in 
the pancreatic islet, yolk syncytial layer (ysl), muscle, heart and neurons (Figure 6.2C, Figure 6.3). 
However, no statistically significant differences could be detected between the A and G alleles in 
terms of frequency of expression domains (Table 6.3). Interestingly, none of the embryos injected 
with the Fugu control region linked to prox1 zebrafish promoter led to detectable expression in 
the pancreas (n=246), suggesting that the human PROX1 candidate enhancer was responsible for 
this activity. Constructs containing PROX1 candidate also showed a significant enrichment in 
tissues such as heart and neurons, when compared to the Fugu control, which suggests that these 
domains are attributable to the candidate enhancer (Table 6.3). 
In order to find out whether PROX1 was autonomously capable of driving expression in the 
pancreas, and to determine whether heart and neuronal expression patterns were an artefact 
from the construct used, both enhancer variants and the Fugu control region were cloned into a 
different context: upstream of a heterologous minimal promoter (hsp70) in a pDB896 vector 
containing short Tol2 arms. Three experimental replicates confirmed that both G and A allelic 
variants could drive pancreas specific expression in 2.7% (n=298) and 1.85% (n=334) of the 
injected embryos respectively, whereas reporter gene expression was not detectable in this 
domain with the control vector (n=215). These results suggested that PROX1 human enhancer, 
and not the zebrafish prox1 promoter, was responsible for the activity in the endocrine pancreas. 
Ectopic lens expression driven by hsp70 zebrafish promoter (Blechinger et al., 2002) was detected 
in embryos injected with PROX1 putative enhancer variants, although surprisingly it was not 
shown by the Fugu region linked to the promoter only. On average, the frequency of heart 
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expression was reduced 12% in embryos injected with PROX1 variants (Figure 6.3B), suggesting 
that either a cryptic vector sequence from the Gateway vector, the Tol2 arms or a specific 
interaction between PROX1 candidate enhancer and prox1 promoter were responsible for the 
enhanced expression in this domain. 
 
 
Figure 6.3 Rates of tissue expression driven by PROX1 human element constructs linked to 
zebrafish prox1 and hsp70 zebrafish promoters.  
Percentage of 72 hpf zebrafish injected embryos showing reporter gene expression driven by 
PROX1 candidate enhancer variants and the Fugu control region linked to prox1 promoter (top) 
and hsp70 promoter (bottom). Reporter expression could be detected in muscle, yolk syncytial 
layer (ysl), heart, neurons and endocrine islet when PROX1 candidate enhancer was linked to 
prox1 promoter. When PROX1 is linked to hsp70 promoter, the candidate enhancer is 
autonomously capable of driving reporter gene expression in the ysl, heart, neurons and 
pancreatic. Expression in the lens is ectopic activity from hsp70 core promoter (Blechinger et 
al., 2002). For detailed expression frequencies refer to Table 6.3. 
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 Table 6.3 Quantitation of reporter gene expression driven by PROX1 putative enhancer in protruding-mouth embryos. 
 
Table legend: Transgene-driven reporter expression at 72 hpf is depicted as a ratio between the number of embryos showing tissue-specific activity 
versus the total number of embryos injected with the enhancer-containing construct or Fugu region and promoter-containing control vector. Merged 
numbers from 3 independent injection experiments are shown. YSL= yolk syncytial layer.  
 
Tested CRE 
Zebrafish 
promoter 
used 
No. of 
injected 
embryos 
Reporter gene expression (%)   Percentage of 
expressing 
embryos 
No. of 
replicates  
Muscle  YSL Heart  Neurons Pancreatic islet Lens 
PROX1-G allele prox1  284 4.2 3.5 16.9 13.0 2.1 0.0 35.9 3 
PROX1-A allele prox1  352 2.8 2.8 15.3 17.3 2.0 0.0 50.9 3 
Fugu control region prox1  246 2.0 8.9 3.3 4.5 0.0 0.0 44.7 3 
PROX1-G allele hsp70 298 0.0 1.0 3.7 7.4 2.7 6.7 19.8 3 
PROX1-A allele hsp70 334 0.0 1.2 3.6 9.0 1.8 6.0 28.7 3 
Fugu control region hsp70 215 0.0 0.0 0.0 0.0 0.0 0.0 0.9 3 
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6.3.3.2 Verification of pancreatic islet specific activity of PROX1 candidate enhancer by 
co-localization analysis with Tg(ins-mCherry) jh2 line 
In order to confirm the pancreatic islet-specific activity attributed to PROX1 candidate enhancer 
as well as to attempt to quantitate differences between PROX1 allelic variants, I carried out an 
additional reporter analysis thereby I compared PROX1 driven Venus reporter activity to embryos 
from the Tg(ins:mCherry)jh2 line, which accurately label insulin-producing β-cells in red (Pisharath 
et al., 2007). To this end, vectors containing PROX1 allelic variants linked to a prox1 endogenous 
promoter (namely pTol2/Hs.PROX1(G)-Dr.prox1:Venus and pTol2/Hs.PROX1(A)-Dr.prox1:Venus) 
were injected into heterozygous embryos of the Tg(ins:mCherry)jh2 line, and co-localization of the 
two fluorescence reporters was evaluated at 3 dpf (Table 6.4, Figure 6.4). 
Table 6.4 Summary of co-localization events with PROX1 set of constructs 
Construct 
No. of 
injected 
embryos 
No. of 
expressing 
embryos 
No. of embryos 
with co-
localization 
Co-localization 
frequency (%) 
pTol2/Hs.PROX1(G)-Dr.prox1:Venus 230 82 15 18,3 
pTol2/Hs.PROX1(A)-Dr.prox1:Venus 196 68 10 14,7 
pTol2/Fugu:Dr.prox1:Venus 205 72 0 0,0 
Co-localization between PROX1 enhancer-driven reporter expression and insulin-driven reporter 
in the endocrine pancreas was found in 18.3% of embryos (n=230) injected with the common 
rs4282786 allele (G) and in 14.7% embryos (n=196) injected with the infrequent variant (A). None 
of the embryos injected with the Fugu control region linked to prox1 promoter 
(pTol2/Fugu:Dr.prox1:Venus vector) showed co-localization events (Table 6.4). However, there 
was no statistically significant difference in the frequency of co-localization events between the 
two alleles (P=0.6617), suggesting that rs4282786 SNP was not essential for the regulation of the 
pancreas-specific activity.  
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Figure 6.4 Co-localization events between PROX1 candidate enhancer (green) and pancreatic 
islet specific transgenic line (red).  
Reporter expression (YFP), insulin transgenic expression (mCherry), brightfield image and an 
overlay of channels are shown for representative embryos injected with PROX1-containing 
variants linked to prox1 zebrafish promoter. All zebrafish embryos are 72 hpf oriented with 
anterior to the right. Scale bar indicates 250 µm.  
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6.3.3.3 Validation of TCF7L2 putative human enhancer containing SNP rs7903146 
In order to test whether the 239 bp open chromatin region evaluated by Gaulton and colleagues 
was active in zebrafish, and whether the allelic variants of SNP rs7903146 (C>T) could lead to a 
differential enhancer activity, TCF7L2 candidate enhancer was cloned upstream of the zebrafish 
tcf7l2 endogenous minimal promoter (Figure 6.1) and Venus reporter gene, and its activity 
analysed in transgenesis assays. This region was not conserved at a sequence level with zebrafish 
and was enriched in H3K4me1, H3K27ac and H2AZ histone variant (Figure 6.5A). 
Fluorescent microscopy analysis of reporter expression during the first five days of embryo 
development revealed that TCF7L2 enhancer variants could not drive any tissue specific activity 
that differed from the Fugu control vector in three experimental batches of independently 
injected embryos (n=878). Because the lack of activity could have been caused by the limited 
sensitivity of the stereo-fluorescence microscope used, we decided to increase the transgene 
detection sensitivity. Thus, we carried out three additional experiments where 72 hpf injected 
embryos were plated and imaged by the ScanR high-throughput imaging station (Liebel et al., 
2003). Twenty images from each embryo group were overlaid using the Adobe Photoshop CS6 
software to create an overview of mosaic expression patterns (Figure 6.5B). A diversity of ectopic 
expression was found (mainly in the yolk syncytial layer) but neither pancreas specific expression 
nor diencephalic expression (which is relevant to the expression of the zebrafish tcf7l2 gene) was 
detected, suggesting that there was no specific reporter activity driven by TCF7L2 human putative 
enhancer (Figure 6.5B).  
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Figure 6.5 Chromatin landscape and activity of putative human regulatory element TCF7L2.  
A. UCSC Genome Browser screenshot, courtesy of Lorenzo Pasquali, displaying custom tracks of 
FAIRE-Seq data, histone modifications, RNA Seq and DNA sequence conservation. The solid line 
box contains the cloned element. B. Composite overviews of in vivo Venus expression data from 
20 individual zebrafish embryos. All embryos are 72 hpf oriented dorsally. Yolk syncytial layer (ysl) 
ectopic expression was detected in embryos injected with TCF7L2 human element. Scale bar 
indicates 100 µm.  
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6.3.3.4 Validation of DGKB-TMEM195 putative human enhancer and SNP rs2191349 
SNP rs2191349 (G>T), which is located on a gene desert between DGKB and TMEM195, was also 
significantly associated to T2D by GWAS (Dupuis et al., 2010). DGKB encodes a catalytic domain of 
diacylglycerol kinase and TMEM195 encodes a transmembrane protein expressed in liver. A 
region of 1,031 bp surrounding the lead SNP rs2191349 that overlapped with an open chromatin 
site and was enriched in H3K4me1 and H3K27ac marks, was used for in vivo tests in zebrafish 
(Figure 6.6A). 
In order to test the functionality of this SNP, both allelic variants were cloned upstream of the 
zebrafish hsp70 minimal promoter and injected in zebrafish WT embryos. Pancreas specific 
activity was not detected in embryos injected with any of the constructs (total number of injected 
embryos n=979, three experimental repeats). Only lens activity was detected in 71.7% (n=211) of 
embryos injected with the common allele variant and by 63.8% (n=232) of embryos injected with 
the T2D-associated variant (Figure 6.6B). Zebrafish hsp70 minimal promoter can drive 
autonomously expression in the lens (Blechinger et al., 2002), suggesting that the lens reporter 
activity seen in embryos injected with constructs containing the enhancer variants was due to the 
hsp70 promoter itself and that the candidate enhancer could not drive any tissue-specific activity 
in injected embryos. 
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Figure 6.6 Chromatin landscape and activity of putative human regulatory element DGKB-
TMEM195.  
A. UCSC Genome Browser screenshot (courtesy of Lorenzo Pasquali) displaying custom tracks of 
FAIRE-Seq data, histone modifications, RNA Seq and DNA sequence conservation. The solid line 
box contains the cloned element. B. Transient expression pattern driven by DGKB-DMEM195 
candidate enhancer. Representative dorsal and lateral view images of 72 hpf embryos injected 
with G (top) and T (bottom) variants of SNP rs2191349 are shown. Scale bar indicates 100 µm.  
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6.3.3.5 Validation of ADCY5 putative human enhancer and SNP rs11708067 
T2D-associated SNP rs11708067 (A>G) is located on an intronic region of ADCY5, which encodes 
Adenylate Cyclase-5 (Dupuis et al., 2010). This enzyme catalyses the generation of cAMP, a 
signalling molecule in beta cells of the pancreatic islet. An open chromatin site enriched in 
H3K4me1 and H3K27ac marks of 1,200 bp in length, was identified as a putative regulatory 
enhancer and used in reporter assays (Figure 6.7A). This region was cloned upstream of the hsp70 
minimal promoter and tested, as described before. No tissue-specific expression pattern could be 
detected with either the common or the disease-associated variant across three experimental 
replicates (total number of injected embryos n=379 and n=408, respectively, Figure 6.7B), 
suggesting that human ADCY5 putative element was not able to direct tissue specific activity in 
zebrafish. 
6.3.4 Establishing Tol2-based stable transgenic lines in order to detect differences  
To ask whether enhancer-specific reporter function could have been missed by the potentially low 
resolution and sensitivity of transient transgenic assays, around 200 embryos were injected with 
each construct to generate stable transgenic lines. The injected embryos were grown up in the 
animal facility to study transmission of transgenes to the next generations. We reasoned that by 
avoiding the mosaicism typical of transient transgenic embryos, the analysis of the stable 
transgenic lines could potentially reveal more faithfully the expression pattern driven by the 
candidate enhancers. Adult founders were outcrossed with WT fish and the F1 progeny were 
screened for potential enhancer-driven Venus expression. For each founder at least 100 or more 
offspring embryos were analysed before deemed to be negative for transgene activity. 
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Figure 6.7 Chromatin landscape and activity of putative human regulatory element ADCY5.  
A. UCSC Genome Browser screenshot displaying custom tracks of FAIRE-Seq data, histone 
modifications, RNA Seq and DNA sequence conservation. The solid line box contains the cloned 
candidate enhancer. This screenshot is courtesy of Lorenzo Pasquali. B. Transient expression 
pattern driven by ADCY5 human candidate enhancer. Representative embryo injected with the 
common variant of SNP rs11708067 (left) and with the infrequent variant (right). Representative 
dorsal and lateral view images of 72 hpf embryos are shown. Scale bar indicates 100 µm. 
  
 169 
 
6.3.4.1 Analysis of PROX1 candidate enhancer-containing stable transgenic lines 
Four stable transgenic lines with PROX1 rs4282786 common G allele (named Tg(Hs.PROX1(G):-
0.4Dr.prox1:Venus G1-G7) and 3 transgenic lines with the disease-associated A allele (named 
Tg(Hs.PROX1 (A):-0.4Dr.prox1:Venus A1-A12) were identified by reporter gene expression (Table 
6.5). Furthermore, 3 lines were generated with the Fugu control region linked to the prox1 
promoter (named Tg(Fr.ek:-0.4Dr.prox1:Venus) L1-5), which served as a control for the 
background activity expected without the enhancer (Figure 6.8, Figure 6.9, Figure 6.10). In order 
to dissect which domains of reporter activity were driven by the candidate human enhancer and 
distinguish them from position effects, we identified all the expression domains in enhancer-
containing transgenic lines and evaluated their reproducibility in comparison to the promoter only 
control transgenic lines, and to publicly available WISH data of the zebrafish orthologous gene 
patterns (Table 6.6). From 17 patterns identified among all transgenic lines, trigeminal and lateral 
line ganglia (#4 and #5) and spinal cord neurons (#6) expression domains were shared between 
the enhancer-less control lines and the PROX1-containing lines, and therefore could be attributed 
to prox1 promoter function. The pancreatic islet (#13), which is an expression domain of prox1 
gene, was only present in one of the lines containing the human enhancer, but not in the 
promoter-only lines. Although the presence of a single line being active in the pancreas might not 
allow us to draw a significant correlation with the candidate enhancer, together with the transient 
transgenic data, it suggested that it could be driven by the PROX1 putative enhancer. Reporter 
expression in midbrain neurons (#15) and heart (#16) domains were only present in PROX1 
containing lines, which suggested that they were driven by the human enhancer. This is supported 
by their presence in transient transgenesis. Nevertheless, there were other ectopic expression 
domains that could not be attributed to the enhancer unambiguously. This variation of patterns is 
commonly seen in Tol2-based transgenesis, a system prone to position effects due to the random 
integration of the transgene into the host genome. 
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Table 6.5 Summary of transgenic lines established using PROX1 human element and T2D-associated SNP rs4282786 
  
Transgenic Line 
No of 
screened 
founders 
No of 
positive 
founders 
Germline 
transmission 
rate (%) 
Line 
ID Domains of expression 
No. of 
embryos 
analysed 
Transmission 
rate per 
pattern (%) 
Tg(Hs.PROX1 (G):-
0.4Dr.prox1:Venus) 20 4 20.0 
G1 Pan neuronal 120 12.5 
G2 Pancreatic islet 154 11.0 
G3 Forebrain, Midbrain, Hindbrain neurons 70 30.0 
G7 Hindbrain neurons 98 39.8 
Tg(Hs.PROX1 (A):-
0.4Dr.prox1:Venus) 14 3 21.4 
A1 Forebrain,  
90 
7.8 
A4 Forebrain, tectum, midbrain-hindbrain  boundary, pericardium 8.9 
A5 Tectum, hindbrain 150 13.3 
A12 Tectum, tegmentum, hindbrain, pericardium 70 14.3 
Tg(Fr.ek:-0.4Dr.prox1:Venus) 15 3 20.0 
L1 Central nervous system 240 23.3 
L3 Cranial ganglia 50 10.0 
L5 Retina, optic tectum 82 19.5 
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Table 6.6 Analysis of the domains of Venus reporter expression and their distribution among PROX1-containing Tol2 transgenic lines. 
Domains of reporter gene 
expression 
Zebrafish prox1 
expression 
pattern 
Tol2-based stable transgenic lines 
Tg(Fr.ek:-
0.4Dr.prox1:Venus) Tg(Hs.PROX1 (G):-0.4Dr.prox1:Venus) Tg(Hs.PROX1 (A):-0.4Dr.prox1:Venus) 
L1 L3 L5 G1 G2 G3 G7 A1 A4 A5 A12 
  Habenula                         
  Liver                         
1 Retina                         
2 Diencephalon                         
3 Dorsal hindbrain                         
4 Trigeminal ganglia                         
5 Lateral line ganglia                         
6 Spinal cord neurons                         
7 Telencephalon                         
8 Ventral midbrain                         
9 Tegmentum                         
10 Optic tectum                         
11 Lens                         
12 Yolk syncytial layer                         
13 Pancreatic islet                         
14 Forebrain neurons                         
15 Midbrain neurons                         
16 Heart                         
17 Midbrain-Hindbrain boundary                         
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Figure 6.8 Tol2-based transgenic lines established with PROX1 containing rs4282786 G allele 
Expression patterns shown by Tol2 transgenic lines injected with Hs.PROX1(G):Dr.prox1:Venus 
construct. Tol2 patterns are numbered from 1 to 17 as described in Table 6.6. Dorsal and lateral 
views of YFP and brightfield channels are shown. Larvae are protruding mouth stage 
(approximately 3 dpf ) with anterior to the left. Scale bar indicates 100 μm. 
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Figure 6.9 Tol2-based transgenic lines established with PROX1-containing rs4282786A allele 
Expression patterns shown by Tol2 transgenic lines injected with Hs.PROX1(A):Dr.prox1:Venus 
construct. Tol2 patterns are numbered from 1 to 17 as described in Table 6.6. Dorsal and lateral 
views of YFP and brightfield channels are shown. Larvae are protruding mouth stage 
(approximately 3 dpf ) with anterior to the left. Scale bar indicates 100 μm. 
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Figure 6.10 Tol2-based transgenic lines established with zebrafish prox1 endogenous promoter 
Expression patterns shown by Tol2 transgenic lines injected with pTol2/Fr.ek:Dr.prox1:Venus 
construct. Tol2 patterns are numbered from 1 to 17 as described in Table 6.6. Dorsal and lateral 
views of YFP and brightfield channels are shown. Larvae are protruding mouth stage 
(approximately 3 dpf ) with anterior to the left. Scale bar indicates 100 μm. 
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6.3.4.2 Analysis of TCF7L2 candidate enhancer-containing transgenic lines 
In order to analyse the expression patterns attributable to TCF7L2 human putative enhancer we 
undertook the same approach described for PROX1 human enhancer candidate. One line carrying 
the tcf7l2 zebrafish promote only (named Tg(Fr.ek:-0.6Dr.tcf7l2:Venus) L1) , and 6 lines containing 
TCF7L2 human enhancer variants (named Tg(Hs.TCF7L2(C):-0.6Dr.tcf7l2:Venus) C1-5 and 
Tg(Hs.TCF7L2(T):-0.6Dr.tcf7l2:Venus) L1) were identified (Table 6.7, Figure 6.11, Figure 6.12). 
There was a lack of overlap in reporter expression patterns among the transgenic lines established 
with the enhancer-containing constructs, as well as between these lines and the zebrafish tcf7l2 
gene endogenous pattern, suggesting strong position effect variability, and the lack of identifiable 
tissue-specificity attributed to TC7FL2 candidate enhancer (Table 6.8). Because a reduced number 
of cells specify endocrine pancreas fate, the presence of islet activity in C4 transgenic line (Table 
6.7) suggested enhancer-driven activity. However, lack of reproducibility in other enhancer-
containing lines prevented us from making accurate conclusions on this. 
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Table 6.7 Summary of transgenic lines established using TCF7L2 human element and T2D-associated SNP rs7903146. 
Transgenic Line 
No. of 
screened 
founders 
No. of 
positive 
founders 
Germline 
transmission 
rate (%) 
Line ID Domains of expression 
N of 
embryos 
analysed 
Transmission 
rate per pattern 
(%) 
Tg(Hs.TCF7L2(C):-0.6Dr.tcf7l2:Venus) 10 2 20.0 
C1 Diencephalon 
97 
10.3 
C2 Diencephalon + hindbrain 7.2 
C3 Neural tube 15.5 
C4 Pancreatic islet, trigeminal ganglia 
155 
43.9 
C5 Diencephalon 13.5 
Tg(Hs.TCF7L2(T):-0.6Dr.tcf7l2:Venus) 15 1 6.7 T1 Midbrain-Hindbrain boundary, pericardium, cranial ganglia 96 8.3 
Tg(Fr.ek:-0.6Dr.tcf7l2:Venus) 15 1 6.7 L1 Hindbrain, jaw 100 10.0 
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Figure 6.11 Tol2-based transgenic lines established with TCF7L2 common C allele 
Expression patterns shown by Tol2 transgenic lines injected with pTol2/Hs.TCF7L2(C):Dr.tcf7l2:Venus construct. Expression patterns are numbered 
from 1 to 15 as described in Table 6.8. 
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Figure 6.12 Tol2-based transgenic lines established with TCF7L2 infrequent T allele and zebrafish 
tcf7l2 promoter only. 
Expression patterns shown by Tol2 transgenic lines injected with 
pTol2/Hs.TCF7L2(C):Dr.tcf7l2:Venus construct. Expression patterns are numbered from 1 to 15 as 
described in Table 6.8). Dorsal and lateral views of YFP and brightfield channels are shown. Larvae 
are protruding mouth stage (approximately 3 dpf ) with anterior to the left. Scale bar indicates 
100 μm.  
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Table 6.8 Analysis of the domains of Venus reporter expression and their distribution among 
TCF7L2 enhancer candidate containing Tol2 transgenic lines compared to endogenous patterns. 
 
Domains of expression 
Zebrafish 
tcf7l2 
expression 
pattern 
Tol2-based stable transgenic lines 
Tg(Fr.ek:-
0.6Dr.tcf7l2:Venus) 
Tg(Hs.TCF7L2(C):-
0.6Dr.tcf7l2:Venus) 
Tg(Hs.TCF7L2(T):-
0.6Dr.tcf7l2:Venus) 
L1 C1 C2 C3 C4 C5 T1 
1 Dorsal diencephalon         
2 Midbrain         
3 Rostral hindbrain         
4 Brachial arches         
5 Ventral telencephalon         
6 Tectum         
7 Cranial ganglia         
8 Heart         
9 Telencephalon         
1
0 Optic stalks         
1
1 Retina         
1
2 Central nervous system         
1
3 Dorsal hindbrain         
1
4 
Midbrain-Hindbrain 
boundary         
1
5 Pancreatic islet         
 
  
 180 
 
6.3.5 Analysis of DGKB-TMEM195 and ADCY5 candidate enhancer containing- 
transgenic lines 
Despite screening an equivalent number of adult founder fish injected with constructs containing 
DGKB-TMEM and ADCY5 enhancer variants, I could not identify any founder whose offspring was 
positive for reporter gene expression (Table 6.9). This result combined with the lack of activity in 
transient transgenic experiments argued for these candidate enhancers not functioning as 
transcriptional enhancers in zebrafish. 
 
Table 6.9 Summary of transgenic lines established using DGKB-TMEM195 and ADCY5 putative 
enhancers. 
Line No. of screened founders 
No. of Venus 
positive 
founders 
Germline 
transmission rate 
(%) 
Tg(Hs.DGKB-TMEM195 (G):Dr.hsp70:Venus) 25 0 0.0 
Tg(Hs.DGKB-TMEM195 (G):Dr.hsp70:Venus) 21 0 0.0 
Tg(Hs.ADCY5 (A):Dr.hsp70:Venus) 22 0 0.0 
Tg(Hs.ADCY5 (G):Dr.hsp70:Venus) 16 0 0.0 
Tg(Fr.ek:Dr.hsp70:Venus) 20 0 0.0 
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6.4 DISCUSSION 
In this chapter I aimed to establish a method to detect in vivo quantitative differences between 
T2D-associated allelic variants using Tol2-based transient and stable transgenesis assays in 
zebrafish embryos. Functional test of 4 candidate human enhancers with T2D-associated SNPs 
(Dupuis et al., 2010) revealed that only a conserved region in PROX1 human gene could drive 
reporter gene expression in the developing endocrine pancreas consistently in transient and 
stable transgenesis experiments. However, no differential expression patterns caused by the 
allelic variants could be detected with our approaches so far. The lack of detectable reporter gene 
expression with DGKB-TMEM195 and ADCY5 candidate enhancers argued that neither the 
putative CRE nor the allelic variants were functional in the zebrafish embryo or that these regions 
lacked enhancer function. Additionally, despite previous evidence suggesting that TCF7L2 
candidate enhancer was active in pancreas-specific cell lines (Gaulton et al., 2010), the lack of 
detectable reporter gene activity in transient transgenesis experiments and the lack of 
reproducibility in stable transgenic lines prevented us to conclude accurately on TCF7L2 function. 
6.4.1 Utilizing Tol2-based transient transgenesis assays for allele quantification 
Transient transgenesis assays in zebrafish allow the generation of hundreds of injected embryos, 
with a mosaic reporter gene expression, where typically each embryo displays reporter gene 
activity in a few cells (Pashos et al., 2008). Nevertheless, because each injected embryo 
represents a different transgene integration event, the position effects might be statistically 
eliminated by observing reproducible patterns in large numbers of embryos (Muller et al., 1997; 
Muller et al., 1999; Dickmeis et al., 2004; Gehrig et al., 2009; Rada-Iglesias and Wysocka, 2011; 
Taher et al., 2011). Mosaicism could however hinder the analysis of the activity of certain CREs in 
small tissues, such as the endocrine pancreas, which has approximately 20 β-cells at 3 dpf 
(Parsons et al., 2009). Our transient reporter assays with PROX1 candidate enhancer revealed that 
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on average 2% of the injected embryos were showing a pancreatic-specific signal. It could be 
argued that pancreas expression was not specific, and that it was a result of the random cell 
targeting of an otherwise non-tissue specific element. However, when PROX1 candidate enhancer 
was linked to a minimal hsp70 promoter, the pancreas activity was still reproducible, suggesting 
that PROX1 could autonomously drive expression in the pancreatic islet. 
Interestingly, PROX1 reporter gene expression was not restricted to this domain. The rest of the 
expressing embryos showed reporter activity in tissues such as muscle, neurons and heart. From 
these domains, only expression in the neurons and in the heart was reproducible when two 
different zebrafish promoters were tested, suggesting that the activity in neurons and heart was 
attributable to the PROX1 enhancer. Consistent with this, zebrafish prox1 gene expression is 
detected in the pancreas, liver, otic and lens placodes, lateral line and central nervous system 
(Pistocchi et al., 2008), and has proven to be essential for liver organogenesis, neuronal 
development and functionality of the lateral line (Pistocchi et al., 2009). 
Overall, the analysis of transient transgenic data did not reveal statistically significant differences 
between the candidate enhancer variants. And even when the co-localization approach increased 
our accuracy in detecting pancreatic specific expression, the mosaicism of the embryos could have 
hindered the detection of expression differences, suggesting that an alternative approach was 
required. 
6.4.2 Establishing Tol2-based stable transgenic lines to quantitate allelic variants  
The establishment of stable transgenic lines can be advantageous in order to detect weak 
enhancer function by avoiding the mosaicism of injected embryos and could thus be used to 
validate expression patterns detected by transient transgenic assays. Nevertheless, we observed a 
high variability of expression patterns among PROX1 and TCF7L2 candidate enhancer containing 
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transgenic lines. The variability of expression patterns caused by Tol2-based transgenesis is larger 
than the subtle changes expected by the SNPs, which hindered our attempt to quantify subtle 
differences caused by disease-associated SNPs. 
A BAC enhancer-trap study established that regulatory variation within Tcf7l2 was leading to over-
expression of the gene, which could be the underlying cause of T2D. However, this work also 
failed to detect allele-specific differences in vivo (Savic et al., 2011). Conflicting observations 
between in vivo and in vitro models may also be explained because the interaction of the region 
of interest outside the pancreas cannot be reproduced, as it is when using an animal model. In 
fact, when Savic and colleagues tested the same 239 bp region in a variety of cell lines, they 
detected enhancer activity in beta-pancreatic, as well as in neuron, bone and myoblast cell lines 
(Savic et al., 2013). Certainly, an experimental design where allelic specific differences can be 
measured will be difficult to achieve using transgenesis assays due to position effect, copy 
number variation and mosaicism. This is why the preferred approach in most studies relies on the 
use of cell lines. 
6.4.3 Alternative approaches for quantitation of variant enhancer activity 
Since differences in tissue specificity between allelic variants could not be detected by manual 
inspection of mosaic transgenic embryos, it could be argued that the use of an high-throughput 
automated measurement of the number of cells and intensity of fluorescence in embryos may 
provide a more accurate and unbiased spatial detection of the reporter activity (Gehrig et al., 
2009). Nevertheless, the published pipeline was developed for the analysis of 36-42 hpf embryos 
and re-designing the existing software required computational and engineering support that was 
not available during this project.  
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An alternative approach would be to use BAC transgenesis to improve synergistic enhancer 
function detection (Balciunas et al., 2006; Suster et al., 2009). The use of BACs is more 
advantageous than the use of smaller vectors because their large size can include regulatory 
elements that are scattered in long distances (Yang et al., 2006). Besides, it permits to control the 
genomic context. Although these results have not been shown in this chapter, I created a 
modified human BAC containing PROX1 human locus and followed an enhancer trap strategy to 
replace the 5´end of the second intron, where the candidate enhancer was located, with hsp70 
minimal promoter and eGFP reporter gene. However, the injection of the modified BAC of PROX1 
human gene did not drive any specific tissue-specific expression in the zebrafish embryos. This 
could be explained by the BAC itself, by the enhancer trap approach or by weakness of the 
pattern. Due to the lack of activity, we decided not to proceed with this time-consuming method 
and decided to investigate alternative approaches for allelic quantification. 
6.4.4 Site-directed transgenesis as an alternative to Tol2-based transgenesis 
Random transgene integration and position effects are a major drawback of Tol2-based 
transgenesis. As I have shown in this chapter, it often leads to the creation of a large number of 
transgenic lines per construct, among which there is substantial variation of expression patterns 
that hinders the analysis of function. A promising alternative to aid the screening of CREs by 
reducing the position effect variation would be the development of a transgenesis system 
mediated by site-specific recombinases. The validation of a targeted integration system for 
enhancer testing will be discussed in the next chapter. 
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Chapter Seven: DEVELOPMENT OF PHIC31 TARGETED 
INTEGRATION SYSTEM FOR SNP QUANTITATION 
FOREWORD 
The results presented in this chapter have been partially published in (Roberts et al., 2014). 
The site-specific integration system mediated by PhiC31 integrase in zebrafish was designed by a 
collaboration between the labs of Ferenc Müller and Darius Balciunas (Temple University, US). 
Jennifer Roberts (former PhD student from the lab) initiated the development of this system as 
her PhD project (Roberts, 2013) until November 2012. I decided to extend this preliminary work 
with the final aim of using this system to quantitate SNP variants. I also carried out a series of 
experiments aiming to validate the targeting system for enhancer testing and to prove that the 
system was indeed capable of eliminating position effect variation. 
• All the plasmids used for EL161 enhancer testing were made by Jennifer Roberts, as well 
as the docking transgenic lines Tg(Xla.crygc:attP-GFP)uobL6 and uobL12. 
• The plasmid pCS2+PhiC31o-nos1-3’UTR was a kind gift from Shannon Fisher 
• The plasmid pTol2/Xla.crygc:attP-GFP (pDB896) was made by Darius Balciunas 
 
Information about the construction of these and other plasmids is presented in (Roberts et al., 
2014). 
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7.1 INTRODUCTION 
7.1.1 Site-specific recombination systems used in transgenesis 
Functional analysis in zebrafish usually involves the injection of constructs containing predicted 
cis-regulatory elements placed upstream of a minimal promoter linked to a fluorescent reporter 
gene. The expression of fluorescent reporter gene in the injected embryos is then used as readout 
for CRE activity. In most cases, Tol2 transposase-based transgenesis is used to facilitate the 
integration of the transgene into the host genome (Kawakami, 2005; Fisher et al., 2006b). 
However, one of the main limitations of Tol2-based transgenesis is position effect variation 
caused by the random integration of the transgene into the genome. The term "position effect" 
describes alterations of expression pattern and subsequent variation among individuals injected 
with the same transgene, due to the influence of the genomic context where the construct was 
integrated (Jaenisch et al., 1981; Wilson et al., 1990; Rossant et al., 2011). As a consequence of 
position effects, stable lines generated from the same construct usually display different 
expression patterns that hinder the assessment of the function of the tested CRE, besides forcing 
the generation of many stable transgenic lines to conclude on the correct expression pattern of an 
element. 
Position effect variation can be reduced by the use of site-specific recombinases (SSR). They 
function by recognizing target DNA sequences, bringing them together in a synapse and 
exchanging DNA strands after cleavage (Stark et al., 1992). There are two main families of SSR 
with different mechanisms of action. Cre from Bacteriophage P1 and Flp recombinase from S. 
cerevisiae belong to the λ family of integrases and can recombine DNA without accessory co-
factors (Bischof and Basler, 2008). They recognize loxP and FRT target sites respectively that 
consist of two identical 13 bp palindromic repeats separated by an asymmetric 8 bp core (Hoess 
et al., 1982; McLeod et al., 1986). Depending on the directionality of these target sites, the 
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recombination process can result in excision, inversion or integration of DNA fragments. A main 
limitation of Cre/lox and Flp/FRT systems is the bidirectional and reversible nature of the 
recombination reaction, which makes integration particularly unstable (Sauer and Henderson, 
1990). In contrast, PhiC31 integrase from Streptomyces phage Φ31, a member of the resolvase 
family of SRR, can catalyse directional or irreversible recombination of heterotypic attP and attB 
sites autonomously (Thorpe and Smith, 1998). The resultant attL and attR hybrid sites cannot be 
used as a substrate by the integrase, which is advantageous when integration is the only goal 
(Thorpe et al., 2000). The natural function of PhiC31 integrase is to facilitate the integration of the 
phage genome into the bacterial host genome by binding to two recognition sites, attP and attB, 
cleaving four DNA strands in a synaptic complex, rotating 180° one pair of half sites and ligating 
DNA strands (Smith et al., 2004). PhiC31 integrase has been shown to be active and efficient in 
mediating site-specific integration in several animal systems that include human cells (Groth et al., 
2000), mice (Belteki et al., 2003), flies (Olivares et al., 2002; Groth et al., 2004) and frogs (Allen 
and Weeks, 2005). 
7.1.2 PhiC31 integrase-based systems in zebrafish 
In zebrafish the first reports of PhiC31 integrase being active in somatic cells and the germline 
used a cassette-excision based strategy (Lister, 2010; Lu et al., 2011). This system´s design allowed 
them to monitor the rate of PhiC31-mediated intramolecular recombination by flanking a GFP 
fluorescent reporter gene with attP and attB sites, which would be excised if recombination 
happened (Lister, 2010). They also proved that the mouse-codon optimized version of the PhiC31 
integrase was twice as efficient in zebrafish than the native one (Raymond and Soriano, 2007).  
PhiC31 also allows for recombination-based cassette exchange, as demonstrated by (Hu et al., 
2011). This strategy, which is also functional in Drosophila (Bateman et al., 2006), was employed 
to exchange a reporter gene on targeted transgenes that had been incorporated into the 
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zebrafish germline through Tol2-based experiments. They also tested PhiC31 integrase fused with 
3´UTR of a primordial germ cell-specific nanos1 gene and concluded that it was significantly 
increasing the rate of recombination events in the germline (Hu et al., 2011). 
The great potential of PhiC31 integrase-based technology is the creation of attB/attP containing 
docking sites in the host genome, where site-directed recombination is possible, using either 
cassette exchange or integration approaches. This method would circumvent the need to create 
multiple transgenic lines and reduce significantly the position effects variation derived from the 
random integration of the transgenes in the genome. More importantly, a robust targeted 
integration system would aid in the exploitation of the transgenic zebrafish model for the 
functional analysis of SNP variants in CREs identified in large numbers by genome wide disease 
association studies (Maurano et al., 2012), particularly on those cases where the SNP was 
expected to cause only subtle, quantitative changes in gene expression (Gaulton et al., 2010; 
Rada-Iglesias et al., 2013), that would not be detected with a conventional technology prone to 
position effects, such as the commonly used Tol2-based transgenesis. 
7.1.3 Aims: 
In order to be able to quantitate expression differences caused by enhancer variants, we decided 
to develop a PhiC31-based method for transgene integration in zebrafish. We hypothesized that 
PhiC31 integrase-mediated transgenesis could reduce the variability to allow for a sensitive 
system that could detect subtle variations in expression patterns, such as those caused by 
disease-linked SNP variants. Within this global aim we set the following specific objectives: 
• To identify a single-copy recipient transgenic line that allows for robust enhancer tests. 
• To examine PhiC31-mediated recombination frequency and test the toxicity of the two 
PhiC31 integrase mRNA variants described in the literature. 
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• To use PhiC31 mediated transgenesis to quantitate subtle differences caused by disease-
associated SNP variants within enhancers. 
 
7.2 Preliminary data leading to the project: Development of PhiC31-based 
transgenesis system in the zebrafish embryo 
In collaboration with Darius Balciunas (Temple University, US), Ferenc Müller and Jennifer Roberts 
designed a site-specific integration system mediated by PhiC31 integrase in zebrafish. This system 
consists of two components: a "recipient transgenic line" containing a docking attP site in the 
genome and a targeting plasmid containing a donor attB site. To facilitate the screening of site-
specific integrations, a phenotypic selection tool based on fluorescent reporter colour change in 
the lens was designed (Figure 7.1A). 
Recipient transgenic lines Tg(Xla.crygc:attP-GFP) contained a lens-specific promoter (gamma-
crystallin from Xenopus laevis (Davidson et al., 2003), and attP site located upstream of GFP. The 
crygc:attP-GFP cassette drives green fluorescent expression in the lens. When the recipient 
transgenic line is injected with a targeting vector (pJET-attB-mCherry, (Roberts et al., 2014)) 
containing attB site upstream of a red fluorescent reporter gene (mCherry) and integrase mRNA, 
PhiC31 mediated integration is expected to produce crygc:attR-mCherry recombinant site, which 
can be scored by green to red colour change in the lens (Figure 7.1B). 
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Figure 7.1 In vivo detection system for targeted integration of reporter constructs in zebrafish.  
A. Schematic of PhiC31 targeted integration system. Transgenic embryo containing attP docking 
site shows green lens activity due to crystalline promoter driving GFP reporter gene. ITR labels 
Tol2 recognition sequences. Injection of a circular plasmid with attB and red reporter (targeting 
vector) leads to eye colour change upon PhiC31 targeted integration B. Detection of eye colour 
change upon PhiC31 mediated integration in the transgenic recipient Tg(Xla.crygc:attP-GFP)uobL6 
line. Top row shows a 5 dpf transgenic larva where PhiC31 legitimate recombination of attB-
mCherry cassette into the attP-GFP docking site has taken place. Bottom row shows an embryo 
where recombination did not occur. Side views of larvae with anterior to the left are shown. Scale 
bar indicates 100 µm. 
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7.3 RESULTS 
7.3.1 Analysis of the zygosity of zebrafish recipient transgenic lines 
In order to study changes in gene expression due to enhancer SNPs by targeted transgenesis, the 
transgenic recipient lines must carry a single and stable landing site, that is, only one copy of the 
Xla.crygc:attP-GFP transgene in the genome. Tol2-based Tg(Xla.crygc:attP-GFP)uobL6 and 
Tg(Xla.crygc:attP-GFP)uobL12 recipient transgenic lines (aka uobL6 and uobL12 for short) had 
been established by Jennifer Roberts by injecting WT embryos with pTol2/Xla.crygc:attP-GFP 
(pDB896) vector and growing up lens-GFP positive embryos, as described in (Roberts et al., 2014). 
To establish that the recipient line contained only a single copy of the attP site, I studied the 
germline transmission rates of multiple individuals from different generations of the recipient 
lines available at that time in the lab (uobL6F2 and F3 and uobL12 F2) in order to assess whether 
they approached Mendelian rates. Transgenic adults were bred to wild-type fish (1:1 crosses) and 
the offspring was analysed for green lens expression at 5 dpf. On average, transmission rates 
were close to 50% (Table 7.1) for individuals from uobL6 and uobL12, suggesting that there was 
only one integration site in the genome. I also identified two adult females from Tg(Xla.crygc:attP-
GFP)uobL6 F2 that produced 100% of GFP positive embryos, indicating that they were 
homozygous and had resulted from an incross of uobL6F1 individuals. 
Table 7.1. Germline transmission rate of existing transgenic recipient lines 
Transgenic line ID Generation 
Number of 
individuals 
outcrossed 
Total number of 
embryos analysed 
at 5 dpf 
Germline 
transmission, 
average (%) 
Tg(pTol2/Xla.Cryg-attP:GFP)uobL6  
 F3 8 648 51.4 
F2  2 269 100.0 
Tg(pTol2/Xla.Cryg-attP:GFP)uobL12  F2 15 2764 49.8 
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7.3.2 Molecular characterization of location, integrity and copy number of integration 
events in transgenic recipient lines 
As a first step towards the potential generation of a library of attP-containing recipient transgenic 
lines, I characterized molecularly the transgene integration events of the uncharacterized lines 
existing in the lab. In order to map the genomic locus harbouring the Xla.crygc:attP-GFP transgene 
in uobL6 and uobL12 recipient lines, extension primer tag selection linker-mediated PCR (EPTS-
LMPCR) was carried out on GFP+ clutches of outcrossed embryos from uobL12 F2, uobL6 F2 and 
F3 transgenic recipient lines. EPTS-LMPCR is a variation of LMPCR where genomic DNA fragments 
containing the transgene(s) are purified using a biotinylated primer that anneals to the Tol2 
terminal arms, therefore only allowing the mapping of transposon-mediated integration events. 
High-quality genomic DNA was extracted from 5 dpf embryo clutches and EPTS-LMPCR was 
carried out following a protocol described for Xenopus (Yergeau et al., 2007).  
By EPTS-LMPCR I could map in uobL6F2 and F3 lines a single Tol2-mediated transgene insertion in 
an intergenic region of chromosome 18 (Figure 7.2), 40 Kb away from the nearest coding gene. 
This integration site was further verified by PCR using primers specific to the zebrafish genome 
(not shown). However, backbone sequence from pTol2/Xla.crygc:attP-GFP (pDB896) were found 
flanking the transposon integration sites in the uobL12 F2 line, suggesting that there had been an 
illegitimate insertion of Tol2, where not only the Tol2-flanked cassette but also plasmid backbone 
had been integrated. Inverse PCR carried out by Jorune Balciunene and Darius Balciunas could 
map the integration site of uobL12 to an intergenic region of chromosome 1 (Roberts et al., 2014). 
In order to verify the transgene copy number in both lines, I performed Southern blotting of 5 dpf 
lens-GFP+ and GFP- clutches of embryos coming from uobL6 F2 homozygous and uobL12 F2 
heterozygous outcrosses (Figure 7.2B,C). We reasoned that if uobL6 homozygous recipient line 
contained one integration site in homozygosis, 100% of its offspring would be harbouring the 
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docking Xla.crygc:attP-GFP cassette and therefore could be used for efficient SNP testing. Two 
sets of enzymes had to be used to be able to confirm copy numbers: SacI with BamHI, which cut 
once in the construct backbone and once upstream attP site, respectively and BamHI and ApaI, 
cutting twice in the transgene (Figure 7.2D). Southern blot analyses confirmed that uobL12 
carried a Tol2-mediated multimer integration of the transgene with an approximate copy number 
of 11.6 (Figure 7.2B, C, D). Surprisingly, the Southern blot and Phosphoimager quantification also 
indicated that uobL6 homozygous individuals carried two independent copies of the 
Xla.crygc:attP-GFP transgene, one of them potentially being an insertion of the whole 
(pTol2/Xla.crygc:attP-GFP (pDB896) vector plasmid (Figure 7.2B).  
Because uobL6 F1 had been incrossed to produce F2, we hypothesized that there might have 
been a mixed population of transgenic fish in F1, where some fish were carrying the legitimate 
Tol2-mediated chr18 insertion identified by LMPCR, and some others were carrying the latter plus 
a full plasmid copy, which was located on a different chromosome and could therefore segregate. 
In order to test this hypothesis, regular PCRs were carried out with oligos present in the backbone 
of the pTol2/Xla.crygc:attP-GFP (pDB896) vector using genomic DNA from different uobL6 F2 and 
F3 individuals (Figure 7.3). PCR results indicated that the extra plasmid insertion was only present 
in F2 homozygous female 3 (uobL6F2.3) and therefore could segregate. These PCR results 
together with Southern blot carried out on uobL6 heterozygous fish by collaborator Darius 
Balciunas, showed that uobL6 F3 individuals did not carry the extra copy, and were therefore used 
for further experiments and to establish the next generation of uobL6. 
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Figure 7.2 Molecular analysis of uobL6 and uobL12 transgenic recipient lines by EPTS-LMPCR 
and Southern blot. 
A. USCS screenshots displaying the genomic context of transgene integration in uobL6 recipient 
line (grey vertical rectangle). The insertion site is 40 kb downstream of si:dkeyp-86e4.1 and 65 kb 
upstream of the nucb2b gene. B. Southern blot analysis of uobL6 and uobL12 recipient transgenic 
lines. Genomic DNA from batches of GFP-positive and GFP-negative embryos was digested with 
BamHI and ApaI, cutting once in the transgene and once in the backbone. Southern hybridization 
was performed with a radioactively labelled attP:GFP:Tol2 1.3 Kb probe (depicted in D). C. Copy 
number analysis of uobL12 was performed by digesting genomic DNA with BamHI and ApaI, which 
cuts in the backbone of pTol2/Xla.crygc:attP-GFP (pDB896) vector producing an expected band of 
1.3 Kb. Phosphoimager analysis suggests uobL12 carries 11.6 copies. D. Schematic of 
pTol2/Xla.crygc:attP-GFP (pDB896) vector including restriction sites used for Southern blot 
analysis and distances between them. Probe sequence is depicted by a dashed red rectangle.  
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Figure 7.3 Diagnostic PCR to evaluate the presence of plasmid backbone in the uobL6 F2 
homozygous fish 
Two sets of primers annealing in the Xla.crygc:attP-GFP transgene (GFP and X. laevis gamma-
crystallin promoter) and in pTol2/Xla.crygc:attP-GFP (pDB896) backbone construct (Ampicillin 
promoter reverse) were used to test whether the two homozygous individuals from uobL6 
(uobL6F2.2 and uobL6F2.3), and heterozygous individuals from uobL6F3 (F3.1, F3.4, F3.6), carried 
a plasmid integration non-mediated by Tol2 that could explain the double bands found at the 
Southern blot (Figure 5.3). Black arrow points at the expected band produced by a successful 
amplification of pTol2/Xla.crygc:attP-GFP (pDB896) backbone. L indicates 100 bp DNA Ladder 
from New England Biolabs.  
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7.3.3 Analysis of position effect variability in Tol2 and PhiC31-mediated transgenesis 
A common obstacle in transgenesis assays aiming to characterize enhancer function is position 
effect variability derived from the random integration of the transgene into the host genome, as 
discussed in Chapter 6. In order to test whether site-directed transgenesis mediated by PhiC31 
would help to reduce the position effect variability of expression patterns, we decided to evaluate 
enhancer activity driven by a highly conserved zebrafish element after integration in the genome 
by Tol2 or PhiC31-based transgenesis. The selected candidate enhancer, named EL161, showed 
more than 80% sequence identity with humans and was identified by collaborator Remo Sanges 
(Stazione Zoologica Anton Dohrn, Italy) as described in (Roberts et al., 2014). It is located on the 
last intron of esrrga zebrafish gene (Bardet et al., 2004; Thisse et al., 2004) and was postulated to 
regulate esrrga expression. In a preliminary study carried out in the lab, EL161 was cloned 
upstream of the krt4 gene minimal promoter, which shows minimal transcriptional activity 
(Gehrig et al., 2009), and tested in a Tol2-based transient assay in zebrafish. EL161 was shown to 
be active in the brain, however the expression was highly variable due to position effects (Yavor 
Hadzhiev, unpublished data).  
The same Tol2-based cassette containing EL161 element linked to krt4 promoter and Venus 
(Tol2/EL161-krt4:Venus) was cloned and tested by both Tol2 and PhiC31 transgenesis. The 
resulting vectors, namely pTol2/EL161-krt4:Venus and pattB-mCherry,Tol2/EL161-krt4:Venus, 
were injected in WT or uobL6/L12 embryos, respectively, as described in (Roberts et al., 2014). 
Tol2-mediated transgenesis is expected to integrate only the Tol2/EL161-krt4:Venus cassette into 
the genome (Figure 7.4A top), while PhiC31-mediated transgenesis integrates the whole vector, 
including Tol2/EL161-krt4:Venus and attB:mCherry cassettes (Figure 7.4B top). When injected 
embryos reached adulthood, founders were screened for positive offspring. Among 20 adults 
injected with Tol2 construct, 4 positive founders were identified (TF1-4, Table 7.2), where ten 
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different enhancer-driven complex expression patterns were recovered (numbered TP1-10, Table 
7.3, Figure 7.5). These results suggest multiple integration sites and that Tol2/EL161-krt4:Venus is 
highly susceptible to position effects (Figure 7.4A). Screening the offspring of all 29 surviving adult 
founders from uobL6 and uobL12 injected with PhiC31 integrase mRNA resulted in the 
identification of 4 positive founders (Table 7.2). Their offspring showed eye colour change during 
larval development together with EL161-driven YFP expression pattern, indicating site-specific 
integration events (Figure 7.4B, Figure 7.6). Notably, the 3 founders with targeted integration into 
the uobL6 line showed remarkable similarity in their expression patterns, in contrast to Tol2 
mediated transgene integrations, which were characterized by widely varying patterns (Figure 
7.4). 
 
 
 
 
 
Figure 7.4 Variability of position effects is sharply reduced among PhiC31-mediated transgenic 
lines when compared to Tol2 transgenesis 
A. Schematic of pTol2/EL161-krt4:Venus construct co-injected with Tol2 transposase mRNA. 
Below examples of expression patterns of transgenic F1 larvae (3 dpf). TP indicates Tol2 mediated 
expression patterns. Venus expression domains are labelled as in Figure 7.7B.  B. Schematic 
drawing on top indicates the recombination of the targeting plasmid pattB-mCherry,Tol2/EL161-
krt4:Venus into the attP docking site of transgenic recipient line Tg(Xla.crygc:attP-GFP)uobL6. 
Larvae from three different founders (IF1, IF2, IF8) targeted with PhiC31 integrase are shown. 
Venus expression domains are labelled as in Figure 7.7B. Lens activity driven by mCherry (arrows 
in bottom row) demonstrates PhiC31-mediated integration. Insert in bottom right shows bright 
field representation of the head region imaged. Arrows in red channel indicate auto-fluorescence 
of the yolk syncytial layer. Dorsal views of larvae head are shown. Scale bar is 100µm. 
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(See previous page for figure legend)   
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Figure 7.5 Tol2 transgenic founders show variable position effects on EL161 driven reporter 
activity. 
All of the different expression patterns shown by Tol2 transgenic lines injected with pTol2/EL161-
krt4: Venus construct. Tol2 patterns (TP) are numbered from 1 to 10. Dorsal and lateral views of 
YFP and brightfield channels are shown and annotated domains correspond to the expression 
domains described in Figure 7.7. Larvae are protruding mouth stage (approximately 3 dpf) with 
anterior to the left. Scale bar indicates 100 μm. 
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Table 7.2 Survival and transmission rates of PhiC31 and Tol2 founders 
Strain injected Method of transgenesis Targeting vector 
Number of screened 
individuals Transmission rates % (n) 
AB*WT  Tol2 transposase pTol2/EL161-krt4:Venus 20 20 (4) 
Tg(pTol2/Xla.Cryg-attP:GFP)uobL6 PhiC31 integrase pattB-mCherry,Tol2/EL161-krt4:Venus 25 12.0 (3) 
Tg(pTol2/Xla.Cryg-attP:GFP)uobL12  PhiC31 integrase pattB-mCherry,Tol2/EL161-krt4:Venus 4 25.0 (1) 
 
 
Table 7.3 Analysis of the offspring of Tol2 founders 
Founder ID 
Total number 
of embryos 
analysed 
Transmission rates (%) Tol2 patterns Transmission rate per pattern (%) 
Tol2 founder 1 (TF1) 246 15.0 
TP1 2.8 
TP2 2.0 
TP3 3.3 
TP4 5.7 
TP5 1.2 
Tol2 founder 2 (TF2) 109 5.5 
TP6 4.0 
TP7 6.7 
Tol2 founder 3 (TF3) 236 10.7 
TP8 4.7 
TP9 0.8 
Tol2 founder 4 (TF4) 150 12.6 TP10 12.6 
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Table 7.4 Analysis of the offspring of integrase founders 
  
Founder ID 
Total number 
of F1 embryos 
analysed 
Percentage of 
green lens 
embryos (n) 
Percentage of red lens 
embryos with YFP pattern 
(n) 
Percentage of 
embryos with YFP 
pattern only (n) 
Percentage of 
embryos with green 
and red lenses(n) 
Percentage of 
negative 
embryos (n) 
uobL6- Founder1 (IF1) 228 35.2 (81) 11.7 (27) 0.0 (0) 0.0 (0) 52.6 (120) 
uobL6- Founder 2 (IF2) 116  36.2 (42) 6.0 (7) 0.0 (0) 0.0 (0) 57.8 (67) 
uobL6- Founder8 (IF8) 372 43.0 (160) 11.0 (41)  0.0 (0) 0.0 (0) 51.1 (190) 
uobL12- Founder1 (IF1) 100 22.0 (22) 15.0 (15) 0.0 (0) 21.0 (21) 42.0 (42) 
  
 
202 
 
Figure 7.6 PhiC31-mediated transgenic founders show highly reproducible expression patterns. 
Neuronal expression patterns obtained in integrase injected founders uobL6 IF1, uobL6 IF2, uobL6 IF8 and uobL12 IF1. Red lens indicates legitimate 
PhiC31-mediated integration into the Xla.crygc:attP-GFP cassette from either Tg(Xla.crygc:attP-GFP)uobL6 or Tg(Xla.crygc:attP-GFP)uobL12. Auto-
fluorescent yolk syncytial layer (ysl) is marked by arrows in mCherry images. YFP channel shows EL161-driven expression patterns are listed in Figure 7.7. 
Larvae are at protruding mouth stage (3 dpf) with anterior to the left. Scale bar indicates 100 μm.  
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7.3.4 Evaluation of EL161 enhancer function using PhiC31-mediated transgenesis 
To evaluate the specific reporter activity driven by EL161 element and to dissect enhancer driven 
activity from position effects, we identified distinct expression domains and analysed the 
frequency of their occurrence in targeted and random transgene integration loci. A total of 20 
domains of activity labelled 1-20 were identified (Figure 7.7). PhiC31 integrase-mediated activity 
was present in 7 distinguishable expression domains in the neural tube (Figure 7.4B, Figure 7.6), 
six out of which were shared between the 3 integrase lines with targeting events in the same 
uobL6 docking site. Only one additional domain (Domain 7) was registered in one of these lines 
(uobL6 IF1) indicating mild variation (Figure 7.7B) that was not due to mutations of the integrated 
transgene. In contrast, Tol2 lines showed a total of 21 expression domains with a variation 
between 7-12 domains per pattern, which included a variety of tissues such as somatic muscle, 
pectoral fins and heart besides neural tube activity (Figure 7.7, Figure 7.5). This result indicated 
that integrase-mediated targeting of a single locus (in uobL6) led to reduced variability of 
expression patterns induced by a neural enhancer among transgenic lines. 
The expression domains 1-6 were shared among uobL6 and uobL12 integrase founders and were 
present in 8 out of 10 Tol2-mediated patterns, which together suggested autonomous enhancer 
activity in these neural domains. This result demonstrated that the shared expression patterns 
were unlikely to be due to position effect at the uobL6 locus and were an autonomous property of 
the targeting transgene (Figure 7.7). Notably, these 6 shared expression domains including 
epiphysis, diencephalic and hindbrain nuclei and tegmentum, overlapped with expression 
domains of the esrrga gene (Figure 7.8, www.zfin.org, (Bardet et al., 2004) suggesting that EL161 
may contribute to the activity of esrrga in these neural subdomains. Low level of variability was 
still observed in the integrase transgenic lines, at least in part explained by variation in focal 
planes of imaging as well as by potential differences in developmental stage of the individuals 
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imaged. For stage-dependent variation of transgene activity see Figure 7.9. Nevertheless, the 
variability of expression patterns among PhiC31-mediated targeted integrants was significantly 
lower than those found among Tol2-mediated transgene integrants (Likelihood Ratio = 15.0, DF = 
1, p = 0.0001). Taken together, the low variability of transgene activity observed in PhiC31 
targeted integration events demonstrated superior reproducibility and robustness of enhancer 
driven expression patterns as compared to that obtained by transposase mediated integration. 
These experiments demonstrated that PhiC31-mediated system could limit if not completely 
overcome position effect variability, and therefore represented a refined alternative for SNP 
quantitation. 
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Figure 7.7 Reproducible Venus expression patterns upon targeted integration of EL161 enhancer 
construct demonstrate cis-regulatory function in the brain 
A. Brain-specific enhancer effect of a transgene inserted in different integration sites. Domains of 
Venus activity are specified in panel B. Dorsal (top) and lateral (bottom) views onto the head of 3 
dpf F1 transgenic larvae. Scale bar is 100 µm. B. Domains of Venus reporter expression and their 
distribution among targeted (PhiC31 integrase) and randomly (Tol2 transposase) transgenic lines. 
Abbreviations: IF- integrase injected founders, IP- integrase mediated expression patterns, TF- 
Tol2 injected founders and TP-Tol2 mediated expression patterns. Blue depicts expression 
domains overlapping with esrrga activity, whereas red colour indicates additional domains. Light 
blue indicates weak expression. 
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Figure 7.8 Tissue-specific activity driven by EL161 element overlaps with endogenous expression domains of endogenous esrrga gene. 
60 hpf embryos probed with esrrga (left) share 5 expression domains with integrant founders from uobL6 (right) probed with Venus. Dorsal and lateral 
images are shown. Expression domains are labelled as listed in Figure 7.7. Note that esrrga domain 1 (epiphysis) is weakly expressed at this stage, but 
shows a strong expression earlier in development. Lens from bottom left embryo was removed to allow visualization of inner brain domains. Scale bar 
indicates 100 μm. 
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Figure 7.9 EL161 putative enhancer from essrga locus drives a complex and dynamic neuronal 
pattern. 
Complexity and dynamic pattern of pattB-mCherry,Tol2/EL161-krt4:Venus construct integrated in 
uobL6 IF1 are shown from 60 hpf to 96 hpf. Red lens indicates PhiC31-mediated legitimate 
integration. YFP channel shows the dynamic expression pattern driven by the injected construct. 
Domains of expression are listed in Figure 7.7. All larvae are oriented anterior to the left. Scale bar 
indicates 100 μm.  
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7.3.5 Analysis of the effect of PhiC31 integrase mRNA on embryo and PGC survival 
It was recently demonstrated that PhiC31-nos1-3’UTR to PhiC31 mRNA lead to improved embryo 
survival and germline transmission of recombination events in zebrafish (Hu et al., 2011). We 
reasoned that the usage of an integrase variant that led to higher survival and similar germline 
transmission rates could be advantageous for our SNP experiments, where large numbers of 
transgenic lines would be needed in order to quantify predictably subtle differences in expression 
pattern and/or intensity. Therefore, I injected uobL6 F3 embryos (the recipient line carrying one 
single integration site) with both the WT and PhiC31-nos1-3’UTR version of PhiC31 integrase 
mRNA and analysed the survival rates over 72 hpf (Table 7.5). 
In accordance with previous findings (Hu et al., 2011), we observed that PhiC31 mRNA in vitro 
transcribed from pCS2+ vector was highly toxic to zebrafish embryos using as little as 15 pg of 
integrase (Table 7.5). We also consistently observed improved survival upon PhiC31-nos1-3’UTR 
injection when compared to PhiC31 wild type version, while the red lens conversion efficiency 
remained similar (8.52% n=171 embryos using PhiC31-nos1-3’UTR versus 5.74%, n=100 using the 
regular PhiC31 mRNA). 
Table 7.5: PhiC31 integrase mRNA toxicity rates and embryo survival analysis 
Injection solution 
Total number 
of injected 
embryos 
Survival rate 
at 72 hpf 
(average % ± 
st dev) 
Number 
of 
replicates 
15 ng/μL pCS2+PhiC31 integrase RNA 465 25.8 ± 0.15 3 
30 ng/μL pCS2+PhiC31 integrase RNA 422 13.8 ± 0.05 3 
15 ng/μL pCS2+PhiC31-nos1-3'UTR integrase RNA 385 85.8 ± 0.03 3 
30 ng/μL pCS2+PhiC31-nos1-3'UTR integrase RNA 395 74.8 ± 0.03 3 
 
Although the mechanism by which PhiC31 exerts its actions is not known, we thought that if 
PhiC31-nos1-3’UTR mRNA was differentially more stable in the primordial germ cells (PGCs, 
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(Koprunner et al., 2001)), its toxicity could potentially deplete them and produce a high level of 
sterility among adults, even though previous studies with PhiC31-nos1-3’UTR had not reported it 
(Hu et al., 2011). In order to test the viability of PGCs, uobL6 F3 embryos were injected with 
PhiC31 and PhiC31o-nos1-3’UTR mRNA (15 and 30 ng/µl) and PGCs were stained using anti-vasa 
antibody (kind gift from Holger Knaut). Vasa protein is restricted to the germ line (Knaut et al., 
2000) and therefore it is a suitable marker for the assessment of PGC number and viability. Our 
results showed that injection of PhiC31-nos1-3’UTR mRNA did not substantially reduce the 
viability of primordial germ cells (Table 7.6, Figure 7.10), and therefore there was no indication 
against using PhiC31o-nos1-3’UTR for further experiments. 
Table 7.6 Primordial germ cells survival rates upon PhiC31 integrase injections. 
Injection solution Total number of embryos analysed 
Number of PGCs 
at 24 hpf 
(average ± st 
dev) 
15 ng/μL pCS2+PhiC31 integrase RNA 21 19.4 ± 4.19 
30 ng/μL pCS2+PhiC31 integrase RNA 17 18.5 ± 4.77 
15 ng/μL pCS2+PhiC31-nos1-3'UTR integrase RNA 25 19.2 ± 5.55 
30 ng/μL pCS2+PhiC31-nos1-3'UTR integrase RNA 12 19.6 ± 5.13 
Uninjected group 30 20.3 ± 5.22 
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Figure 7.10 Analysis of PGC survival in embryos injected with PhiC31 mRNA 
Lateral view of 24 hpf embryo (anterior to the left) stained with anti-vasa antibody (kind gift from 
Holger Knaut). Magnified view of the genital ridge area (bottom right insert) showing stained 
PGCs (arrow). 
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7.3.6 Design of an attB-containing vector to harbour enhancers and measure allelic 
differences  
In order to facilitate the test of multiple enhancers and promoters, a vector containing a 
multicloning site upstream attB-mCherry targeting cassette in pJET-attB-mCherry plasmid 
(Roberts et al., 2014) was designed, where cis-regulatory elements of interest could be easily 
exchanged using cloning (Figure 7.11A). 
A multicloning site was placed upstream attB targeting site and as a reporter gene YFP was 
chosen, so that there was no spectrum overlap with mCherry reporter gene. This design allows for 
the insertion of promoters using AgeI/XhoI sites and the cloning of enhancers using EcoRI, EcoRV, 
SpeI or HindIII sites. For enhancers, in-fusion cloning (see Chapter 2) is the preferred option, since 
only one restriction site from the vector is needed. The expectation is that when this construct 
containing an enhancer:promoter:YFP cassette upstream attB-mCherry transgene is co-injected 
with nanos-Phic31 mRNA in uobL6 transgenic recipient line and PhiC31-mediated recombination 
happens, transgenic fish will exhibit red lens in approximately 8-9% of the cases (see above) 
together with enhancer pattern driven YFP expression (Figure 7.11B). Previous experience testing 
this system with wild-type version of PhiC31 mRNA and the zebrafish EL161 enhancer indicated 
that random integration of the targeting vector in the genome was extremely unlikely to result in 
red lens co-occurring with enhancer-driven YFP pattern.  
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Figure 7.11 Overview of PhiC31 transgenesis system for the detection of SNP variants. 
A. Map of the construct designed to test enhancer containing SNP variants using PhiC31-mediated 
transgenesis system. A vector containing attB-mCherry targeting site, was modified to contain a 
putative enhancer linked to a promoter and YFP reporter gene. In this example TCF7L2 putative 
enhancer (Gaulton et al., 2010) containing the C common variant of SNP rs7903146 was cloned 
upstream endogenous zebrafish tcf7l2 promoter. B. Schematic drawing of the targeting plasmid 
pJETattB-mCherry,TCF7L2:tfc7l2:YFP co-injected with PhiC31 mRNA into the docking site of 
Tg(Xla.crygc:attP-GFP) transgenic recipient line and the resultant genomic recombination 
occurring in injected embryos.  
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7.3.7 Selection of SNP-containing enhancers to be tested by PhiC31-mediated 
transgenesis 
To test whether PhiC31-mediated transgenesis system could be used for the quantitative analysis 
of SNP variants, human enhancers containing disease-associated SNPs were cloned into our 
customised attB-containing construct and the system efficiency was evaluated by establishing 
transgenic lines. In order to test the system, four sets of human enhancers associated with 
disease were selected (Table 7.7). These putative enhancers contained SNPs linked to type-two 
diabetes (T2D) and for all of them there is in vitro evidence that the SNP variant was causing a 
significant difference in the enhancer activity by luciferase assays in pancreas cell lines (Gaulton et 
al., 2010; Pasquali et al., 2014). 
Table 7.7. Type-2-diabetes associated putative enhancers selected for SNP quantitation assays 
Human Cis-
regulatory 
element 
Genomic coordinates 
(Hg18) 
Disease-
associated 
SNP 
Allelic 
variants GWAS Reference 
Zebrafish 
promoter 
used in assays 
TCF7L2 chr10:114748258-114748496 rs7903146 C>T (Cauchi et al., 2007) tcf7l2 
ZFAND3 chr6:37883254-37883831 rs58692659 C>T (Cho et al., 2012) hsp70 
C2CD4A chr15:60178441-60179347 rs7163757 C>T (Schaub et al., 2012) hsp70 
PROX1 chr1:212242977-212243697 rs4282786 G>A (Stitzel et al., 2010)  prox1 
 
The selection of an appropriate promoter is important for testing enhancer function, as it has 
been discussed throughout this thesis (Chapters 3, 4 and 6). In the case of putative enhancers 
located in introns (PROX1 and TCF7L2), we decided to take the minimal promoter of the 
endogenous gene harbouring the enhancer candidates. In the case of putative enhancers located 
in gene deserts (12 kb upstream the closest coding gene in the case of ZFAND3 enhancer and 
27kb downstream the closest coding gene for C2CD4A enhancer), we decided to use a minimal 
promoter hsp70, which had been shown to give a minimal to non-existing background in previous 
analyses (Gehrig et al., 2009; Pasquali et al., 2014). 
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7.3.8 Transient analyses of attB containing enhancer constructs injected in uobL6 
For each tested putative human enhancer tested in vivo three constructs were made: two vectors 
contained the enhancer carrying either the common or the non-common allelic variant of the 
T2D-associated SNP, linked to the zebrafish promoter and YFP fluorescent protein. Moreover, an 
enhancer-less (promoter only) control was used to assess the regulatory activity originating from 
the zebrafish gene promoter (Table 7.8). 
These constructs were co-injected with 15 ng/µl PhiC31o-nos1-3’UTR mRNA in embryos resulting 
from outcrosses between uobL6 F3 individuals and AB* WT zebrafish adults. YFP-driven 
expression pattern and GFP to mCherry lens colour switch was monitored and at 5 dpf, all 
transgenic fish were grown up (Table 7.9). The lack of enhancer driven-YFP expression was initially 
attributed to the lack of expression shown by this element when tested in Tol2-mediated 
transgenesis (as discussed in the previous chapter) and due to the PGCs-specific targeting driven 
by PhiC31o-nos1-3’UTR. 
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Table 7.8 Primers used to clone human putative enhancers and zebrafish promoters into attB containing vector 
Cis regulatory element 
Forward primer (5’-3’) Reverse primer(5’-3’) Element size 
  (Hg18 or Zv9) 
TCF7L2 TTTTGATATCAATTCATGGGCTTTCTCTGC AAAAACTAGTGTGAAGTGCCCAAGCTTCTC 239 bp 
ZFAND3 CATGGAATTCACTAGTTCATGTTTCCCCCGTATGT AGGCGCCAAAACTAGTCCTGCCCCAAGTTGCACAG 578 bp 
C2CD4A CATGGAATTCACTAGTACATCCCTTACCCTTACTGGA AGGCGCCAAAACTAGTGGCAATGCGGGCTCTTTTT 907 bp 
PROX1 CATGGAATTCACTAGTGCAAAAATGAACTTGAGAAATCC AGGCGCCAAAACTAGCATTCCCTTTAATATCCCATGC 721 bp 
hsp70 zebrafish 
promoter AAAAAACCGGTTTGATTGGTCGAACATGCTGG AAAAACTCGAGCAGTCCGCTCGCTGTCTCGCT 149 bp 
prox1 zebrafish promoter AAAAACCGGTTCCGCACAGAGAACGTATTG AAAAGTCGACTGAGCTTCTTCGCGATAGTG 423 bp 
tcf7l2 zebrafish promoter CCCCACCGGTTCAGCCTCTTCTGTTTTGAGCAG TTTTCTCGAGTTTAAGTTTAGGGACTCGCAGTGG 641 bp 
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7.3.9 Analysis of T2D-associated TCF7L2 enhancer using PhiC31-mediated transgenesis 
Due to time constraints only TCF7L2 enhancer was tested and included in this thesis. TCF7L2 
putative enhancer was one of the most interesting examples, since regulatory variation within 
SNP rs7903146 has the strongest link effect to T2D demonstrated so far (Cauchi et al 2007). In 
order to determine whether we could effectively use PhiC31-based transgenesis in zebrafish to 
quantitate small differences in either intensity or pattern coming from TCF7L2, we decided to 
analyse the offspring of sexually mature injected founders outcrossed with WT fish. We found at 
least three transgenic founders per injected construct (Table 7.9) giving mosaic offspring with red 
lens during development (Table 7.10), indicating that PhiC31-mediated integration had occurred 
and that PhiC31o-nos1-3’UTR mRNA variant could efficiently mediate site-specific integration. 
However, the progeny did not show any enhancer-driven YFP tissue-specific expression (Figure 
7.12). Suspecting YFP translational problems, we decided to fix 96 hpf embryos showing red-lens 
conversion and performed WISH using a DIG-labelled YFP antisense probe (Figure 7.13), but none 
of the embryos showed any enhancer driven expression, whilst sibling negative embryos probed 
with esrrga transcription factor showed a clear neuronal pattern that matched the expected 
endogenous gene activity. These negative results could be attributed to an extreme weakness of 
the YFP signal caused by the presence of a single copy in the genome. Alternative explanations 
include that the docking site in uobL6 might not provide the right genomic environment for this 
enhancer or that zebrafish cells cannot interpret functionally this non-conserved human element; 
or that this element does not hold regulatory potential. 
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Table 7.9 Germline transmission rates of PhiC31 founders 
Line Number of lens-GFP + embryos grown up (5 dpf) 
Number of screened 
individuals 
Number of red lens 
positive founders 
Germline 
transmission 
rates % (n) 
Tg(γcry:ATTR-mCherry,Hs.TCF7L2-C-tcf7l2:YFP-ATTR-GFP) 164 54 5 9.3 (5) 
Tg(γcry:ATTR-mCherry,Hs.TCF7L2-T-tcf7l2:YFP-ATTR-GFP) 179 22 3 13.6 (3) 
Tg(γcrya:ATTR-mCherry,tcf7l2:YFP-ATTR-GFP) 134 40 3 7.5 (3) 
 
 
Table 7.10 Analysis of the offspring of integrase founders 
Line Founder ID 
Total number of F1 
embryos analysed 
Percentage of red lens 
embryos %,(n) 
Percentage of embryos with 
enhancer YFP pattern %,(n) 
Tg(γcry:ATTR-mCherry,Hs.TCF7L2-C-tcf7l2:YFP-ATTR-GFP) 
C9 69 13.0 (9) 0.0 (0) 
C11 108 1.8 (2) 0.0 (0) 
C12 21 4.8 (1) 0.0 (0) 
C18 126 15.9 (20) 0.0 (0) 
C19 58 29.3 (17) 0.0 (0) 
Tg(γcry:ATTR-mCherry,Hs.TCF7L2-T-tcf7l2:YFP-ATTR-GFP) 
T1 120 5.8 (7) 0.0 (0) 
T3 348 10.9 (38) 0.0 (0) 
T28 126 20.6 (26) 0.0 (0) 
Tg(γcrya:ATTR-mCherry,tcf7l2:YFP-ATTR-GFP) 
ek1 225 13.3 (30) 0.0 (0) 
ek13 98 16.3 (16) 0.0 (0) 
ek31 234 23.1 (54) 0.0 (0)) 
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Figure 7.12 PhiC31-mediated integration detected by conversion of reporter expression in 
TCF7L2-containing transgenic lines  
96 hpf representative embryos from TCF7L2 containing transgenic lines. Lens activity driven by 
mCherry demonstrates PhiC31-mediated integration. Transgenic founders are named as in Table 
7.10. Arrows in green and red channels indicate auto-fluorescence of the yolk syncytial layer. 
Lateral views of larvae head to the left are shown. Scale bar represents 100µm.  
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Figure 7.13 Absence of TCF7L2 enhancer-driven pattern demonstrated by WISH 
Representative embryos from each transgenic line probed with DIG-labelled YFP antisense probe. 
None of the embryos showed any tissue-specific activity despite PhiC31-mediated integration 
evidenced by red lens conversion. Technical control embryos of Tg(ARE:hsp70:YFP) transgenic line 
probed with YFP showed the expected jaw-specific expression pattern (bottom left panel). TCF7L2 
transgenic founders are named as in Table 7.10. All embryos are 96 hpf, oriented laterally, 
anterior to the left. Scale bar represents 100µm.  
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7.3.10 Establishment of new transgenic recipient lines  
Due to the finding that uobL12 contained a Tol2-mediated multimer integration, which 
contradicted previous literature of Tol2 transposon only mediating a single insertion site into the 
genome (Kawakami et al., 2000), I decided to establish new transgenic recipient lines, widening 
the choice of landing sites for enhancer testing. 
Wild-type embryos were co-injected with 15 ng/µl of pTol2/Xla.crygc:attP-GFP (pDB896) and Tol2 
mRNA and positive embryos were grown up to sexual maturity. Then, adults were outcrossed 
with wild type fish and the offspring was screened for green lens. Out of 10 individuals screened 2 
positive founders were identified. EPTS-LMPCR results from one of the lines suggest that there is a 
single integration site on an intergenic region on chromosome 17 (coordinates for Zv9 are 
chr17:38,691,215). It is 215 kb downstream mbip and 50 kb upstream sptb coding genes and 
could potentially be used for further enhancer assays. 
7.3.11 Further perspectives 
At the time this thesis was prepared, founder fish injected with ZFAND3, PROX1 and C2CD4A 
enhancers associated with T2D had reached sexual maturity. Outcrosses will be carried out, as 
described in this chapter for TCF7L2 and the co-occurrence of YFP enhancer expression and red 
lens will be used as indicators of PhiC31 mediated integration into the germline. Expectations are 
that if these human elements can be interpreted by the zebrafish embryo, SNP differences will be 
quantified by fluoresce imaging, WISH and quantitative PCR of the reporter gene. 
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7.4 DISCUSSION 
In this chapter we report the design of a site-directed integration system mediated by PhiC31 
integrase in zebrafish, where docking transgenic lines containing attP sites in known genomic 
locations can be targeted by attB containing donor vectors that include CREs of interest. By using 
site-specific transgenesis, we expect to reduce position effect variation and therefore create a 
more robust system for the detection of subtle differences coming from SNP variants in CREs. 
There are examples in the literature of SSR functioning in zebrafish (Boniface et al., 2009) but 
PhiC31 is particularly efficient because of its directional recombination between heterotypic attB 
and attP target sites (Thorpe et al., 2000). Using this system reproducible expression pattern 
driven by EL161 predicted transcriptional enhancer was found, where the observed expression 
domains appeared to match broadly the endogenous activity of esrrga, the predicted target gene. 
Given that enhancers can act at distances as far as 1 Mb, reviewed by (Krivega and Dean, 2012), 
unambiguous identification of target genes remains challenging. Nevertheless, several esrrga 
expression domains with reproducible activity in independent genomic integration sites could be 
identified. Tol2 transgenics also showed several of the enhancer-specific patterns but were mostly 
coupled to a variety of additional ectopic patterns.  
In concordance with previous reports, PhiC31 integrase mRNA can be highly toxic in zebrafish 
embryos (Hu et al., 2011). We have shown that the use of PhiC31 fused with 3´UTR of nanos1 can 
significantly reduce the toxicity after injection (Table 7.5), without affecting the recombination 
rate measured by red lens colour change or the viability of the PGCs. We have also demonstrated 
germline transmission of site-specific integration of around 15% in adult founders, which is higher 
than our previous work with codon-optimized PhiC31 integrase (Roberts et al., 2014).  
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For TCF7L2 enhancer test we chose uobL6, a well characterised landing line that had proven to be 
an excellent docking site for the analysis of esrrga zebrafish enhancer. An additional advantage of 
a site-directed transgenesis system based on the creation of attP landing sites is that it allows for 
evaluation of the genomic landscape the transgene was integrated into. However, careful 
molecular analysis of the docking lines is required to ensure that a single attP containing 
transgene is harboured. Our transgenic docking lines were created by Tol2 transgenesis and 
despite having been described to integrate a single copy of Tol2 arms-flanked transgenes 
(Kawakami et al., 2000), Tol2 independent integration events of full plasmid or fragments are not 
unheard of and are actually expected to happen in low frequency via NHEJ. 
Similar complications during the selection of recipient transgenic lines have been reported by 
Mosimann and colleagues, who designed a similar site-specific approach in zebrafish based on the 
creation of several transgenic lines harbouring attP landing sites targeted by attB containing 
donor Gateway constructs (Mosimann et al., 2013). They characterized three functional Tol2 
transgenic lines carrying a single attP site that allows for attB flanked transgene integration. 
However, the authors encountered difficulties during the characterization process, since one of 
the lines was defective and another one showed ectopic transgene expression, attributed to 
enhancer trapping of the attP containing Tol2 transgene (Mosimann et al., 2013). 
Nevertheless, such systems provide the basis for creating a library of transgenic docking sites 
where optimal genomic environments for CREs can be identified and where the effect of genomic 
locations on different enhancers or enhancer-promoter combinations could be tested. Such 
efforts have started in Drosophila, where around 100 attP transgenic lines have been 
characterized (Groth et al., 2004; Bateman et al., 2006; Bischof and Basler, 2008; Venken and 
Bellen, 2012) and attempts to measure position effects in various loci have led to the conclusion 
that an attP docking site that permits optimal transgene expression in one tissue might not be as 
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effective in another, and that the perfect attP site might not even exist in any vertebrate genome 
(Markstein et al., 2008). 
Despite describing a readily available system consisting of fully characterized transgenic lines 
carrying single functional attP sites, custom-made attB containing donor vectors that allow easy 
cloning of enhancers and promoters and highly efficient PhiC31 mRNA, we have not been able to 
prove TCF7L2 human enhancer function using this system or have been able to quantitate 
differences coming from SNP variants within this CRE. We can possibly attribute the negative 
enhancer results to a suboptimal genomic location of the landing site or to the fact that this non-
conserved enhancer does not actually harbour regulatory potential in zebrafish. As discussed in 
the previous chapter, we have obtained inconclusive results regarding TCF7L2 enhancer specificity 
with Tol2-based transgenesis. Although mosaic transient transgenic experiments showed no 
reporter activity, the fact that islet-specific expression was found among the expression patterns 
displayed by stable transgenic lines, suggested that this activity was enhancer driven. The fact 
that SNP rs7903146 is the strongest link to T2D so far also underlines the relevance of this 
experiment. 
To identify optimal sites for CREs, more docking lines need to be created and molecularly 
characterized, which is both laborious and time consuming. A short term improvement in the 
current recombination efficiency would require the creation of homozygous attP adult fish, where 
100% of the offspring would be bearing the docking site and therefore would double the number 
of recombinants per injected clutch and reduce labour time by skipping the selection of positive 
transgenic embryos after injections. Future experiments should also include testing a known 
human enhancer that is functional in zebrafish and that includes a disease associated SNP. 
Breeding of the fish already injected with human enhancers associated with T2D (Table 7.7) 
should shed light on the feasibility of this system. Additionally, the application of recent genome 
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editing tools such as TALENs or CRISPRs opens the future to engineered attP site-containing 
transgenic recipient lines, which would circumvent drawbacks derived from the random 
integration mediated by commonly used transposons and provide a higher flexibility in choosing 
the genomic landscape of landing sites. 
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Chapter Eight: GENERAL DISCUSSION AND PRESPECTIVES 
8.1 Using zebrafish transgenics to validate human enhancers 
The identification of cis-regulatory elements remains a challenging task due to the lack of 
distinguishing signatures at the sequence level and our poor understanding of CRE structure and 
genomic distribution. Recently, the combination of approaches based on cross-species sequence 
conservation, genome-wide maps of epigenetic marks, binding data of transcriptional co-factors 
and open chromatin sites, have proven successful in predicting regulatory regions (Visel et al., 
2009a; Rada-Iglesias et al., 2011; Djebali et al., 2012). However, computational predictions have 
led to the identification of large numbers of candidate CREs with unknown function. Thus, the 
main objective of this thesis was to evaluate the utility of the transgenic zebrafish embryo for 
detecting the functionality of human regulatory regions predicted by various genome-wide 
strategies  
I studied the function of 5 evolutionarily conserved candidate enhancers defined in human 
isolated islets by the presence of pancreas-specific TF binding events and active histone 
modification marks, including H3K4me1 and H3K27ac (Chapter 3). Rapid transient transgenesis 
assays demonstrated that all of the tested candidates were active in the zebrafish embryo, 
whereas control regions devoid of epigenetic marks failed to drive any tissue-specific expression, 
arguing for the specificity of the enhancer selection process. Three of the tested CREs showed 
reproducible reporter expression in the endocrine pancreas, both in transient and stable lines, 
and two of them in neuronal tissues, broadly reproducing the expression pattern of the predicted 
zebrafish candidate genes. Overall, these results suggest that there are conserved regulatory 
codes acting in vertebrate pancreas development, indicating that zebrafish would be a valuable 
tool to study pancreas cis-regulation in humans. 
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Interestingly, these experiments also showed that enhancers behave differently when coupled to 
different promoters in vivo. Functional test of CRE3-5, which is located in the second intron of 
RFX2, revealed that the gata2 promoter was more sensitive to regulatory input from the 
candidate enhancer than hsp70 and could activate an additional expression pattern in the 
pancreatic islet of zebrafish; confirming the findings of other studies that have tested putative 
enhancers with several promoters (Allende et al., 2006; Bessa et al., 2009; Gehrig et al., 2009; 
Navratilova et al., 2009). In fact, there is a wide variety of promoters used for enhancer tests in 
the literature, ranging from heterologous minimal promoters, such as EB1 (Li et al., 2010b; Ritter 
et al., 2010; Ritter et al., 2012) or hsp70 (Rada-Iglesias et al., 2011), to large gene promoters such 
as cardiac myosin (Shin et al., 2005) or gata2 promoters (Bessa et al., 2009; Navratilova et al., 
2009; Royo et al., 2011; Royo et al., 2012; Bhatia et al., 2013). Our results and others mentioned 
here highlight the importance of enhancer-promoter interactions in vivo and argue that the 
promoter choice will influence our capacity to detect enhancer function. 
In Chapter 5 we tested whether bidirectional transcription, detected at enhancer locations by the 
FANTOM5 Consortium, could be used as a novel enhancer predictive tool, and whether predicted 
enhancers would be functional in the context of an organism. Transient transgenesis assays 
demonstrated that 3 out of 5 bidirectionally transcribed enhancers were active in zebrafish, 
recapitulating the tissue-specificity shown by the human sequences in vitro. These results 
suggested that bidirectional transcription is predictive of active enhancers and that the zebrafish 
could interpret 60% of the enhancers showing sequence homology. The limited set of enhancers 
tested prevented us from establishing statistical correlations between sequence conservation and 
conserved expression. However, there are a few studies in the literature that have analysed this in 
detail by testing the same candidate enhancer in more than one model and orthologous 
enhancers in the same species (Navratilova et al., 2009; Ritter et al., 2010). To distinguish 
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between cis- and trans-regulatory changes Ritter and colleagues analysed human CREs tested in 
zebrafish (HZ), human CREs tested in mouse (HM) and orthologous conserved zebrafish CREs 
tested in zebrafish (ZZ). Their results indicated that cis-regulatory changes, which are caused 
when function was discordant between HZ and ZZ tests, are two times more frequent than trans-
regulatory changes, which happen when function was disparate between HZ and HM experiments 
(Ritter et al., 2010). 
We also used the zebrafish embryo to test whether an inherited region downstream of PTF1A in 
patients with pancreas agenesis could act as a long-range CRE, and whether the potentially 
pathogenic variants found in the probands could affect the regulatory activity of the candidate 
enhancer (Chapter 4). Transient transgenesis assays were unable to detect any tissue-specific 
activity in the zebrafish embryo, suggesting that either lack of sequence homology, enhancer-
promoter interaction, or enhancer function in vivo, could be the reason for the lack of reporter 
activity in zebrafish. Similarly negative results were obtained when we tested T2D-associated 
enhancers that were not conserved at a sequence level in zebrafish but were enriched in key 
histone modification marks and bound by pancreas-specific TFs (Chapter 6), suggesting that 
prediction tools require further refinement and that further studies are needed to understand the 
limitations of zebrafish to test human enhancers. 
8.2 Correlation between enhancer structure and predicted function 
There are several characteristics that could aid in predicting enhancer activity, such as the degree 
of sequence conservation, their length, the strength of the predictors used in the computational 
analyses or the presence of TFBS.  
The length of the elements tested in this thesis was on average 1 kb, in accordance with similar 
studies in the literature (Shin et al., 2005; Abbasi et al., 2007; Ritter et al., 2010; Rada-Iglesias et 
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al., 2011; Ritter et al., 2012). We argued that longer sequences could represent the full functional 
element required for autonomous activity. In agreement with this, recent studies using bimodal 
enrichment of H3K27ac and H3K4me1 histone tails as a predictive tool indicated that enhancers 
are in average 3 nucleosomes in length, that is, approximately 600 bp (Figure 5.1, (Bernstein et 
al., 2012). However, despite the candidate enhancers tested had comparable lengths, not all of 
them were able to modulate reporter gene expression, suggesting that the chosen length may not 
reflect the true size of the enhancer. 
The strength of predictors used, such as enrichment in histone modification marks and 
bidirectional transcription, were comparable within groups, as demonstrated by the robust 
computational analysis performed by our collaborators. It could be argued that TFBS composition 
could correlate with enhancer function; however, it was out of the scope of this thesis to perform 
an in-depth analysis of TFBS in the tested candidate enhancers. Due to the lack of appropriate 
zebrafish antibodies there is limited experimental ChIP-Seq data on the specific binding of TFs of 
interest. In addition to that, certain computational predictions of TFs have been shown to be 
poorly correlated with in vivo measurements (Kaplan et al., 2011), and discerning whether 
predicted binding is functional is not trivial, suggesting that this approach would be unreliable. 
Interestingly, sequence conservation seems to be strongly correlated with enhancer function in 
our dataset (Table 8.1). In this study, the activity of 27 predicted enhancers and enhancer variants 
was evaluated, along with 5 control regions. Among the candidate enhancers, 15 were conserved 
at the sequence level (using as criteria 70% of conservation over 100 bp, Chapters 3, 5, 6) and 12 
were not conserved (Chapter 4, Chapter 6). Our transient transgenic analyses showed 
reproducible reporter expression in 10 out of the 15 the conserved enhancers, whereas none of 
the 12 non-conserved enhancer variants could drive tissue-specific activity (Table 8.1). These 
results suggest that sequence conservation has a strong influence on functionality, in keeping   
 229 
 
Table 8.1 Overview of human candidate enhancers tested in this thesis 
Human enhancer 
ID 
Closest coding 
gene(s) 
Conserved 
with 
zebrafish 
Reproducible enhancer-
driven pattern 
Enriched 
in 
H3K4me1 
and/or 
H3K27ac 
Bidirectionally 
transcribed Transient 
assays 
Transgenic 
lines 
C3-1 AGPAT9 and NKX6-1  Yes Yes - Yes - 
C3-3 ISL1 and PELO  Yes Yes 3/3 Yes - 
C3-4 PROX1 and SMYD2 Yes Yes 1/1 Yes - 
C3-5 LOC100128568 and RFX2 Yes Yes 5/5 Yes - 
C3-6 TCF7L2 and HABP2 Yes Yes - Yes - 
C2-11 KIF26B and SMYD3 No No - No - 
C5-14 LINC00499 and CCRN4L No No - No - 
PROX1- A  PROX1 Yes Yes 0/4 Yes - 
PROX1-G  PROX1 Yes Yes 0/4 Yes - 
TCF7L2- C TCF7L2  No No 0/5 Yes - 
TCF7L2-T  TCF7L2  No No 0/1 Yes - 
DGKB-TMEM195-G  DGKB and TMEM195 No No - Yes - 
DGKB-TMEM195-T  DGKB and TMEM195 No No - Yes - 
ADCY5-A  ADCY5 No No - Yes - 
ADCY5-G  ADCY5 No No - Yes - 
PTF1A-short-WT PTF1A No No - Yes - 
PTF1A-short-363G PTF1A No No - Yes - 
PTF1A-short-305G PTF1A No No - Yes - 
PTF1A-long-WT PTF1A No No - Yes - 
PTF1A-long-363G PTF1A No No - Yes - 
PTF1A-long-305G PTF1A No No - Yes - 
CRE1 TMEM161b and MEF2C Yes Yes 5/5 n/a Yes 
CRE2 POU3F2 Yes Yes - n/a Yes 
CRE3 SOX7 Yes Yes 0/2 n/a Yes 
CRE4 PAX6 and RCN1 Yes No - n/a Yes 
CRE5 DLX1 and DLX2 Yes No - n/a Yes 
ubi1 GTF2A Yes No - Yes Yes 
ubi2 GPR84 Yes No - Yes Yes 
ubi3 ZBTB16 Yes No - Yes Yes 
Control region 1 C11orf74 No No - No No 
Control region 2 DSCAM No No - No No 
Control region 3 PBX1 No No - No No 
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with studies that have argued that sequence conservation is relevant to enhancer function (de la 
Calle-Mustienes et al., 2005; Shin et al., 2005; Woolfe et al., 2005; Abbasi et al., 2007; Navratilova 
et al., 2009; Li et al., 2010b; Punnamoottil et al., 2010; Ritter et al., 2010; Chatterjee et al., 2011; 
Ritter et al., 2012). Nevertheless, our observations contrast with other publications where non-
conserved human CREs maintained functionality in zebrafish (Fisher et al., 2006a; Rada-Iglesias et 
al., 2011); and with reports that found a comparable level of sequence conservation between 
enhancers that showed specific activity and those that did not (Li et al., 2010b). Along these lines, 
Ritter and colleagues concluded that a higher degree of conservation is not a better indicator of 
conserved function, whereas TFBS distribution is (Ritter et al., 2010). 
8.3 Using zebrafish transgenesis to quantitate enhancer variants 
Several studies have demonstrated that common SNP variants can lead to phenotypical 
consequences and increased susceptibility to human disorders (Lettice et al., 2003; Rahimov et al., 
2008; Pomerantz et al., 2009; Musunuru et al., 2010; Harismendy et al., 2011; Smemo et al., 
2014). Nevertheless, most studies have revealed subtle expression differences between enhancer 
variants in vitro (Gaulton et al., 2010; Stitzel et al., 2010; Rada-Iglesias et al., 2013), and it 
remained largely unexplored whether these variants would elicit detectable changes in the spatial 
or temporal activity of enhancers in vivo. Therefore, a second aim of this thesis was to investigate 
if zebrafish transgenesis could be used to detect change in enhancer function caused by sequence 
variation. Thus, we attempted to quantitate T2D-associated enhancer allelic variants in vivo using 
Tol2 transgenesis (Chapter 6). Our results showed that two non-conserved candidate enhancers 
were not functional in zebrafish. Furthermore, it was not possible to determine unambiguously 
the function of TCF7L2 enhancer variants, due to the lack of activity in transient transgenic assays 
and lack of reproducibility in transgenic lines (Table 8.1). Along these lines, the variability of 
position effects in the transgenic lines containing PROX1 enhancer hindered quantitation of 
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enhancer variants using transposon-based transgenesis (Chapter 6). These results contrast with a 
recent study that has used Tol2 transgenesis to demonstrate that a risk SNP can alter enhancer 
function substantially (Spieler et al., 2014), suggesting that certain enhancer might be more prone 
to position effects and their activity may only be detected in a system that controls the genomic 
environment of the integration site. 
In order to improve the reliability of zebrafish transgenesis, I contributed significantly to the 
development of a more refined site-directed transgenesis system mediated by PhiC31 integrase. 
This technology was validated for enhancer testing (Chapter 7) and proved to reduce position 
effect variation commonly found in conventional, transposon-based transgenesis experiments. 
Nevertheless, when the system was used to quantify TCF7L2-associated enhancer variants, 
enhancer-driven expression pattern could not be detected. These negative results may be 
explained by lack of sequence homology, by a suboptimal genomic or epigenomic environment of 
the integration site, because the tested element does not represent the full autonomous 
enhancer, or because it is not transcriptionally active in zebrafish. Genomic influence cannot be 
completely avoided using PhiC31-based transgenesis, since the recipient transgenic lines are 
created by randomly integrating the attP containing transgene into the genome. However, the 
creation of libraries of recipient lines represents the first step towards a more robust transgenesis 
system for enhancer tests. These results also indicate the need for further studies to understand 
the limitations of zebrafish model in functional analysis of human enhancers.  
Overall, by utilizing zebrafish in novel projects of enhancer prediction and aiding in the 
development of a site-directed transgenesis method that can reduce position effect variability, 
the results presented in this thesis contribute to the establishment of the zebrafish embryo as a 
valuable model to test the function of predicted human enhancers.  
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